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Abstract 
BACKGROUND 
Urinary Bladder Cancer (UBC) is the 5
th
 most common cancer in the West (Cancer Research UK 2014).  
Continuous efforts have been made to develop non-invasive urine-based biomarkers with high 
sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of 
cystoscopies (Bryan et al. 2010). This can then be utilized as part of a multi-biomarker panel to develop 
a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools 
(Brentnall et al. 2012). 
METHODS  
Using a (LC-MS/MS) proteomic approach, 8 UBC and 1 normal bladder cell secretomes were analysed 
to identify secreted proteins that can be potential candidate biomarkers. phorbol 12-myristate 13-acetate 
(PMA) a PKC activator was used to treat whole secretomes and investigate all proteins released by cells 
whereas secretomes that were treated with the broad-spectrum inhibitor, Marimastat underwent 
ultracentrifugation to focus on proteins being shedded. Protein quantification was based upon stable 
isotope labelling by peptide demethylation (Chen et al. 2003). Two methods were utilized to select 
candidate biomarkers: Human Protein Atlas and Ingenuity Pathway Analysis. This project was 
interlinked to investigate Epithelial cell adhesion molecule (EpCAM) biology, a type I membrane 
protein that is cleaved by ADAM-17. This was done by examining the effects of PMA and Marimastat 
on its ectodomain shedding. The expression of its extracellular domain in cell lysates was determined by 
western blotting. This was followed by subsequent experiments to investigate cell phenotype and the 
effect of knocking down ADAM-17. This was concluded by measuring matrix metalloproteinase MMP-
1 in urine of 323 UBC patients to investigate its potential use as a biomarker.  
RESULTS:  
Findings revealed 83 potential biomarkers in PMA-treated secretomes have been discovered by HPA 
analysis. Using the Biomarker Filter tab on IPA software four potential biomarkers were elucidated:  
GSTM1, AMARC, LAMC2 and APEG. IPA core analysis revealed many proteins were related to 
carcinogenic events such as invasion, proliferation, progression, metastasis and hyperplasia. PMA 
stimulates EpCAM release and increases cell viability and migration. Alternatively, Marimastat inhibits 
EpCAM release and has no noticeable effect on cell viability and migration. MMP-1 was elevated in a 
proportion of patients. In relation to stage, Mann-Whitney test revealed there was no significant 
difference found in Ta, T1 but there was a significant difference found in T2 whereas for grade, there 
was no significant difference for G1 and G2 but there was for G3. The AUC score for grade and stage 
was 0.653 and 0.605 respectively. 
CONCLUSION:  
PMA increases secretion and shedding of proteins and has an effect on the cell phenotype. Despite 
Marimastat inhibits shedding of EpCAM, it does not have an effect on cell phenotype. Urinary MMP1 is 
not a useful neither prognostic nor diagnostic biomarker of UBC. Elevated MMP-1 levels are only 
apparent in high stages and grade. 
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1.0 Introduction 
Urinary Bladder cancer (UBC) is the most common malignancy of the urinary tract (Dunn et al. 
2013). It has a global incidence of more than 356,000 and prevalence approximately 2.7 million that 
continues to increase annually (Chen et al. 2012; Aben 2009). It mainly affects elderly people and 
the average age at the time of diagnosis is 73 (American Cancer Society 2014). Higher incidence 
rates are observed in North America, Europe and Australia compared to Far Eastern countries 
(Bartonová 2012). In the UK alone there are approximately 10,400 new cases attributed to bladder 
cancer yearly (7,500 men and 2,900 women) (Cancer Research UK 2014).  In the USA the number 
of cases is estimated to be 74,690 new cases (about 56,390 in men and 18,300 in women) whereas 
in the EU there are 123,135 cases (approximately 96442 in men and 26693 in women) (American 
Cancer Society 2014, International Agency for Research on Cancer 2014). Possible explanations of 
the higher incidence in men than women are attributed to different historical cigarette smoking 
patterns; although it is not known whether hormonal differences play a role as well (Lotan et al. 
2013; National Health Service, 2014). Mortality rates have risen; there are 5,000, 15,200 and 40,252 
deaths in the UK, USA and EU respectively per annum (American Cancer Society 2014; Cancer 
Research UK 2014; International Agency for Research on Cancer 2014). However, reports have 
predicted that the burden of UBC will increase in developing areas. This is due to a combination of 
aging and growth of global population and exposure to cigarette smoking (Aben 2009).  
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1.1 Types of Bladder Cancer 
1.1.1 Urothelial carcinoma of the bladder 
Urothelial carcinoma of the bladder (UCB) accounts for 90% of UBC cases (Feldman 2009; 
Steinberg 2014). Table 1 shows the Tumour, Node, Metastases (TNM) 2002 classification that is 
used to identify stages and is approved by the Union International Centre in Cancer (Algaba et al. 
2006). Stages Ta/T1 (confined to the mucosa/submucosa) are non-muscle invasive cancer (NMIBC) 
which was previously known as 'superficial' bladder cancer presents 70% of UCB cases (Bartonova 
2012, Feldman 2009, Dunn et al. 2013, Netto 2012, Adab et al. 2002). It has a tendency to recur but 
is not immediately life-threatening (Bartonova 2012, Feldman 2009). Muscle-invasive cancers 
(MIBC) account for the remainder of UCB cases and represent life –threatening disease requiring 
radical therapy (Bartonova 2012, Feldman 2009, National Health Service 2014, Adab et al. 2002).  
       Table 1: The pathology of bladder cancer TNM classification of UBC (Algaba et al. 2006).                
                   
 
P a g e  | 12 
 
1.1.2 Other types of UBC  
There are other cancers besides UCB that initiate in the bladder but are rare. For instance, squamous 
cell bladder cancer that account for 5% of UBC cases (Cancer Research 2014). Under microscopic 
examination, squamous cells are flat cells that form the moist, skin-like tissues that line the body 
(American Cancer Society 2014, Cancer Research UK 2014). Majority of squamous cell carcinomas 
are invasive (American Cancer Society 2014). They are commonly found in developing countries 
that have a high incidence of bilharzias; a worm infection (Cancer Research UK 2014).  
 
Adenocarcinoma accounts for 1-2% of cases and is a rare type of UBC. It develops from the mucus-
secreting cells in the bladder lining (American Cancer Society 2014, Cancer Research UK 2014). 
Majority of adenocarcinomas are also invasive (American Cancer Society 2014). 
 
Some bladder cancers are even rarer and are not formed from the urothelial lining. For instance, 
sarcomas that initiate in the muscle cells of the bladder (American Cancer Society 2014). Another 
example is Small cell carcinomas of the bladder (SCCB) that account for 1% of cases. They initiate 
as neuroendocrine cells which are nerve-like cells that develop quickly (American Cancer Society 
2014). SCCB patients are treated with chemotherapeutic regimens used for small cell carcinoma of 
the lungs (SCLC) due to similarities found between both types of cancer (American Cancer Society 
2014, Ismaili 2011).  
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1.2 Causal factors of UBC 
Many studies have been conducted to investigate the aetiology of UBC; however the exact cause 
has not been elucidated (Chu 2013). Cigarette smoking and occupational exposure to chemicals are 
the two main factors that have been confirmed to increase UBC risk (Burger et al. 2013, Chu 2013). 
They account for 50% and 20% of cases respectively (Burger et al. 2013).  
There are other factors that have been associated with UBC such as dietary factors, family history, 
race and socioeconomic status (Lotan 2013). It is important to note that some individuals with many 
risk factors do not actually have it whereas there are other individuals with bladder cancer that have 
several or no known risk factors (American Cancer Society 2014). This implies that having a risk 
factor or a combination of them does not indicate that one will develop bladder cancer (American 
Cancer Society 2014). 
1.3 Symptoms 
1.3.1 Haematuria 
Haematuria (blood in urine) is the cardinal symptom of UBC and is normally painless (Bryan 
2013b, National Health Service 2014). Statistics have shown that 85% of patients with bladder 
cancer have gross or microscopic haematuria (Feldman 2009, Budman 2008). However, a variety of 
benign inflammatory conditions that has no relation to UBC can also cause haematuria (Budman 
2008, Feldman 2009).  
1.3.2 Other symptoms 
There are other symptoms such as frequent or sudden passing of urine and pain whilst urinating. 
However these symptoms are also associated with urine infection especially if there is no blood 
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present. Another explanation of these symptoms would be if the patient was male, this may be due 
to an enlarged prostate gland (Cancer Research UK 2014c).  On the contrary, if it is cancer; the 
earlier it is diagnosed the easier it is to treat (Cancer Research UK 2014c). 
1.4 Diagnosis 
Early detection of UBC is necessary to improve prognosis and increase survival rates (Diamandis 
2010a, Budman 2008). There are multiple diagnostic procedures for further investigations of 
patients suspected of having UBC. Generally, this compromises of imaging, biopsy and invasive 
evaluation with cystoscopy (Dawam 2012). Cystoscopy involves examining inside the bladder for 
tumours (The Patient Education Institute 2011). In some cases; the tumour can be removed during 
the procedure (The Patient Education Institute 2011). 
1.5 Treatments 
1.5.1. Treatments for NMIBC 
Transurethral resection of bladder tumour (TURBT) is the first-line treatment for patients with 
NMIBC (Dunn et al. 2013). TURBT is a surgical procedure that removes the bladder tumour 
preventing it from metastasising to other organs of the body. A biopsy can also be taken at the same 
time and sent for examination  (Guy’s and  St Thomas’NHS Foundation Trust n.d.). Chemotherapy 
following TURBT can reduce the recurrence rate by 39% in patients with low risk of recurrence and 
progression (Dunn et al. 2013).  
 
Adjuvant treatments are often used due to risk of recurrence and progression to MIBC such as 
Bacillus Calmette–Guérin (BCG). BCG is a vaccine for tuberculosis and it promotes immune cells 
to become active in the bladder lining (Cancer Research UK 2014b). It can also work as an 
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immunotherapeutic agent to eliminate cancer cells that grow back or have remained behind in the 
bladder lining (Cancer Research UK 2014b). BCG is inserted directly to the bladder and this is 
known as intravesical treatment (Cancer Research UK 2014b). If the cancer re-occurs and 
progresses; cystectomy takes place which is a major operation to remove the tumour and not 
everyone is suitable for this surgical procedure (Cancer Research UK 2014b, UCLA 2014). Thus 
additional BCG treatment or chemotherapy is inserted which sometimes does not work well (Cancer 
Research UK 2013).  
However, recent advances such as BCG in combination with instillation of hyperthermic 
mitomycin-C have proven to be effective (Cancer Research UK 2013, Compérat et al. 2011). 
Hypothermia is a treatment in which the bladder is heated to approximately 42oC (Cancer Research 
UK 2013). Mitomycin C is a chemotherapy and is inserted through the bladder via a catheter; a tube 
(Cancer Research UK 2014a). The type of instillation is dependent on several factors such as stage, 
grade and multifocality of the tumour (Dunn et al. 2013).  
1.5.2 High-risk recurrent NMIBC and MIBC 
High-risk recurrent NMIBC and MIBC can be treated with curative intent by radical therapies such 
as radiotherapy, chemotherapy, and radical cystectomy (Diefenbach et al. 2012, Dunn et al. 2013, 
Choueriri 2008).  
Recent findings suggested that the risk of recurrence after cystectomy has reduced from 40% to 6-
13% and is dependent on tumour grade, stage and node status at the time of cystectomy (Diefenbach 
et al. 2012). In addition, studies have portrayed that radiotherapy and cystectomy have similiar long-
term survival rates and there is no apparent changes linked to mode of treatment (Bryan 2010). 
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Therefore, long-term surveillance and treatment is necessary and current protocol states that 
cystoscopy adjunct with cytology (microscopic examination of cells present in the urine) should be 
implemented every 3 months for the first initial 1-2 years followed by every 6 months for 1-5 years 
and then annually as long as no recurrence has occurred (Budman 2008).  
1.6 Disadvantages of current diagnostic procedures 
The current protocol has significantly high cumulative costs of healthcare resources and patient time 
especially when patients’ risk of recurrence is unequal (Bryan 2011, Budman 2008).  
Furthermore, despite cystoscopy is a highly sensitive fundamental technique for most tumours, 
detection of Carcinoma in situ (CIS) or small papillary tumours that account for early recurrence 
can be suboptimal and can lead to incomplete resection (Chen et al. 2012, Bryan 2010, Parker 2011, 
Budman 2008).  
However, there have been technological advances to improve the quality of TURBT and cystoscopy 
by limiting the number of cystoscopies or improving its sensitivity (Dunn et al. 2013). Amongst 
these is photodynamic diagnosis (PDD) and narrow-band imaging (NBI). They improve and 
increases detection rates of urothelial lesions compared to white-light cystoscopies (WLC) (Burger 
et al. 2008, Geavlete et al. 2012, Kausch et al. 2010). PDD is also known as fluorescence 
cystoscopy and utilizes 5-aminolevulinic acid (ALA) or its hexyl ester, hexaminolevulinate 5-ALA 
(Douglass 2007). NBI cystoscopy is a technique with high resolution that does not involve use of 
dyes (Geavlete et al. 2012). This leads to more patients having a complete resection and longer 
survival rates without recurrence (known as Recurrence-free survival), costs and better patient 
management (Burger et al. 2008, Kausch et al. 2010).  
Nevertheless, cystoscopy is still as invasive and is a source of patient anxiety (Budman 2008).   
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Moreover, urine cytology as opposed to WLC is non-invasive. It has poor sensitivity but high 
specificity for low-grade, well-differentiated lesions. On the other hand, it has good sensitivity and 
specificity to detect high grade tumours (American Cancer Society 2014, Chen et al. 2012, Budman 
2008). In addition, cytology can be challenging as it is dependent on the competency of the 
cytopathologist (Steinberg 2008).  
1.7 Solutions 
There is a need for the development of a non-invasive and inexpensive diagnostic tool such as 
urinary-based biomarkers with high sensitivity and specificity to detect UBC and/or differentiate 
between NMIBC and MIBC as alternative tools for the detection and surveillance of bladder cancer 
(Bryan 2010, Boustead et al. 2001). This would significantly improve diagnosis; lower healthcare 
costs, reduce morbidity and improve patient quality of life (Chen et al. 2012, Bryan 2010). Another 
potential utility of urinary biomarkers is that current evidence suggests that they have high 
sensitivity and specificity (>90%) for diagnosis of MIBC; this will lower the risk of delayed 
treatment (Bryan et al. 2013b).  
1.8 Introduction to Biomarkers 
Biomarkers are defined as biological molecules that can be objectively detected and measured in 
bodily fluids, tissues and cell lines (Chan 2013, National Institute of Health 2014). They can be 
mRNA, proteins, metabolites, DNA or mechanisms for instance proliferation, apoptosis and 
angiogenesis (Diamandis 2007). There are two types of biomarkers that offer distinct and obvious 
advantages: biomarkers of exposure, which are used in risk prediction, and biomarkers of disease, 
which are used in screening, diagnosis, recurrence, monitoring disease progression and response to 
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therapy (Diamandis 2007, Mayeux 2004). However, due to the minimal cancer prevalence, a 
biomarker has not yet been developed that meets all of these criteria (Diamandis 2007).  
1.8.1 Classes of Biomarkers 
There are several distinct types of cancer biomarkers based on different areas: genetics, proteomics, 
epigenetics, metabolomics, imaging technology and general physical techniques (Geng 2009).  
1.8.1.1 DNA/cell-free DNA 
Elevated levels of serum DNA concentrations are linked with cancer. Examples of substances that 
can serve as DNA biomarkers are alterations in DNA copy number and chromosomal aberrations 
(Weinstein 2014). Reports have shown that certain genes are hypemethylated in a range of cancers 
and some have been reported as biomarkers for UBC diagnosis. Bondaruk et al. revealed 6 potential 
methylation markers for UBC: SOX11, DBC1, MYO3A, PENK, CA10 and NKX6-2. Their 
sensitivity and specificity in urine elevate when measured as a panel. This further signifies how a 
panel of biomarkers increases both sensitivity and specificity. 
1.8.1.2 RNA/microRNA 
MicroRNAs (miRNAs) are small (22 nucleotides) non-coding RNAs that regulate the stability and 
translation of mRNA transcripts and play vital roles in various biological processes (Barik 2011, 
Choi et al. 2012). Choi et al. discovered that cell-free miRNAs were both present and stable in 
urine; specifically miR-145 levels were assessed and were able to distinguish between UBC patients 
and non-cancer controls. A higher recurrence risk was observed amongst NMIBC patients with 
lower miR-200a level compared to patients with higher miR-200a. This emphasises how miRNAs 
have shown for urine biomarker discovery. 
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1.8.1.3 Metabolic biomarkers 
Metabolomics is the latest of the omics technologies and plays a critical role in early UBC diagnosis 
(Kim et al. 2014). Recent studies revealed potential candidate biomarkers via mass spectrometry-
based metabolomics of urine of UBC patients that are useful for diagnosis and prognosis (Albericea 
et al. 2013). Examples of metabolites include tyrosine, histidine, phenylalanine and tryptophan that 
has been previously revealed but their role with cancer progression has only been established 
(Albericea et al. 2013).  
1.8.1.4 Proteins 
Proteins are another strategy for biomarker development. The proteome is the group of proteins that 
are encoded by the genome whereas the large-scale analysis of the structure and function of proteins 
is known as proteomics (Hudler 2014, Conrads et al. 2003). Proteins are attractive as biomarkers 
due to point of care testing, cost, reproducibility and great diversity (Brentnall et al. 2012). They are 
the end-point of many biological mechanisms and therefore they can precisely reveal the pathogenic 
phenotype (Hudler 2014). 
1.8.2 Current biomarkers 
The Food and Drug Administration (FDA) have approved several urine-based biomarkers (Cancer 
Research UK 2014, Bryan et al. 2011).  
1.8.2.1 Nuclear Matrix Protein-22 (NMP22) 
Nuclear matrix is a non-chromatin structure that normally provides support to the nucleus, gene 
expression and RNA transcription (Budman 2008). NMP-22 resides in the nuclear matrix whose 
role is to distribute chromatin to daughter cells during cell division (Steinberg 2013). It is released 
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from nuclei of tumour cells after they undergo apoptosis and are detected in urine (Steinberg 2013). 
Levels are higher in malignant than normal urothelial cells (Cancer Research UK 2014). The NMP-
22 immunoassay test has many advantages than cytology. Amongst these advantages are it does not 
require prolonged times for examination nor need intact cells. Thus results can be obtained within 
half an hour, less costly and more sensitive than cytological analysis (Steinberg 2013). 
1.8.2.2 Bladder Tumour Antigen (BTA) 
BTA is another urine biomarker that can be released by normal and tumour cells where in the 
former as a response to autoimmune attack whereas in the latter to aid in evading the host’s immune 
response (Cancer Research UK 2014, Budman 2008). BTA tests measures complement factor H–
related protein (CFHrp) and complement factor H in urine that is picked up by two monoclonal 
antibodies (Cancer Research UK 2014, Steinberg 2013). The role of both factors is to inhibit the 
complement cascade which in turn inhibits cell lysis (Steinberg 2013). Dahse et al. revealed that 
CFHrp blocks C5 convertase activity and intervenes with C5b surface deposition and Membrane 
Attack Complex (MAC) synthesis. This mechanism is different to CFH and both proteins manage 
the complement pathway in an orderly manner. They bind to the same cellular surface sites and 
CFHrp activity increases as CFH prevents C3 convertase. Both factors reside in bladder cell lines 
and if detected there are a high risk of recurrence (Cancer Research UK 2014, Steinberg 2013). 
Many studies have been conducted where there is variability in terms of sensitivity and specificity 
(Steinberg 2013). 
1.8.2.3 UroVysion 
Chromosomal mutations have been linked with UCB. UroVysion is a multi-target interphase 
Fluorescence in situ hybridization (FISH) assay that can be utilized to identify urinary cells with 
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aneuploidy in chromosomes 17, 3, 7 and deletion of 9p21. Aneuploidy is an abnormal number of 
chromosomes (Gelbart 2000).  This technique contains probes for centromeres of chromosomes 
mentioned and have been linked with high sensitivity and specificity. Studies have discovered that 
FISH is more sensitive and specific than urine cytology (Diefenbach et al. 2012). It is used to aid in 
initial diagnosis of UBC patients with haematuria and monitor tumour recurrence in patients that 
were diagnosed previously with UBC (Steinberg 2013). 
1.8.2.4 Mcm5 
Mcm5 test is a new test in which trials have discovered that its reliability and accuracy 
complements NMP22 test and a combination of both may aid in diagnosis (Cancer Research UK 
2014). Mcm5 is a cell cycle biomarker of dysregulated growth (Burling et al. 2012). Studies have 
shown that the dual test detects 95% of significant diseases (Burling et al. 2012).  
1.8.2.5 Disadvantages of current biomarkers 
There are issues with current available biomarkers, they are less specific but have high sensitivity 
than cytology and some markers are unable to distinguish between urothelial malignancy and 
inflammation and other benign urological conditions (Budman 2008). FISH results may be used 
mainly when urine cytology results are inconclusive (Dunn et al. 2013).  
Therefore, these biomarkers can act as adjunct to cystoscopy but is insufficient to replace it (Bryan 
2010). There is an increase consensus by researchers that a panel of biomarkers is needed to elevate 
specificity and sensitivity for accurate diagnostic purposes and replace cystoscopies that a sole 
biomarker cannot fulfil (Hudler 2014). 
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1.9 Introduction to proteomics 
The advent of proteomics play crucial roles in the identification, quantification and characterization 
of proteins that are involved in characterizing disease states, investigating cell signaling pathways, 
discovery of biomarkers and drug targets (Diamandis 2010b, Wehr 2006). Mass spectrometry (MS) 
is utilized with diverse separation ways and is the fundamental methodology of proteomics (Wehr 
2006). There are two types of proteomics: top-down and bottom-up/shot-gun proteomics (Hudler 
2014). The latter is usually used for such pursuits whereas the former can also be applied to many of 
these cases. Bottom-up proteomics consists of complex protein mixtures, purified mixtures that 
undergo proteolytic cleavage/enzymatic digestion into peptides. The peptides are then analysed by 
MS to identify the proteins (Hudler 2014, Wehr 2006).  
Alternatively, Top-down proteomics consists of large protein fragments or intact proteins that 
undergo gas-phase fragmentation for analysis via MS without previous digestion into peptides 
(Wehr 2006). For characterization, proteins are extracted from the sample which is followed by 
fractionation. The fractions are then analysed by MS/MS (Wehr 2006). This is typically done by 
electrospray ionisation where the multiple charging increases dissociation and identifies intact 
protein by comparing the masses of the original precursor and product ion with the protein sequence 
databases (Wehr 2006).  
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1.9.1 Mass Spectrometer 
Amongst the MS used are Liquid Chromatography – Mass Spectrometry (LC/MS) and Matrix 
Assisted Laser Desorption/Ionization (MALDI). 
1.9.2.1 LC/MS 
This technique consists of HPLC with MS. An interface is a particle beam that divides sample from 
solvent. It is needed to remove solvent and create gas phase ions. They are then transferred to optics 
of MS (Waters European Marketing n.d.). Majority of instruments have atmospheric pressure 
ionization (API) method in which removing the solvent and ionization are united in the source at 
atmospheric pressure (Waters European Marketing n.d.). There is also another type in which the 
step of solvent elimination and ionization are not together. This is known as electron impact 
ionization (EI). EI is useful in two major respects: when molecules do not undergo ionization with 
API and when electron impact spectrum is needed (Waters European Marketing n.d.). 
1.9.2.2 MALDI-TOF MS 
The sample is mixed with matrix; this is followed by the matrix absorbing the ultraviolet light. This 
results in conversion to heat energy. Some of the matrix is then heated rapidly and undergoes 
vapourisation with the sample as shown in Figure 1a overleaf. The next step is Time of Flight Mass 
Spectrometry (TOF MS) as shown in Figure 1b overleaf. There are different sizes of charged ions 
on sample slide. The variation in velocity between sample slide and ground will determine and 
attract the direction in which ions will travel. Lighter ions i.e those with smaller mass to charge 
ratios and those with highly charged ions shifts rapidly via the drift space until they reach detector 
(Shimadzu Corporation 2014). 
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Figure 1: An illustrated diagram of the principles of MALDI-TOF 
In (a) It illustrates the MALDI principle where the sample and the matrix is missed before laser 
irradiation. Some of the matrix undergo vaporization with the sample. In (b) It illustrates the TOF 
principle whereby the direction of where the irons will travel is dependent on the charge size. Lighter 
ions (small m/z ratio) and those with highly charged ions move quicker than heavy ions (big m/z ratio). 
(Shimadzu Corporation 2014). 
 
 
 
1.9.3 Advantages of proteomics 
Proteomic technologies accelerates biomarker discovery and will aid in the understanding of gene 
function as well as identifying peptides/proteins in their post-translational modification such as 
phosphorylation or glycosylation, protein-protein interactions and comparing protein levels with 
potential application in growth and disease (Adams 2008, Gauthier et al. 2013). It will also have a 
dramatic change in cancer research and care (Srinivas 2002).   
In particularly for bottom-up approaches, reversed-phase HPLC allows separation of peptides with 
solvents at high resolution. It has also allowed identification of proteins in complex mixtures such 
as cell lysates using capillary HPLC-MS-MS. In expression proteomics, staple isotope labeling and 
affinity tags have been developed in order to distinguish down-regulated and up-regulated proteins 
(Wehr 2006). 
a b 
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Stable isotope labeling is used in quantitative proteomics.  Oxygen-18, deuterium, nitrogen-15 and 
carbon-13 isotopes are commonly used. They are incorporated via two methods: post-metabolically 
in peptides and proteins or metabolically in cells. When labeled peptide ions segregate in mass 
spectrometer, their intensity values are used for quantification (Impens et al. 2008). 
In addition, top-down proteomics has advantages: enzymatic digestion of proteins is a time-
consuming process and is not needed in this approach. The complete protein sequence can be 
accessed (Wehr 2006). Thus, degradation products, sequence variants and a mixture of post-
translational modifications can be discovered (Doucette 2008, Flugge 1984).  
1.9.4 Limitations of proteomics 
There are limitations to the bottom-up approach such as partial characterization of different splice 
forms, endogenous protein cleavages and alternative modifications such as methylation and 
acetylation. Combinations of these forms can complex patterns of intact proteins isoforms (Kelleher 
et al. 2014). Another issue is high abundant peptides cause inadequate information about low 
abundant proteins (Wehr 2006). 
Furthermore, top-down approaches is a relatively new field compared to bottom-up method. 
Amongst the limitations are: they do not work effectively with intact proteins that are larger than 50 
kDa. Bioinformatic tools are primitive in contrast to bottom-up proteomics (Wehr 2006). Single-
nucleotide polymorphisms, post-translational modifications, disulphide bonds and cleavages can 
alter the precursor mass and influence the fragment ion spectra. In addition, multiple protein 
fragments and co-isolation are identified in a single spectrum (Kim 2003). 
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1.9.5 Sources of biomarkers for proteomics  
Previous attempts have been conducted to discover potential biomarkers using different sources 
(Bryan 2010). Amongst these are tissue samples which are not easily accessible and they having a 
heterogenous nature of cells (Hudler 2014). Thus for clinical diagnosis, it is better to use specimens 
that are minimally invasive, easily obtained, inexpensive and reproducible such as bodily fluids 
(Andersson et al. 2011).  However, one of the limitations for their use is their complexity (Hudler 
2014). For instance, blood has some highly abundant proteins such as albumin or globulin that can 
influence the detection of less abundant proteins (Andersson et al. 2011). Alternatively, urine has 
posed as a solution as abundant proteins presence is less than in serum and has direct contact with 
tumour (Bryan 2010). Cancer secretomes have shown to be a potential source for oncoproteomic 
use where cell lines and proximal fluids can be utilized that is easily accessible (Andersson et al. 
2011, Diamandis 2010b, Makridakis 2010). 
1.9.5.1 Secretomes 
Secretomes consists of secreted proteins that compromise 10% of human genome (Diamandis 
2010b). It mirrors the roles of cancer cells and consists of proteins that are secreted from cell 
surface and intracellular proteins that are released into supernatant due to cell lysis and apoptosis 
(Makridakis 2010).  They also include proteins shed from the cell membrane due to proteolytic 
cleavage such as growth factors and cytokines (Makridakis 2010). They play key roles in cell 
signalling, communication and migration (Makridakis 2010). They may represent putative 
biomarkers or therapeutic targets for diverse range of cancers particularly UBC and can be detected 
in urine (Diamandis 2010b). There are two prominent pathways in which proteins are released 
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extracellularly (Chung et al. 2013). An overview of protein secretion pathways need to be addressed 
to increase understanding of secretome analysis. 
1.9.5.1.1 Protein secretion pathways 
The classical secretory mechanism of protein synthesis and sorting compromises proteins that are 
synthesized by ribosomes contain an (endoplasmic reticulum) ER-signal peptide that associates with 
rough ER (Baltimore et al. 2000). Translation is completed in ER where new proteins are either 
integrated into transport vesicles that combine together to create cis-Golgi vesicles or they remain in 
the ER such as structural proteins or enzymes (Baltimore et al. 2000). The cis-Golgi cisterna 
converts to trans. Membrane-bound and luminal proteins undergo post-translation modifications 
such as associating with oligosaccharide chains (Baltimore et al. 2000). This is subsequently 
followed by another protein movement where some proteins move to the cell surface via small 
vesicles and undergo consistent secretion (Baltimore et al. 2000). Vesicles that bound to plasma 
membrane cause luminal protein release into the extracellular space (Nickel 2003). Other proteins 
travel to lysosomes and some remain in trans-Golgi cisternae (Baltimore et al. 2000).  
The absence of ER/Golgi system in exporting proteins is known as the non-classical secretory 
pathways. There are a number of different types illustrated in Figure 2. For instance, export can take 
place via integrating into vesicles such as Engrailed 2 (En2) and High-mobility group box 
1 (HMGB1). Another way is to transport proteins to extracellular space via translocation across 
plasma membrane as seen by Fibroblast growth factors (FGF) (Nickel 2003). In addition, it can also 
involve exosome synthesis which are labile vesicles formed at the cell surface via membrane 
blebbing. Proteins secreted through exosomes are released into extracellular space (Nickel 2003). 
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Tumour cells are in direct contact with the extracellular space. This allows them to progress via 
other hallmarks of cancer such as angiogenesis and metastasis where in order to facilitate the latter, 
extracellular matrix is degraded (Chung et al. 2013). These carcinogenic events are induced by key 
proteins secreted by tumour cells such as proteases, cytokines, chemokines, receptors and adhesion 
molecules (Chung et al. 2013). There is evidence that exosomes may play crucial roles in cancer 
development and progression (Blonder et al. 2009). In addition, tumour cells recruit stromal cells 
that also release secreted proteins. Thus, cancer secretomes consist of proteins that are secreted from 
secretory pathways in addition to proteins released by stromal cells and/or shedded from the cell 
surface that are potential candidate biomarkers (Chung et al. 2013) 
Figure 2 Classical and Non-classical protein secretion pathway (Nickel 2003) 
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1.9.5.1.2 Limitations of cancer secretome analysis 
Many studies conducted with secretomes have utilized conditioned medium (CM) of cultured 
cancer cell lines due to limitations of analysis of biological fluids (Chung et al. 2013). It is less 
complex which improves detection of less abundant proteins despite not representing the whole 
tumour microenvironment. However, secretome analysis also has its limitations. For instance, Fetal 
Bovine Serum (FBS) is added to the media and secreted proteins are covered by serum proteins. 
Secreted proteins are at low concentrations due to volumes of media utilized. Another challenge is 
contamination of intracellular proteins that occurs frequently during lysis (Chung et al. 2013). 
However, recent advances in proteomic technologies have led to improvements in resolution, 
sensitivity, and accuracy of mass spectrometry (Goodlett 2010). 
1.9.5.2 Disadvantages of biomarkers 
Many researchers have discovered potential candidate biomarkers to be used in routine clinical 
practice (Chan et al. 2013). Reasons why biomarkers fail to reach clinic is summarised in Figure 3. 
One of the confounding issues are growing costs of equipment, limited knowledge as to what is 
required for a clinical assay to be successful (Chan et al. 2013, Brentnall et al. 2012, Hudler 2014). 
Better bioinformatics is needed to process the large amount of data (Brentnall et al. 2012). 
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1.9.6 Potential biomarkers from previous studies 
1.9.6.1 HAI and Midkine 
Our group has previously published data on potential candidate biomarkers. Bryan et al. utilized 
shotgun proteomic approach combined with transcriptome analysis and discovered 10 biomarker 
candidates. This was based on the following approach: two microarray datasets compared 12-14 
normal bladders with 15 Ta UCBs. A 2.5 fold change and P<0.001 criteria was used to select 44 
genes upregulated in both data sets (Bryan et al. 2013a). This was then compared with protein list 
identified by two or more peptides in at least two of cell line secretomes. Two secreted proteins 
were then assessed for their potential in urine: Hepatocyte growth factor activator inhibitor type 1 
(HAI-1) and midkine as they were secreted. The membrane-linked ligand for NKG2D receptor, 
ULBP-2, was used as a control as it was identified in secretomes but not substantially elevated in 
microarray data. ULBP-2 levels are higher in malignant than normal cells. It is also shed by 
proteases (Bryan et al. 2013a). 
Figure 3: Summary of reasons for 
biomarker failure to reach the 
clinic. Apparent failures in 
diagnostics can be classified into 
three distinct categories as 
shown:Fraud, True Discovery and 
False Discovery (Diamandis 2012). 
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HAI-1 is a membrane-bound serine proteinase inhibitor that resides in epithelial cells.  An example 
of proteinases it inhibits is matriptase (Hamasuna et al. 2000). It is shed into the ECM and is 
involved in cancer progression (Bryan et al. 2013a).  
Midkine is an angiogenic growth factor and previous studies have shown it is up-regulated in UCB 
and is linked with late stages (Bryan et al. 2013a). 
Findings suggest that levels were higher in invasive disease and were too high to be explained by 
haematuria and were likely due to tumour secretion (Bryan et al. 2013a).  
1.9.6.2 Calreticulin 
Arai et al. identified calreticulin, an endoplasmic reticulum chaperone as well as other candidate 
biomarkers via proteomic analysis. They discovered it to be elevated in UBC and their reported 
sensitivity and specificity were 73% and 86% respectively. The same group later discovered a 
soluble isoform of catechol-o-methyltransferase (s-COMT) snf gamma -synuclein (SNCG) (Arai et 
al. 2004). They then combined all three biomarkers and measured it in urine. The overall sensitivity 
and specificity was 76.8% and 77.4% respectively which was higher than when calreticulin was 
measured alone and had 71.4% and 77.8% respectively. This further signifies how a panel of 
biomarkers will improve UBC diagnosis. 
The differences between our group study and Arai et al. is that our study utilized transciptome data 
combined with the proteomic data, whereas the latter utilized only the proteomic data. Amongst the 
advantages of using transcriptome data is it is publically available, lots of genome is included and 
the secreted proteins that are up-regulated do not incorporate as proteins in tissue and may have 
high mRNA levels instead (Bryan et al. 2013a).  
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In addition, Arai et al. evaluated the diagnostic capacity of a combination of biomarkers in a panel, 
whereas Bryan et al. were investigating potential biomarkers to be part of a panel of biomarkers. 
1.9.6.3 EpCAM 
Our group found several plasma membrane proteins via proteomic analysis whose extracellular 
domains have shown their potential as biomarkers. Extracellular domain of EpCAM that is cleaved 
by ADAM 17 kinase is being shed and also EGFR by UBC and can be potential prognostic 
biomarkers (Bryan et al. 2014). They discovered after measuring EpCAM in urine of UBC patients 
that levels increased with grade and stage. Thus, an increase of shedding of EpCAM and other 
cancer-associated proteins may be a source for biomarker discovery and may promote cell 
proliferation (Bryan et al. 2014).  
1.9.6.4 Engrailed-2 
Engrailed-2 (EN2) transcription factor protein is another potential biomarker that has been 
discovered by our group. It has an overall sensitivity of 82% and specificity of 75% in patients with 
NMIBC (Bryan et al. 2013c). Thus EN2 is a potential biomarker with higher sensitivity and 
specificity than current tests. 
Ultimately, the proteomic approach, metabolomics, next-generation sequencing or a combination 
can will improve urine biomarker discovery and provide multi-marker urine test to detect bladder 
cancer and aid in therapeutic strategies (Goodlett 2010). Nevertheless, compared to other 
malignancies, bladder cancer research is significantly underfunded; hindering progress in improving 
diagnosis and therapeutics for patients with the disease (Bryan 2010).  
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2.0 Aims 
 To use proteomic analysis of UBC cell lines secretomes to discover candidate urinary 
biomarkers for UBC. This can be achieved by identifying and focusing on proteins shedded 
from the surface of in vitro cultured UBC cells: 
A) ‘Whole’ secretomes ± PMA. 
Hypothesis: phorbol 12-myristate 13-acetate (PMA) is a PKC activator that stimulates secretion and 
shedding. It was used to treat whole secretomes and investigate all proteins released by cells 
(secreted and shedded proteins). Up-regulated proteins emphasises regulated release. 
B) Ultracentrifugation of ± PMA secretomes 
Hypothesis: After ultracentrifugation, vesicles/membranes are removed and any integral membrane 
proteins left must be shed extracellular domains. The proteolytic cleavage of the extracellular 
domains of membranes is known as ectodomain shedding. The focus will be on shedded proteins. 
C) Ultracentrifuged secretomes ± Marimastat.   
Hypothesis: Proteases that induce shedding are known as ‘sheddases’. There are two types: a 
distegrin and metalloproteinase (ADAMs) and matrix metalloproteases (MMPs) that has potency 
against majority of MMPs. Marimastat, a broad spectrum metalloprotease inhibitor was utilized that 
covalently associates with the zinc atom at the active site of MMPs and inhibits these sheddases. 
Therefore, Marimastat can be used to confirm protease-based shedding. 
D) ADAM17 siRNA to specifically inhibit this ‘sheddase’ 
Hypothesis: There is evidence that ADAM17 induces proteolytic cleavage via its extracellular site. 
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 To measure one of the potential candidate biomarkers in bladder cancer patients’ urine 
samples to make initial estimates of sensitivity and specificity. 
3.0-Materials and Methods 
3.1 Cell lines 
A summary of bladder cell lines 8 UBC + one normal urothelium cell line were utilized in this study 
and are summarised in Table 2. HB-CLS-2 and 5637 were acquired from Cell Lines Service (CLS) 
GmbH (Eppelheim Germany). UROTsa was given as a kind gift from one of the members in the 
BCPP programme. The remaining cell lines were from Leeds from Professor Margaret Knowles.   
Table 2: A Range of bladder cell lines used in the project representing different stages of Bladder cancer 
presenting a range of different grades profiles.  
Name of bladder 
cell line  
 Description  
RT4  Transitional papillary tumour clinical stage T2, histological grade G1.  
UROtsa  Isolated from normal human urothelium through immortalization with a 
construct containing the SV40 large T antigen.  
5637  Derived from primary bladder carcinoma grade II.  
RTII2M  Transitional cell carcinoma (histological grade G2)  
VMCUB  Transitional cell carcinoma.  
T24  Transitional cell carcinoma; grade III  
MGH-U3  Transitional cell carcinoma grade I  
HB-CLS-2  Derived from primary bladder carcinoma grading III 
SW780  Derived from grade I papillary transitional cell carcinoma  
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3.2 Chemicals and Inhibitors 
To stimulate cells in culture, PMA was diluted to a final concentration of 2mM. Marimastat was 
diluted to a concentration of 5µM. Both are from Sigma-Aldrich (Dorset UK).  
3.3 Tissue Culture 
All cell lines were maintained according to the distributors' instructions. HB-CLS-2, 5637, RT112M 
and UROTsa were grown in RPMI-1640 media and 10% Fetal Calf Serum (FCS). SW780, T24 and 
VMCUB were grown in Dulbecco’s Modified Eagle Medium (DMEM) and 10% FCS. RT4 was 
grown in McCoy’s 5A Modified Medium and 10% FCS. MGH-U3 was grown in DMEM 
supplemenented with10% FCS and 1% amino acids. The mediums excluding McCoy’s 5A medium 
were purchased from Sigma Aldrich (Dorset, UK). McCoy’s 5A medium was purchased from (Life 
Technologies, Paisley, UK). 
3.4 Harvesting of secretomes from cancer cell lines 
Cells were grown to 80% confluence in T75cm2 Corning Cell Culture vessels (Sigma Aldrich, 
Dorset, UK) in a 370C/5% CO2 RS Biotech Galaxy R incubator (C & M Scientific, West Lothian, 
UK). They were then washed four times with 10ml of relevant serum-free media per flask and 
incubated with for 18 hours with 6mL of relevant serum-free media per flask under several 
conditions (control, PMA, Marimastat, both PMA and Marimastat). The conditioned media were 
then spun down at 3.300 x g for 20 minutes utilizing Megafuges 2.0 R Universal Centrifuges 
(Heraeus, Hanau, Germany). They were then collected and concentrated using a 3kDa MWCO 
Millipore Amicon Ultra (Millipore, Darmstadt, Germany), spinning down at 3.300 x g until the final 
volume was 1ml.  
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For membrane fragment removal, 500µl of secretome was centrifuged at 136,000 x g for 90 minutes 
in a Beckman Optima Max instrument with TLASS rotor (Beckman Coulter, High Wycombe, UK). 
The supernatant were transferred to new tubes.  
3.5 Trypsin Digestion 
Proteins were prepared by the Filter-aided sample preparation (FASP) method based upon previous 
studies performed by our group (Wisniewski et al. 2009). The disulfide bridges in the  
proteins were reduced by 50mm DTT (Sigma-Aldrich, Dorset, UK). 2% CHAPs detergent 
(Melford, Suffolk, UK) was also added. Protein-detergent complexes and micelles were separated in 
8M Urea presence (Sigma-Aldrich, Dorset, UK) (Wisniewski et al. 2009). They were left for an 
hour before being alkylated with 100mM iodoacetamide (Sigma-Aldrich, Dorset, UK) at room 
temperature for 30 min.  
30kDa MWCO Centrifugal filter units (Sigma Aldrich, Dorset, UK) were subsequently washed 
several times in 100mM Tetraethylammonium bromide (TEAB) buffer before use (Flaker analytical 
#17902). After reduction and alkylation, proteins were added to filters and had several washings 
with TEAB. Utrafiltration was assisted  by centrifugation to remove the DTT, CHAPs, 
iodacetamide and low molecular weight proteins and other components (Wisniewski et al. 2009). 
The protein suspension is digested with sequencing grade modified porcine trypsin (20 mg/mL; 
Promega, Madison, USA). The subsequent peptides are assembled as a filtrate and transferred to 
eppendorf tubes whilst molecules with high molecular weight including trypsin remain on the filter. 
3.6 Protein Quantification 
Protein quantification was based upon stable isotope labelling by peptide demethylation was 
conducted using formaladehyde reagent that labels the N-terminus and ε-amino group of the 
essential α-amino acid Lysine via reductive amination. The control secretome (no PMA) was 
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labelled ‘light’ 12CH2-formaldehyde (light) whereas the experimental sample (PMA-treated 
secretome) underwent a ‘heavy’ labelling.  This was a similar case to Marimastat to identify 
regulated proteins. Peptides were extracted with ACN containing 0.1% TFA v/v via Discovery 
HPLC and SPE C18 cartridges (Sigma Aldrich, Dorset, UK). 
 3.7 MS analysis  
Digests were checked by MALDI-TOF for any presence of peptides (Bruker Daltonics II). This is 
followed with drying under ScanVac SpeedVac vacuum (LaboGenes) followed by adding 110µl of 
Mix mode A into the HPLC tubes and then seperated into 30 fractions  by mixed mode anion 
exchange/reverse-phase HPLC (Ultimate 3000) with a temperature of 250C, 100ul min and inject 
volume of 100µl.  The HPLC spectra programme was called Hystar software Version 3.2. They 
were then spotted on MALDI plate polished steel, 1µl of sample followed by 1µl of matrix α-
Cyano-4-hydroxycinnamic acid (CHCA). They were then dried and dissolved in 0.1% formic acid 
and analysed by LC-MS/MS using a 90 min 0-40% acetonitrile gradient (75µm x 25cm C18 
Pepmap column, Dionex) and Maxis impact mass spectrometer (Bruker Daltonic, Bremen, 
Germany). 
3.8 Peptide Identification. 
Peptides were identified using MASCOT 2.3 to investigate a custom database containing 
SWISSPROT human and bovine sequences and randomised versions thereof (Bovine sequences 
were included as the secretomes will inevitably contain traces of FCS) (Bryan et al. 2013). Mass 
tolerances for parent and fragment ions were 20 ppm and 0.05 Da  respectively and the minimum 
peptide Mowse score was 5. Protein identifications were filtered using both a 1% false discovery 
threshold and a requirement for two or more peptides using Proteinscape 2.1 software.  
 
P a g e  | 38 
 
3.9 Bioinformatics and Proteomic analysis 
Subcellular localizations and categorization of protein function were determined by gene ontology 
tools String software (www.stringdp.org) and Panther software (www.pantherdp.org).  
To select candidate biomarkers, proteomic data were compared with human protein atlas IHC 
(www.proteinatlas.org) data and Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood 
City, CA www.ingenuity.com) analysis. Both methods were conducted based upon previous studies. 
3.9.1 IPA analysis  
Karsani et al. determined cancer-associated proteins by comparing the proteome oral cancer cell 
lines with normal cell lines via two-dimensional gel electrophoresis. MALDI TOF/TOF was then 
utilized to reveal the identity of these proteins that were then classified based on function. IPA core 
analysis was used to determine which proteins were related to cancer development and progression.  
Another study was conducted on lung cancer using IPA analysis (Chen et al. 2012). Atri et al. 
compared renal cell carcinoma with normal renal tissues using label free proteomics. They 
conducted a pathway analysis using IPA software and discovered many cancer-associated processes 
such as glycolysis and oxidative phosphorylation. 
Thus this selection method will be used to look at the cancer associated proteins and use IPA-
Biomarker in which filters was used where it can provide potential biomarker candidates. 
3.9.2 HPA analysis 
Previous studies such as Chen et al. used a scoring method to discover candidate biomarkers by 
quantifying cancer/normal cells and cancer/normal tissues. 
Thus, I will be looking at proteins that have been up-regulated by PMA by two-fold and down-
regulated by Marimastat by half-fold. Further investigations will be conducted by looking at 
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proteins that are observed at high grade (T24, HB-CLS-2, SW780, RT112M and 5637) and not low-
grade (RT4, MGH-U3 and VMCUB).  
3.10 Western blot analysis 
This was used to confirm the expression of EpCAM and ADAM17. For EpCAM, an EpEX antibody 
was used to present the extracellular domain of EpCAM. The protein concentration of cell lysates 
was determined by Pierce BCA Protein Assay (Thermo Fisher Scientific, Rockford, USA). Equal 
amounts of protein were then boiled in SDS-PAGE sample loading buffer containing 50 mM DTT, 
loaded and run on 4-12% NuPAGE gels (Thermo Fisher Scientific, Paiseley, UK). After gel 
electrophoresis, the resolved proteins were blotted transferred onto PVDF membranes 
(Millipore, Darmstadt, Germany). These were blocked with 1% dry milk in TBS. Membranes were 
then incubated overnight at 4 °C with the following primary antibody: anti-EpCAM antibody 
(BAF960; R&D Systems Europe Ltd). Blots were washed three times with TBST before the 
horseradish peroxidase-conjugated secondary antibodies. After three supplementary washes, blots 
were developed using ECL reagents (GE Healthcare). The blot was visualized with SRX-101A 
photon imaging systems (Konica Minolta).  
For detection of ADAM17 in UBC cell lysates, we used Human TACE/ADAM17 Ectodomain 
Antibody (R&D Systems).  
3.11 Knockdown of ADAM proteases by siRNA 
ADAM17 were knocked down by RNA interference. Three different concentrations were utilized 0, 
25, 50nM of siRNA in Darmafect transfection reagent. Three cell lines were utilized RT112M, 
HBCLS2, and 5637. Detection of ADAM17 protein was performed by Western blotting and its 
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effect on EpCAM shedding was investigated by ELISA. siRNA used was Human Adam17 (Thermo 
Scientific, #M-003453-01) 
3.12 ELISA 
All ELISAs of EpCAM, MMP1 were performed according to the manufacturer’s instructions. 
Calibration curves were prepared using purified standards for the protein assessed using 2-fold 
dilutions of 1ng ml-1 standard for borh. Calibration curves were then plotted.  
For MMP1 ELISA (DY901; R&D Systems Europe Ltd, Abingdon, UK), 20µl of PMA-treated 
secretomes was added whilst secretomes in other conditions 100µl was added. Absorbances at 450 
nm of each aliquot were determined using the microplate reader.  
Alternatively, for EpCAM ELISA utilised human EpCAM   (DY960; R&D Systems Europe Ltd, 
Abingdon, UK). To each well of the assay were added 100µl of sample and 50 ml of PBS+ 1% 
BSA. The absorbance at 595 nm of each aliquot was determined using the microplate reader. This 
was performed to measure the levels of EpCAM in bladder cell secretomes and to investigate the 
effect of PMA and Marimastat on its release. 
3.13  Wound healing assays 
1ml of cell suspension with trypsin was added per well of 12 well plate. They were left to grow 
overnight and checked in morning under microscope for confluency. A black marker pen was 
placed to visualised the scratch of a 20µl pipette tip creating a wound. Q imaging (Rolera-XR Nikon 
eclipse) camera was used photographing images at 0, 5 and 20 hours. Wound closure was 
determined as the percentage of wound closure compared to respective negative control (regarded as 
100%). Each experiment was performed in triplicate. 
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3.14 MTT assays  
Cells were incubated in complete medium on 96 well plate for 24 hours. Once confluent, conditions 
were added where they undergo incubation overnight and then the subsequent MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) reagent (Sigma Aldrich, Dorset, UK) is 
added to each well where a 3 hour incubation before reading it on plate reader. The absorbance at 
595 nm of each aliquot was determined using the microplate reader.  
The principle of this method is that MTT is converted into formazan crystals by living cells (Cloos 
2011). This determines the mitochondrial activity that is linked to the quantity of viable cells. The 
MTT assay measures in vitro cytotoxic effects of drugs on cell lines (Cloos 2011). In relation to this 
study, this is performed to see how PMA and Marimastat influences influences cell viability. 
3.15 Patient population and clinical specimens 
Urine samples was collected as part of the Bladder Cancer Prognosis Programme (BCPP) between 
2006 and 2009 (Billingham et al. 2009). Subjects were enrolled based upon initial findings 
suggestive of primary UCB. Before use, urine samples were defrosted at room temperature and 
vortexed using Fisons Whirli mixer. There were also non-cancer controls that consists of patients 
with non-UCB conditions. Information on the patients are summarised in Table 3. A total of 348 
patient samples were investigated that vary in age, gender and grade (323 UBC, 25 non-cancer 
controls). 
3.16 Biomarker validation 
50µl of urine samples was added with 50µl of PBS+1%BSA for MMP-1 ELISA (DY901; R&D 
Systems Europe Ltd, Abingdon, UK). The absorbance at 450 nm of each aliquot was determined 
using the microplate reader. 
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3.17 Data analysis:  
Averages were calculated for all data conducted. For MTT assays, student T-tests were calculated 
and a p-value < 0.05 was considered significant. Error bars were calculated based on standard 
deviation. Mann-Whitney test was performed to compare the different grades and stages. ROC 
analysis was performed on MMP1 concentration for specificity and sensitivity. The area under the 
ROC curve; (AUC) was calculated as a single measure for the discriminative efficacy of candidate 
marker.  
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4.0 Results 
4.1 Comprehensive proteomic analysis of whole bladder cell line secretomes  
One of the ways to investigate and identify proteins shedded from the surface of in vitro cultured 
bladder cancer cells was via Phorbol 12-myristate 13-acetate (PMA) that stimulates shedding. 
Whole secretomes was utilized to investigate all proteins (shedded and secreted) released by the 
cells.  
In total, 2242 human proteins were identified in one or more of the 9 PMA-treated bladder cell line 
secretomes (UROTsa, HB-CLS-2, T24, RT4, VMCUB, SW780, RT112M, 5637, MGUH-3) where 
2075 human proteins had two or more peptides. There was considerable overlap between the 
secretomes with 1122 proteins being identified in at least two out 9 secretomes and 137 were 
detected in all 9 secretomes. The 137 proteins are shown in Appendix A where their cellular 
location, molecular functions and cellular function is summarised using Panther database 
(http://www.pantherdb.org/). 
4.1.1 The effect of PMA on whole secretomes’ localisation 
Proteomic analysis has been conducted to determine what types of secreted proteins have been 
released and identified by mass-spectrometry and whether the locations of these proteins vary across 
the grades and the normal urothelium. Identified proteins were divided into categories based upon 
cellular location using the GO Cellular Components function in STRING 9.0 (www.string-db.org). 
They were distributed in the nucleus, plasma membrane, cytoplasm and extracellular space. 
The secretomes were substantially enriched with extracellular proteins compared with the 
corresponding other cell compartments (nucleus, cytoplasm, plasma membrane). This was 
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consistent throughout the 9 whole secretomes regardless of normal urothelium and different grades. 
Therefore, due to this regular pattern, only three of the 9 secretomes have been presented at Figure 
4: UROTsa; VMCUB (TCC) and HB-CLS-2 (Grade III) to provide an example of the proportion of 
proteins in repartition of each subcellular location. UROTsa (36%), VMCUB (33%) and HB-CLS-2 
(47%) accounts for extracellular proteins. There were more plasma membrane-bound proteins in 
UROTsa than UBC secretomes. In addition, more cytoplasmic proteins are present in VMCUB than 
the higher grade HB-CLS-2 and normal UROTSA.  
Figure 4: Cellular locations of the differentially expressed proteins in UROTsa (normal), VMCUB 
(TCC) and HB-CLS-2 (Grade III) PMA-treated whole secretomes identified by the proteomics 
approach. For UROTSA (extracellular =379 proteins, plasma membrane=202 proteins, cytoplasm=255 
proteins, nucleus=217 proteins). For VMCUB (extracellular=363 proteins, plasma membrane=182 
proteins, cytoplasm=337 proteins, nucleus=205 proteins). For HB-CLS-2 (extracellular=320 proteins, 
plasma membrane=103 proteins, cytoplasm=160 proteins, nucleus=102 proteins)  
       
 
 
 
normal Transitional cell carcinoma Grade III 
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4.1.2 The effect of PMA on whole secretomes’ biological processes. 
The biological function was conducted to see whether it varies across the normal and UBC 
secretomes.  They were determined using STRING 9.0 (www.string-db.org). They correspond to 
eight cellular protein groups, including metabolism-associated proteins, cytoskeleton-associated 
proteins, protein-folding, and translation, modification, apoptosis, proliferation and signal 
transduction. The results were consistent throughout the secretomes were the predominant function 
was metabolism. Thus, like Figure 4, only three secretomes were presented to show how regardless 
of normal/cancer and different grades, the predominant biological function was metabolism. HB-
CLS-2 (Grade 3) had more proteins associated with the role than VMCUB (TCC) and UROTsa 
(normal) as shown in Figure 3B. However, there were a small proportion of proteins found in HB-
CLS-2 (Grade 3) that are involved in proliferation compared to other secretomes. More proteins had 
an apoptotic and cytoskeletal functions in UROTsa (normal) than UBC cell lines. Thus 
differentially expressed proteins mainly located in extracellular and have a role in metabolism 
regardless of grade.  
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Figure 5: Biological processes of the differentially expressed proteins in UROTsa (normal), VMCUB 
(TCC) and HB-CLS-2 (Grade III) PMA-treated whole secretomes identified by the proteomics For 
UROTSA (metabolism=0 proteins, protein folding =92 proteins, translation = 44 proteins, 
Modification=14 proteins, proliferation=41 proteins,apoptosis=42 proteins,signal transduction=12 
proteins, cytoskeleton=4 proteins). For VMCUB proteins’ (metabolism=189 proteins, protein 
folding=82 proteins, translation=24 proteins, modification =118 proteins, proliferation=115 proteins, 
apoptosis=19 proteins, signal transduction=127 proteins, cytoskeleton=22 proteins). For HB-CLS-2 
proteins’(metabolism=144 proteins, protein folding=28 proteins, translation=22 
proteins,modification=21 proteins, proliferation=11 proteins, apoptosis=3 proteins,signal 
transduction=21 proteins, cytoskeleton=2 proteins). 
 
 
 
 
normal Transitional cell carcinoma Grade III 
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4.1.3 Cluster analysis of PMA data 
A cluster analysis was conducted on the PMA data to investigate how similar the data is from one 
cell line to the other. The most similar ones are clustered together and are shown as a ‘heatmap’ 
[data not shown]. It shows that the high grade and low grade were clustered separately.  118 
proteins p<0.05 were between low and high grade.  UROTsa (normal) clustered with high grade cell 
lines. This suggests that the expression of these proteins changes as the disease progresses.  In 
addition, UROTsa may not be a reliable model of normal urothelium. 
4.1.4 Proteins up-regulated by PMA 
Up-regulated proteins emphasises regulated release. Those up-regulated by PMA are shown in 
Appendix B by two-fold. Up-regulated proteins were enriched for plasma membrane and 
extracellular secreted proteins. To identify proteins that have been up-regulated, quantitative 
proteomics was utilized where stable heavy isotope labelling using formaladehyde reagent labels the 
N-terminus and ε-amino group of the essential α-amino acid Lysine via reductive amination (Chen 
et al. 2003). The control secretome (no PMA) was labelled ‘light’ 12CH2-formaldehyde (light) 
whereas the experimental sample (PMA-treated secretome) underwent a ‘heavy’ labelling.  They 
were then vortexed together followed by an addition of sodium cyanoborohydride. Labelling was 
performed post-tryptic digestion and to ensure labelling has worked, it is detected on analysis of 
MALDI and LC/ESI-MS/MS (Chen et al. 2003). This labelling strategy is not influenced by peptide 
traits rather it focuses on mass (Demmers 2012). At the same retention time, the ‘heavy’ and ‘light’  
peptides elute together from LC column and heavy leads to mass shift in mass spectrum the m/z 
value allowing peak isotopic pairs to be observed. Each peaks vary by 4 mass units that consists of 
one ‘heavy’ and one ‘light’ (Demmers 2012).  
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Table 3. A summary of the number of proteins that have been up-regulated and down-regulated by PMA 
across the 9 bladder cell lines Up-regulated proteins were identified by having a normalised median 
(H/L) ratio of >2 (increased by two-fold) whereas those that have been down-regulated were identified 
by having half fold <0.5.  All appear to have more up-regulated proteins than down-regulated with the 
exception of HB-CLS-2 (Grade 3). 
Name of cell line Total number of 
identified proteins 
Total number of 
proteins upregulated 
by PMA 
Total number of 
proteins 
downregulated by 
PMA 
UROTsa (normal) 1008 173 69 
HB-CLS-2 (Grade 3) 581 39 59 
VMCUB (TCC) 712 98 53 
5637 (Grade 2) 1062 102 32 
RT112M (Grade 2) 671 177 152 
SW780 (Grade 1) 1280 100 59 
T24 (Grade 3) 654 57 35 
RT4 (Grade 1) 1161 101 37 
MGUH-3 (Grade 1) 814 51 43 
 
4.1.5 Up-regulation of MMP-1 by PMA 
MMP-1 is amongst the proteins upregulated by PMA. It is an interstitial collagenease that targets 
type I, II and III (National Center for Biotechnology Information 2014). Figure 6 illustrates the MS 
and MS/MS spectra of MMP-. It is up-regulated by PMA in 7 out of 9 cell line secretomes this 
includes normal and UBC secretomes as shown in Table 4.  
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Figure 6. The identification of MMP-1 by MS/MS in dimethyl-labelled UROTsa whole secretome.  
(a) The chromatogram of one HPLC fraction of demethyl-labelled UROTsa (normal) PMA secretome 
where retention time (minutes) plotted against intensity (%), (b) a light peptide of MMP-1  that has a 
relative intensity of 10
-5
, (c) a heavy peptide of MMP-1 that has a relative intensity of 10
-6
. Fractions are 
then analysed by MS where peptides undergo ionization and the mass-to-charge (m/z) ratio is measured 
to yield a precursor ion spectrum shown in (d) Precursor ion spectrum. Selected ions are then 
fragmented by collision-induced dissociation (CID) and the individual fragment ions measured by MS. 
(e) fragment ion spectra (MS/MS) of MMP-1 light and (f) fragment ion spectra (MS/MS) of MMP-1 
heavy. (e) and (f) are continued overleaf. 
 
 
d 
c 
b 
a 
intensity 
m/z 
P a g e  | 50 
 
 
Table 4. The heavy-light (H/L) peptide ratios of MMP-1 in bladder cell secretomes measured by 
LC/MS/MS. UROTsa is a normal urothelium secretome; the rest are UBC secretomes. MMP-1 is 
upregulated in normal and UBC secretomes except for MGH-U3 (Grade 1) and HB-CLS-2 (Grade 3). 
Name of 
PMA-
treated 
secretome 
UROTsa 
(normal) 
MGH-U3 
(Grade 1) 
RT4 
(Grade 1 
SW780 
(Grade 
1) 
RT112M 
(Grade 2 
VMCUB 
(TCC) 
5637 
(Grade 
2) 
T24 
(Grade 
3) 
HB-CLS-2 
(Grade 3) 
(H/L) ratio 19.6  Absent 5.4 21.8 12.8 
 
5.47 11.9 
 
25.4 Absent 
 
 
 
 
 
 
 
 
e 
intensity 
m/z 
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4.1.5.1 PMA stimulate MMP-1 secretion in bladder cell secretomes 
In response to the MS finding, an ELISA experiment was performed to investigate whether PMA 
stimulates MMP-1 secretion in bladder cell secretomes via PKC activation. The outcomes of the 
ELISA are illustrated in Figure 7. Results portrayed that MMP-1 concentration in whole secretomes 
is significantly elevated in presence of PMA than alone. This confirms what is already known that 
MMP-1 is secreted membrane-associated zinc endopeptidases localized in the ECM rather than 
membrane-bound similar to that of MMP-8 and MMP-13 that cleave interstitial fibrillar collagen 
(Acharya et al. 2006, Weizmann Institute of Science 2014).  
Figure 7: Protein levels of MMP-1 in whole bladder cell secretomes. 20µl of PMA-treated secretomes 
whilst for control 100µl was added. Absorbances at 450 nm of each aliquot were determined using the 
microplate reader. PMA induces MMP-1 secretion and this is apparent across all 9 bladder cell 
secretomes. Error bars were plotted based with standard deviation of the data obtained. 
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4.2.The effect of ultracentrifugation on plasma membrane protein release in PMA-treated 
secretomes. 
In order to understand the role of plasma membrane in biological processes, the plasma membrane 
proteome needs to be investigated. A change in membrane proteins is amongst the initial events that 
occur during pathological conditions (Hixson 2011). Thus, plasma membrane proteins are a useful 
source to discover potential biomarkers for diagnosis and prognosis. They are also useful as they 
can be target for drugs and monoclonal antibodies to inhibit enzymes and/or evade receptors 
necessary for cancer progression (Hixon 2011). Previous studies looked at locations and the types of 
membrane proteins present. In addition, our group have discovered that extracellular domains of 
EpCAM are shed into the conditioned media whereby membrane-bound EpCAM is released into 
cytoplasm.  
To test this hypothesis, ultracentrifugation took place on VMCUB (TCC) and 5637 (Grade II) 
PMA-treated secretomes to identify potential target proteins, those proteins that are still membrane-
bound after ultracentrifugation could be potential biomarkers. There were 712 and 1062 proteins 
identified in VMCUB (TCC) and 5637 (Grade II) PMA-treated secretomes respectively whereas for 
supernatants more proteins were identified where 920 and 1251 proteins were identified in VMCUB 
(TCC) and 5637 (Grade II) respectively.  
4.2.1 The presence of plasma membrane bound proteins after ultracentrifugation 
The cellular locations of the proteins in VMCUB (TCC) and 5637 (Grade II) were determined using 
STRING 9.0 (www.string-db.org) and are shown in Figure 8. Findings suggest that there were still 
plasma membrane bound proteins released into the cytoplasm after ultra-centrifugation. There is 
also a slight reduction in the number of proteins located in extracellular space and nucleus. 173 
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proteins were assigned as membrane proteins in VMCUB (TCC) supernatants whereas 141 proteins 
were assigned as membrane proteins in 5637 (Grade II) supernatants.  
Figure 8: Sorting of the identified proteins according to their subcellular localization.  
A) 5637 Whole secretomes (extracellular=157,plasma membrane=251,cytosol=471,nucleus=274)  
B) 5637 supernatants (extracellular=105,plasma 
membrane=114,cytoplasm=775,cytoplasm=775,nucleus=268) 
C) VMCUB Whole secretomes (extracellular=363, plasma membrane=182,cytosol=337,nucleus=205) 
D) VMCUB Supernatants (extracellular=369, plasma membrane=173, cytosol=230,nucleus=133) 
 
 Extracellular               plasma membrane              cytosol               nucleus  
 
        
8%
11%
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4.2.2 Types of Membrane Proteins 
There are different types of membrane proteins that can be divided into basement membrane, 
integral membrane proteins and membrane-associated proteins as presented in Figure 9. Basement 
membrane proteoglycans are not only involved as structural components but also have a role in 
regulating several signalling pathways (Iozzo 2005). They engage in angiogenesis thus play a role in 
cancer progression (Iozzo 2005). Integral membrane proteins have two regions: hydrophilic and 
hydrophobic. It also has two domains: intracellular and extracellular (Srivastava n.d.). Integral 
membrane proteins have roles in many biological processes that include transport, pathogen 
invasion and cell signalling (Baldwin et al. 2010). 
 
The different types of membrane proteins found in 5637 (Grade II) and VMCUB (TCC) with and 
without ultracentrifugation are shown in Figure 9.They were determined using STRING 9.0 
(www.string-db.org). Findings have identified many membrane-associated proteins such as 
extracellular proteins. Large amount of ‘integral to membrane’ were discovered prior ultra 
centrifugation. However, after ultracentrifugation, there was a reduction in the ‘integral to 
membrane’ proteins and an increase in other membrane-associated proteins. Amongst the integral 
membranes found in both secretomes are: DSG2, EXT2, FAT1, GOLM1 and ILF3. In addition, 
there was a small amount of basement membrane proteins covered in both UBC secretomes. 
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Figure 9: Sorting of the identified proteins according to types of membrane proteins found in 5637 
(Grade II) and VMCUB (TCC) whole secretomes and supernatants.  
A) 5637 whole secretomes (basement membrane=18 proteins, integral to membrane=136 proteins, 
other membrane proteins=76 proteins) 
B) 5637 Supernatant (basement membrane=10 proteins, integral to membrane=112 proteins, other 
membrane proteins=115 proteins) 
C) VMCUB whole secretomes (basement membrane=6 proteins, integral to membrane=74 proteins, 
other membrane proteins=99 proteins) 
D) VMCUB Supernatants (basement membrane=3 proteins, integral to membrane=16 proteins, 
other membrane proteins=35 proteins) 
 
Basement membrane        ,            Integral to membrane                     Other membrane proteins   
                                   
                                         
 
 
A B 
C D 
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4.3 Ectodomain shedding of bladder cell lines. 
4.3.1 Comprehensive proteomic analysis of ultracentrifuged bladder cell line secretomes  
The 9 bladder cell secretomes underwent ultra-centrifugation to focus on shedded proteins. 
Marimastat; a broad spectrum MMP inhibitor inhibits the sheddases responsible for the shedding 
and was used to examine whether plasma membrane protein ectodomain were released by 
proteolytic cleavage. 1879 proteins were identified. 775 proteins identified in at least 3 UBC cell 
lines including 63 integral membrane proteins. There were no presence of ADAMs and MMPs 
except for MMP-10 that was down regulated. This was due to inhibitory effect of Marimastat. 
Similar to PMA proteomic analysis results; proteins were found predominately in the extracellular 
location and of a metabolic role and was consistent across all bladder cell secretomes. Appendix C 
summarises the proteins that have been down-regulated by Marimastat. 
Furthermore, there was a biphasic effect on transmembrane proteins.  Release of 40% was inhibited 
by Marimastat and 60% were not affected. This suggests that only some of the proteins are released 
by proteases that are inhibited by Marimastat. 
4.3.2 Cluster analysis of Marimastat proteomic data 
Results show several significant differences between low and high grade. Samples did not cluster, 
fewer proteins were identified and the data was more variable. Possible reasons for this include 
spanning of some proteins down that is partly due to Marimastat and partly due to lack of PMA, and 
also ultracentrifugation.  Other reasons include experiments (digestions, mass spectrometry) that did 
not seem to be working as well later. Therefore, if there is less data and it is more variable then 
differences between the cell lines may not be detected. 
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4.4 EpCAM Biology 
Previous published data from our group portrayed that EpCAM is one of the potential biomarkers of 
UBC. As its ectodomain is released, it can be used to confirm the effect of Marimastat as previous 
reports have implied that Marimastat inhibits ‘sheddases’ called ADAMs which are a family of 
metalloproteases that is responsible for proteolytic cleavage of ErbB ligands (Vaddi et al. 2007). At 
the same time, to investigate the effect of PMA on EpCAM release and what occurs in a 
combination of both PMA and Marimastat.  
4.4.1 Expression of EpCAM in cell lysates 
The abundance of EpCAM in bladder cell lines was investigated using cell lysates via Western blots 
as shown in Figure 11. An attempt has been done using secretomes [data not shown] but the results 
suggested that Western Blots was not sensitive enough to detect EpCAM in the secretomes which is 
why cell lysates were utilized. An EpEX antibody was used to present the extracellular domain of 
EpCAM. Results are consistent with studies that observed EpCAM between 30-40 kDa. UROTsa 
and T24 are EpCAM-negative. There is more abundance of EpCAM in HB-CLS-2, RT4, SW780, 
VMCUB, RT112M. There is lower abundance of EpCAM apparent in MGUH and 5637. 
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Figure 10: EpCAM presence in cell lysates a) Western blot on cell lysates (b) coomassie blue gel. 6µl 
protein marker and 15µl sample buffer and sample. EpECD runs about 30kDa and ICD runs about 
5kDa. EpCAM can be seen between bands 28 and 38kDa.  If EpCAM is glycosylated, it moves forward 
to the gel (33kDa). Cell lysates were loaded in the following order in both cases. 
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4.4.2 The effect of Marimastat on EpCAM shedding  
Although EpCAM was not identified by enough peptides to make it into the proteomic dataset., the 
ELISA data showed that Marimastat inhibits EpCAM release – this can be used to justify 5µM as 
the working concentration. Initially, a range of different concentrations of Marimastat was 
investigated to determine the concentration that shows the most inhibitory effect on EpCAM release 
using SW780 ultracentrifuged secretomes as shown in Figure 11. Findings suggests that 5µM is 
shows more inhibitory effect than other concentrations. Thus 5µM Marimastat was conducted for 
the rest of the secretomes.  
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Figure      :The effect of PMA and Marimastat on SW780 
supernatants
 
 
 
Figure 11: The effect of PMA and different concentrations of Marimastat on EpCAM shedding of 
SW780 supernatants. Sw780 is a Grade 1 bladder cell line. A combination of PMA and Marimastat 
shows some inhibitory release of EpCAM compared to PMA. Marimastat shows more inhibitory effect 
alone at 5µM than combined. PMA does not seem to induce EpCAM release much here. Error bars were 
plotted based upon standard deviation. 
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4.4.2.1 Marimastat inhibits EpCAM shedding in all bladder cell secretomes 
According to the ELISA results shown in Figure 12, there is higher EpCAM levels detected in RT4. 
This is consistent with results of western blot. There are also higher levels of RT112M, VMCUB 
and HBCLS2 similar to that of western blots. There appears to be a low level of EpCAM in 
UROTsa, T24 which opposes findings found in Western blot as there was no EpCAM detected. 
Marimastat reduces shedding of EpCAM. This occurs throughout different grades of bladder cancer 
cell lines and the normal urothelium UROTsa. PMA increases EpCAM shedding and there is a 
reduction in EpCAM release in combination of PMA and Marimastat. However, the reduction in 
EpCAM release is more in Marimastat alone than both as PMA increases its release.  
 
 
               CONTROL 
               MARIMASTAT 
                PMA 
                BOTH 
Figure 12: The effect of Marimastat and PMA on EpCAM release using whole secretomes. 
100µl of secretome and 50 ml of PBS+ 1% BSA was added to each well. Absorbances were 
determined at 595 nm. Results show PMA induces EpCAM release whereas Marimastat 
inhibits its release. A combination of both also inhibits but not as much as when Marimastat is 
alone. Error bars were plotted based upon standard deviation of the data. 
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A repeat was done but in this case with supernatants of secretomes as shown in Figure 13. The 
results complement of that of whole secretomes but at a lower concentration.  
 
4.4.3 The role of ADAM17 in EpCAM sheddase 
An attempt has been made to determine ADAM 17 abundance in cell lysates of UBC secretomes 
and to see its effect when knocked down on EpCAM release as previous studies revealed it to be 
responsible for its shedding. For siRNA knock down of EpCAM, it does not show much reduction 
on EpCAM concentrations on whole as well as ultracentrifugation [data not shown]. This may be 
due to the conditions it was grown in and may emphasise that the siRNA did not knock down 
ADAM 17. 
 
Figure 13: The effect of Marimastat and PMA on EpCAM release using ultracentrifuged secretomes. 100µl 
of secretome and 50 ml of PBS+ 1% BSA was added to each well. Absorbances were determined at 595 
nm. Results show PMA induces EpCAM release whereas Marimastat inhibits its release. A combination of 
both also inhibits but not as much as when Marimastat is alone. Error bars were plotted based upon standard 
deviation of the data. 
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4.5 The effect of Marimastat and PMA on cell phenotype. 
Because Marimastat prevented EpCAM cleavage, the next hypothesis, was that if it may inhibit 
proteolytic cleavage, it can also affect cell behaviour. This was investigated through wound-healing 
and MTT assays to see its affect on cell migration and cell viability respectively. At the same time, 
a hypothesis has been created whether PMA stimulates cell migration and viability, like how it 
stimulates shedding of EpCAM.  
4.5.1 Wound Healing 
 This was performed to see if PMA and Marimastat affect cell migration. Photographs were taken at 
three time intervals: 0, 5 and 20 hours. The length of the wound was measured using a ruler via 
naked eye. Three measurements then work out the average. Figure 14 presents wound healing 
images at the three time intervals. Qualitative analysis suggests that PMA induces cell migration as 
time passes causing the wound to become narrow at 5 hours and then confluent at 20 hours. 
Alternatively, Marimastat did not seem to inhibit cell migration. There was more closure observed 
in Fetal Calf Serum (FCS) than serum-free (SF). 
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Figure 14: Wound Healing images of HB-CLS-2 (Grade III) This was done under different conditions at 
three intervals (0, 5 and 20 hours). It was repeated three times for fair testing and averages were calculated.   
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4.5.1.1 Marimastat does not inhibit cell migration 
No significant inhibitory effect of 5µM Marimastat on cell-migration was found in both serum-free 
and in presence of nutritionally-filled media FCS conditions. Figure 15 presents how Marimastat 
affects percentage wound closure across different cell lines at 5 hours whereas Figure 16 presents 
how Marimastat affects percentage wound closure across different cell lines at 20 hours.  
 
 
. 
 
 
 
 
 
Figure 15: The effect of Marimastat on cell migration at 5 hours Photographs were taken at 
three time intervals: 0, 5 and 20 hours thrice. The length of the wound was measured using a 
ruler via naked eye. Three measurements then the average and standard deviation were 
calculated. Error bars were based upon standard deviations of the data obtained. Below is the 
average closure at 5 hours. It does not appear that Marimastat inhibits cells migration across 
the bladder cell lines. The data was plotted based upon grade; starting from left to right, it 
initiates from normal urothelium to HB-CLS-2 Grade III UBC cell lines. 
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Figure 16: The effect of Marimastat on cell migration at 20 hours  
Photographs were taken at three time intervals: 0, 5 and 20 hours thrice. The length of the wound was 
measured using a ruler via naked eye. Three measurements then the average and standard deviation 
were calculated. Error bars were based upon standard deviations of the data obtained. Below is the 
average closure at 20 hours. It does not appear that Marimastat inhibits cells migration across the 
bladder cell lines especially in Fetal Calf Serum. The data was plotted based upon grade; starting 
from left to right, it initiates from normal urothelium to HB-CLS-2 Grade III UBC cell lines. 
However, analysing the serum-free data, in some UBC cell lines such as RT112M (TCC) VMCUB 
(Grade 2) and 5637(Grade 2), there appears to be some inhibitory effect of cell migration by 
Marimastat compared to the control. This also occurs in normal urothelium serum-free data. 
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4.5.1.2 PMA stimulates cell migration 
Cells have been treated with PMA, to express its effect on different grades of cancer cell lines. It 
was performed using the same method as the Marimastat investigation. Figure 17 presents how 
PMA affects percentage wound closure across different cell lines.  
It is apparent that in presence of PMA in both SF and FCS, it increased cell migration than that of 
controls. This is consistent throughout normal and different grade of UBC cell lines at 5 and 20 
hours. However, at 5 hours, there is more closure in RT112M (Grade II) in FCS than that with and 
without PMA than that of HB-CLS-2 (Grade III) and UROTsa (normal) and 5637 (Grade II). At 24 
hours, for SF, the normal urothelial cell in presence of PMA in SF media did not have 100% wound 
closure whereas of RTT12M (Grade II), 5637(Grade II), HB-CLS-2 (Grade III); there was 100% 
confluency. This emphasises the variability in how PMA influences cell migration as for a normal 
bladder cell line there was still a wound present unlike UBC cell lines.  
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Figure   17: The effect of PMA on cell migration of bladder cell lines. (A)  5 hours, (B) 20 hours. Error 
bars were plotted based upon standard deviation of the data. It is apparent that PMA induces cell 
migration in serum-free and fetal calf serum (more in fetal calf serum) and the controls in serum-free 
and fetal calf serum. This pattern occurs across the normal urothelium and the different grades of 
bladder cancer cell lines. 
(A) 
 
(B) 
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4.5.2 MTT Assay 
This was performed to see whether Marimastat and PMA effects cell viability. The MTT assay 
measured the in vitro cytotoxic effects of Marimastat and PMA on bladder cell lines. 
4.5.2.1 There is limited inhibitory effect of Marimastat on cell viability. 
5µM of Marimastat was used to see its affect on normal urothelial and different grades of UBC 
lines. This is because a preliminary experiment revealed there seems to be no difference doubling 
the concentration to 10µM [data not shown]. It is apparent there is a slight lower viability in 
presence of 5µM Marimastat than that of control whether Serum-free or Fetal Calf Serum across all 
bladder cell lines shown in Figure 19. T-test values had all more than 0.05; except for 5637 (Fetal 
Calf Serum and Serum-Free with and without Marimastat), RT112M (Serum-free with and without 
Marimastat) and VMCUB (serum-free with and without Marimastat) as shown in Appendix D.  
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Figure 19 The effect of Marimastat on cell viability 
All cell lines in serum-free and fetal calf serum were treated with and without 5µM of Marimastat and 
were incubated for 24 hours before doing the MTT assay for cell viability. The bar graph shows the 
absorbance measured at 595nm on a ELISA plate reader. This experiment had three trials for each 
concentration. The averages were plotted, whereas the error bars were plotted based upon standard 
deviation. The bars represent the number of viable cells.  
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4.5.2.2 PMA stimulates cell viability. 
PMA stimulates cell viability and this is seen across all bladder cell lines as shown in Figure 20. T-
test values had all more than 0.05; except for RT4 (Fetal Calf Serum with and without PMA), 
MGUH (Serum-Free with and without PMA) and RT112M (Serum-Free with and without PMA) as 
shown in Appendix E.  
Figure   20: The effect of PMA on cell viability. All cell lines in serum-free and fetal calf serum were 
treated with and without PMA and were incubated for 24 hours before doing the MTT assay for cell 
viability. The bar graph shows the absorbance measured at 595nm on an ELISA plate reader. This 
experiment had three trials for each concentration. The averages were plotted, whereas the error bars 
were plotted based upon standard deviation. The bars represent the number of viable cells.  
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4.6 Selecting biomarkers 
Two methods were utilized to selective candidate biomarkers: HPA (www.proteinatlas.org) and IPA 
(www.ingenuity.com). 
4.6.1 Candidate Biomarkers based on HPA analysis 
HPA project was established in 2003 and is a publically available source that contains 11,200 
proteins that complement more than 50% of genes (Asplund et al. 2011). The HPA 
immunohistochemistry candidate biomarkers were used to compare with the proteomic data. 
4.6.1.1. PMA –HPA comparison 
A Venn diagram was created to compare the HPA immunohistochemistry candidate biomarkers 
with the proteins that were present in 2 or more cell lines of PMA experiments. This was performed 
using the programme Venny (bioinfogp.cnb.csic.es/tools/venny/). 83 potential candidates have been 
revealed to be present in both the PMA proteomic data and HPA as shown in Figure 21. Appendix F 
shows a summary of the proteins including the function and their location using the gene ontology 
tool Panther database (www.pantherdb.org/).  
   
Figure 21: A Venn diagram comparing 
the PMA proteomic data with the HPA 
immunohistochemistry candidate 
biomarkers.  
83 proteins were present in both PMA 
and HPA data. 1038 proteins were 
present only in the proteomic data and 
not in HPA data. 928 proteins were 
presentonly in the HPA data and not 
the proteomic data. 
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The PMA proteomic data consists of secreted and shedded proteins as PMA was added to whole 
secretomes. This was further investigated in relation to presence in high grade (T24, HB-CLS-2, 
SW780, RT112M and 5637) and not low-grade (RT4, MGH-U3 and VMCUB), up-regulation by 
PMA by two-fold and down-regulation by Marimastat by half- fold [data not shown]. Results 
revealed that all 83 proteins were upregulated by PMA. Ephrin-B1 and Fibroblast growth factor 19 
were the only two proteins down-regulated by Marimastat. 17 proteins were higher in low grade 
UBC than high grade cancers (such as CD9, EXT1, GSTP1), 12 proteins were equivalent in both 
high grade (such as IL6, GSTM1, G6PD) and low grade and the remainder were elevated in high 
grade cancers than low grade cancers (such as ANXA, APOE, CALR, CD, CSF, CUL2, EGFR, 
EPCAM, EPHA HSPB1, FAS). This summarised in Appendix G. 
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4.6.1.1. PMA –Marimastat comparison 
A Venn diagram was created to compare the HPA immunohistochemistry candidate biomarkers 
with the proteins that were present in 2 or more cell lines of Marimastat experiments. This was 
performed using the programme Venny (bioinfogp.cnb.csic.es/tools/venny/). 60 potential candidates 
have been revealed to be present in both the Marimastat proteomic data and HPA as shown in 
Figure 22. Using Panther database (www.pantherdb.org/), the locations and roles of these proteins 
have been summarised in Appendix H. 
 
  
 
 
 
 
 
 
 
Figure 22: A Venn diagram comparing 
the Marimastat proteomic data with the 
HPA immunohistochemistry candidate 
biomarkers.  
60 proteins were present in both PMA 
and HPA data. 629 proteins were 
present only in the proteomic data and 
not in HPA data. 951 proteins were 
presentonly in the HPA data and not 
the proteomic data. 
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4.6.2 Candidate Biomarkers based on IPA analysis 
IPA-Biomarkers Filter was used to provide potential and relevant biomarker candidates from the 
experimental data based upon biological characteristics, disease and mechanism (Ingenuity n.d.). 
The following options were selected [Species – Human], [other cell lines], [not detected in 
biofluids] and [diagnostic biomarkers].  
4.6.2.1 PMA-IPA analysis 
Proteins that were present in two or more cell lines from the PMA proteomic data were subjected to 
analysis using IPA. Four potential candidate biomarkers were revealed: Glutathione S-transferase 
Mu 1 (GSTM1), Laminins (LAMC2), alpha-methylacyl-CoA racemase (AMARC) and APEG 
growth factor. GSTM1 is an enzyme located in cytoplasm. LAMC2 is a family consisting of 
extracellular matrix glycoproteins and are an important non-collagenous component of the basement 
membranes (National Center for Biotechnology Information 2014). They are located in the 
extracellular space.  The core analysis revealed that the proteins predicted to be related to cancer are 
involved in a number of carcinogenic events such as metastasis, progression, invasion and 
proliferation. 
4.6.2.2 Marimastat-IPA analysis 
Proteins that were present in two or more cell lines from the Marimastat proteomic data were 
subjected to analysis using IPA. Two potential candidates were revealed: GSTM1 and LAMC. 
These proteins were also present in the PMA-IPA analysis. When Marimastat-based proteins were 
present in two or more cell lines was subjected to analysis using IPA. In relation to the core 
analysis, lots of proteins were predicted to be related to carcinogenic events such as metastasis, 
progression, invasion and proliferation. 
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4.6.3  Validation of Biomarkers 
MMP-1 an interstitial collagenase was measured in urine to investigate whether it could be a 
potential diagnostic biomarker. The urine samples were randomly selected from the BCPP study 
and approximate to the population presenting with primary UCB and are summarised in Table 4 
showing the number of patients in each group and number of males, females and each grade of 
UCB. All other data are presented as medians (lower quartile-upper quartile). 
Table 4. The table presents the number of patients in each group based on the stage of their cancer. The 
gender and grade of UCB are also presented. The Creatinine (µg ml
-1
), MMP1 (pg/ml) and MMP1 C 
were presented as medians (lower quartile-upper quartile) 
Stage n Gender 
Male/female 
Grade 
1/2/3/4 
Age 
(years) 
Creatinine (µg 
ml-1) 
MMP1 
pg/ml 
MMP1 C 
Control 25 N/A N/A N/A N/A N/A 0.077146 
 (0.038167 – 
0.137921) 
pTis 4 4/0 0/0/4 66.28 
(60.49418 
- 
74.68036) 
2771.08 
(2497.696 – 
2965.455) 
160.67 
(127.1412 
– 
200.8163) 
0.05 
 (0.044197 – 
0.075344) 
pTa 135 108/27 57/63/14 70.38 
(61.73511 
–
77.46749) 
1718.59 
(1033.993 - 
2315.38) 
132.751 
(43.49681 
- 
364.6141 
0.074698  
(0.035811 - 0.232378) 
T1 31 26/5 0/10/21 11.315 
(67.04- 
78.355) 
   
T2+ 67 51/16 0/4/62/1 
75.10 
(67.06502-
80.83504) 
364.22 
(119.0459 -
913.254  
1451.98 
(995.6129 
- 
2117.455) 
0.31 (0.105568-
0.518854)  
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4.6.3.1 The relationship between Urinary MMP1 levels with tumour stage and grade. 
To determine and analyse whether the levels of MMP-1 in patients (UBC and non-cancer controls) 
has a possible correlation with grade and tumour stage. The distribution of urinary MMP-1 levels in 
the control subjects and UBC patients with tumour stage (Ta, T1, T2) is shown in Figure 23a. 
Mann-Whitney test showed there was no significant difference found in Ta and T1. However, there 
was a significant difference found in T2 where the p-value was 0.0001. The relationship between 
the urinary MMP-1 levels of patients with tumour grade is shown in Figure 23b. Mann-Whitney 
test showed there was no significant difference for G1 and G2, however there was a significant 
difference for G3. 
Figure 23: Urinary levels of MMP-1 in patients (UBC and non-cancer controls) correlation with stage 
and grade. A) stage B) grade. The data are normalised to urinary creatinine (pg µg -1). 
    
 
 
 
pg µg -1 
A B 
pg µg -1 
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4.6.3.2 MMP-1 as a prognostic biomarker  
A Kaplan-Meier curve was plotted to determine the variation in prognosis. A comparison was 
conducted between high and low urinary MMP-1 levels using a threshold determined as mean +2SD 
in the controls. There is no significant difference for MIBC but there is a significant difference for 
NMIBC as presented in Figure 24. The results emphasises it is not a good prognostic biomarker. 
 
Figure 24: Kaplan-Meier curves comparing high versus low Urinary MMP-1 levels of UBC subjects A) 
MIBC  p value >0.05 no significant difference B) NMIBC. P value <0.05 significant difference 
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4.6.3.3 MMP-1 as a diagnostic biomarker  
To determine and evaluate whether MMP-1 is a suitable diagnostic biomarker for UBC, a Reciever 
Operating Characteristic (ROC) curve and a sensitivity/specificity report was created using the 
MedCalc software. The ROC curves for both tumour grade (low grade vs high grade) and tumour 
stage (low stage vs high stage) are shown in Figure 25 and were plotted based upon Clarke-Pearson 
et al. The ROC curve consists of sensitivity (true positive rate) plotted with 100-specificity (false 
positive rate) for varied cut-off points (MedCalc n.d.). Each point corresponds to 
sensitivity/specificity pair of a specific decision threshold (Med Calc n.d.).  
Figure 25: Reciever Operating Characteristic analysis of MMP-1. (A) Tumour stage (low stage vs high 
stage) (B) Tumour grade (low grade vs high grade). For (A) the sensitivity is 50.0 whereas specificity is 
70.9. For (B) the sensitivity is 78.6 whereas specificity was 52.4. It is a poor diagnostic biomarker. 
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The area under the ROC curve (AUC) for each ROC curve was calculated to determine how well 
MMP-1 can differentiate between the two diagnostic groups for grade and stage.  Campbell revealed 
that if the test went across the chart (upper left corner) with 100% in both sensitivity and specificity, 
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this emphasises that it is a reliable and accurate diagnostic test and the AUC will be 1. Thus, the 
closer the ROC curve to that direction, the more accurate the test is. However, if the variable cannot 
distinguish between the groups being investigated, the AUC score will be 0.5. The results for this 
study show that when comparing low grade and high grade groups (Figure 25a), the AUC score was 
0.653 with 95% confidence interval whereas when comparing low stage and high stage groups 
(Figure 25b), the AUC score was 0.605 with 95% confidence interval. The p-value was <0.05 and 
this emphasises that the AUC is not significantly different from 0.5. Therefore, this is evidence that 
it is a poor diagnostic marker that is unable to distinguish between the two groups for grade and 
stage and in turn does not have potential to detect UBC. 
The Youden index was also calculated. Youden, defined it as: 
                                           J = max {sensitivityc + specificityc - 1 } 
This is where c consists of potential criterion values. J is the Youden index and is maximum vertical 
distance between the ROC curve and the diagonal line. For the ROC curve that corresponds to low 
grade vs high grade, the Youden index is 0.3094. For the ROC curve that corresponds to low grade 
vs high grade, the Youden index is 0.3094. 
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5.0 Discussion 
This project utilized a shotgun proteomic approach to identify potential candidate biomarkers from 
secretomes of a panel of cell lines for urinary biomarker discovery. We have successfully identified 
over 2,242 proteins in the PMA-conditioned media of all 9 cell lines combined whereas in 
Marimastat-based experiments 1879 proteins have been identified. Proteins are identified by 
Demethyl labelling. PMA was added to whole secretomes to observe all proteins (secreted and 
shedded) released by cells whereas Marimastat, a broad-spectrum MMP inhibitor, was added to  
ultracentrifuged secretomes to focus on shedded proteins.  Proteomic analysis on membrane 
proteins post-ultracentrifugation also took place as they have the potential to be biomarkers. Omics 
technology creates an extensive list of candidate markers and many techniques to select potential 
ones have been developed (Chen et al. 2013).  
5.1 Proteomic analysis of UBC whole PMA-treated secretomes 
As shown in Figure 4 and 5, whole secretomes were enriched with extracellular proteins and the 
predominant biological function is metabolism. This reflects the functional role of the bladder and 
emphasises that secretomes contain cytoplasms. The extracellular matrix (ECM) is secreted by cells 
and provides structural and functional support (Blonder et al. 2009). Another feature of the 
extracellular space is vesicles and there are two types intracellular that facilitate in many cellular 
processes such as protein-trafficking in the cell, whereas extracellular vesicles exert their roles 
outside of the cells (Blonder et al. 2009). The ECM is synthesised by various cells in the tumour 
environment. In addition, tumour vesicles are linked to secretion of growth factors in the tumour 
environment such as TGFβ cytokine that increase tumour progression. Vesicles are also linked to 
inducing invasion and ECM degradation (Blonder et al. 2009). ECM degradation facilitates 
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metastasis. Studies have revealed that metalloproteinases such as MMP-9 and MMP-2 are 
connected with vesicles and play a role in ECM degradation (Blonder et al. 2009). Shedding of 
vesicles has been discovered in many cancers that can allow tumours to evade host immune 
response (Blonder et al. 2009). This may explain as to why MMPs have been upregulated by PMA 
that stimulates shedding (Chen et al. 2010, Blonder et al. 2009).  
5.2 Upregulated proteins by PMA 
Upregulated proteins emphasises regulated release by PMA. After ultracentrifugation, there were 
still plasma-membrane bound proteins present as shown in Figure 6. Besides proteolytic enzymes 
such as MMPs that have been upregulated by PMA, other proteases were also upregulated such as 
Complement protease (C1r), Tissue plasminogen activator (TPA) and ADAM9. In addition, other 
proteins that are involved in proteasome activator complex and detoxification enzymes are also up-
regulated.  
5.2.1 C1R 
The C1r is part of the C1 complex (C1q, C1r and C1s subunits) whose role is to commence the 
downstream classic complement cascade (Dobo et al. 2009, Kane et al. 2010). There is evidence 
that the complement increases tumour growth by aiding in cell proliferation and regeneration (Kane 
et al. 2010). Other way of how complement proteins encourages carcinogenesis is by migration, 
angiogenesis, invasion, and evading immunosurveillance (Kane et al. 2010). 
5.2.2 TPA 
Tissue polypeptide antigen (TPA) is one of the constituents of the cytoskeleton of non-squamous 
epithelia. It is found in the cytokeratin’s proteolytic fragments (8, 19, and 8). Ecke et al. revealed 
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that its levels are linked with stages and grades of UBC and can be used to distinguish between 
control and UBC patients. However, it cannot be used to distinguish between MIBC and NMIBC. 
5.2.3 ADAM-9 
ADAM-9 is a member of the ADAM family that all are vital for altering cellular responses (Cho et 
al. 2005). Previous studies have shown that ADAM-9 promotes tumour cell invasion (Cho et al. 
2005). Invasion is regulated by matrix-degrading enzymes, contact with stromal cells and integrins 
(Cho et al. 2005). Cho et al. revealed that in order to promote invasion, ADAM-9 specifically 
associates with α6β4 and α2β1 on cell surface and can cleave laminin. 
5.2.4 Detoxification enzymes  
Detoxification enzymes such as Glutathione S-transferase P (GSTP1), Lactoylglutathione lyase 
(LGUL), Peroxiredoxin-4 (PRDX4) and Superoxide dismutase (SODC)) have also been enhanced 
by PMA. Normally, these detoxification enzymes shield cells against oxidative stress and for them 
to be released from UBC secretomes implies that they protect tumour cells which are frequently 
under oxidative stress. Another enzyme is Triosephosphate isomerase (TPIS) that have been linked 
with metastasis (Karsani et al. 2014).  
It is important to note that the proportion of intracellular proteins does not solely indicate that it is 
due fetal bovine serum (FBS) or apoptosis. Another explanation for their presence is due to a recent 
finding where intracellular proteins have other functions in the extracellular space (Villanueva et al. 
2013). Further evidence from non-classical secretory pathways and analysis of exosomes from 
cancer cells have revealed their presence (Mendez et al. 2013). Thus, ECM is a useful source to 
discover biomarkers for early UBC diagnosis. 
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5.2.5 Other upregulated proteins 
CUL2 was also present which correlates with previous studies as Fernandez-Gomez et al. 
discovered CUL3 that also shows potential for aggressiveness in bladder cancer. 
Dahse et al. revealed that when a biomarker panel that consisted of DSG-2 with 5 other genes 
(BRCA2, ICAM-1, KRT-18, TNFRSF6 and LIG-3) it significantly identified tumour progression 
in NMIBC patients.  
5.3 Ectodomain shedding   
Ectodomain shedding is the proteolytic cleavage of the extracellular domain of membrane proteins. 
Proteases that induce this mechanism are known as ‘sheddases’ and are of two types: a distegrin and 
metalloproteinase (ADAMs) and metalloproteases (MMPs) (Chow 2007). There was no presence of 
ADAMs and MMPs (except for MMP-10 that was down-regulated). This is because Marimastat 
inhibits these sheddases and is a broad spectrum MMP inhibitor that has potency against majority of 
MMPs (Rasmussen 1999). It covalently associated with the zinc atom at the active site of MMPs 
(Eckhardt 2001). In addition there were a low number of proteins identified and the data was more 
variable. Possible reasons for this include spanning of some proteins down that is partly due to 
Marimastat and partly due to lack of PMA, and also ultracentrifugation.  Other reasons include 
experiments (digestions, mass spectrometry) that did not seem to be working as well later. 
Therefore, if there is less data and it is more variable then differences between the cell lines may not 
be detected. 
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5.4 Selecting potential biomarkers 
5.4.1 Potential biomarkers based upon HPA comparison with proteomic data 
For the HPA-PMA analysis, 83 proteins were present in both whereas for the HPA-Marimastat 
analysis, 60 proteins were present as shown in Figure 21 and 22 respectively. The 83 proteins from 
the HPA-PMA analysis underwent further investigation as the PMA was added to whole secretomes 
to reveal both the secreted and shedded proteins. This was done in relation to whether they are 
present in high grade (T24, HB-CLS-2, SW780, RT112M and 5637) and not low-grade (RT4, 
MGH-U3 and VMCUB), up-regulation by PMA by two-fold and down-regulation by Marimastat by 
half- fold.  
Previous studies have been conducted with some of these proteins in relation to cancer. Amongst 
these are EphrinB. This was upregulated by PMA and one of the proteins that were down-regulated 
by Marimastat. It was found in high grade cancers but not low grade cancers. It is a membrane 
bound protein ligand that in combination with the Eph family of receptor tyrosine kinases plays a 
pivotal role in carcinogenesis (Lu et al. 2013). A recent study has shown it to be associated with 
metastasis and its increased expression signifies poor prognosis in breast cancer.  
Fas was one of the proteins up-regulated by PMA but was not down-regulated by Marimastat. It was 
found in high grade cancers but not low grade cancers. Kamp et al. investigated whether Fas and 
Fas ligand expression and synthesis on UBC cell lines of different grades is how they secret. They 
utilized RT112 (Grade 1), RT4 (Grade 1), SUP (Grade 4) and T24 (Grade 3). RT4 (Grade I) and 
T24 (Grade III) was also used in this present study. Results found that Fas was expressed in all UBC 
cell lines however its ligand was expressed in SUP and T24 but not in RT112 and RT4. However, 
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there was no correlation between Fas and its ligand and concluded that they have little clinical 
revelence. 
In addition, GSTM1 is found in both HPA-PMA and HPA-Marimastat data. It was upregulated by 
PMA but not down-regulated by Marimastat. Safarinejad et al. revealed that glutathione-S-
transferases (GSTs) such as GSTM1 and GSTP1, detoxifying enzymes that bind to glutathione to 
aid in removing carcinogenic substances may be linked with bladder cancer susceptibility. 
Furthermore, Busch et al. revealed that APOE a bladder cancer-linked urinary protein correlates 
with increased tumour stage and can be a potential diagnostic biomarker. 
5.4.2 Potential biomarkers based upon IPA comparison with proteomic data 
Using the Biomarker Filter tab on IPA software, four proteins were elucidated:  GSTM1 and 
AMARC, cytsolic enzymes, and LAMC2 and APEG growth factor in extracellular space were also 
revealed. In IPA core analysis, many proteins were predicted to be related to carcinogenic events 
such as invasion, proliferation, progression, metastasis and hyperplasia.  
5.4.2.1 GSTM1 
This was also revealed in HPA analysis. GSTM1 is one of GST’s dimeric enzymes that reside in the 
cytosol (Bandyopadhyay et al. 2013). Carrato et al. revealed that GSTM1 null genotype enhances 
the risk of bladder cancer. 
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5.4.2.2 AMACR 
AMACR enzyme is a biomarker found to be overexpressed in colorectal, renal and prostate cancer 
(Dietel et al. 2008). In relation to bladder cancer, Dietel et al. revealed it is expressed in high grade 
UBC and may have a role in tumour cell metabolism. 
5.4.2.3 LAMC2 
El-Rifai et al. revealed that LAMC is a potential biomarker of bladder cancer and is linked with 
tumour grade and metastasis. 
5.4.3 Potential candidate biomarkers 
The potential biomarkers from selective methods: EGFR, EpCAM, CUL-3, GSTM1 and PTX3 
appear to be promising. This complements some of the results achieved from our group previously 
and other studies. Bryan et al. discovered that urinary levels of EpCAM are elevated and are 
dependent on the grade and stage of UBC but is a poor prognostic biomarker. Recent studies have 
shown CUL-3 to be a significant prognostic marker (Theodorescu 2013). 
EGFR is a 170 kDa transmembrane glycoprotein and a member of tyrosine kinase receptors that 
allows ligands to bind to the extracellular domain (Agarawal et al. 2013). It is overexpressed and is 
a good predictor of poor survival and cancer progression especially in high grade tumours  
(Agarawal et al. 2013). 
Furthermore, GSTM1 is a potential candidate as it was amongst those present in both selection 
methods: HPA and IPA. When further analysis took place with the HPA-PMA data, it was found to 
be present in both high and low grade cancers. It was also up-regulated by PMA, however it was not 
down-regulated by Marimastat.  
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5.5 An introduction to EpCAM biology 
EpCAM is a potential biomarker based on our group’s previous findings relating to EpCAM 
ectodomain shedding that is currently on-going investigations. We decided to investigate this 
process in more detail. PMA and Marimastat and a combination of both were utilized to see their 
effect on EpCAM release from bladder cell secretomes and how tumor necrosis factor α-converting 
enzyme (TACE or ADAM17) a reported protease can specifically inhibit EpCAM shedding. Results 
reveal important aspects of EpCAM biology and also provide interesting insights into the 
mechanisms of morphogenesis. 
5.5.1 PMA stimulates shedding of EpCAM via PKC activation 
PMA stimulates an increased release of ectodomain shedding EpCAM from bladder cancer cell 
secretomes as well as reducing proteolytic processing (Hahn et al. 2003). This stimulatory effect is 
inhibited by peptide hydroxamate MMP1 inhibtors such as Marimastat that inhibit PKC suggesting 
that activation of Protein kinase C (PKC) mediates PMA-induced EpCAM shedding (Parker et al  
2010). PKC consists of a family of serine/threonine kinases (Toker 1998). ADAM 17 mediates the 
PMA-induced release.  
5.5.2 The effect of ADAM-17 on EpCAM release 
Evidence suggests that ADAM17 induces proteolytic cleavage of EpCAM via its extracellular site. 
This increases shedding of EpEX ectodomain. This is subsequently followed by cleavage of the 
transmembrane domain by γ-secretase. This causes EpICD (soluble cytoplasmic peptide) release 
(Giepmans 2013, Gires et al. 2009). EpICD then creates a complex with -catenin, Lef-1 and FHL2 
to initiate gene transcription as shown in Figure 22 (Gires et al. 2009) 
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 Figure 22: The cross talk between EpCAM and WNT signalling pathways (Gires et al. 2009) 
                               
However, according to this present study, the ADAM 17 siRNA did not work despite previous 
studies have confirmed it can knock-down EpCAM as shown in Figure 23 (Gires 2011). This 
emphasises that siRNA did not knock down ADAM17.  
 
 
 
 
 
P a g e  | 89 
 
Figure 23 ADAM-17 siRNA knockdown  using FaDu carcinoma cells. 
An ELISA experiment took place and revealed how the cells that were transfected with ADAM17 
siRNA reduces the number of cells over a period of 3 days than the control siRNA. The mean and 
standard deviations are shown for two independent experiments (Gires 2011) 
  
5.5.3 The role of ADAM-17 in cancer 
ADAM-17 is the strongest evidence of the role of ADAMs in cancer. Other ADAMs involved are 
ADAM-15, ADAM-12, ADAM-10 and ADAM-9. Down-regulation or knocking down ADAM-17 
expression reduces growth of cancer cells and has been reported by previous studies. Baldys 
portrayed that knockdown of ADAM17 using siRNA decreased endothelial cell proliferation and 
invasion in vitro. Blobel et al. revealed that it reduced tumour growth and pathological 
neovascularisation. There are other ADAM proteases that are linked with pathological 
neovascularisation such as ADAM9 and ADAM-15 (Crown et al. 2011).  
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Increased ADAM expression promotes tumour formation, invasion and proliferation (Crown et al. 
2011). One of the predominant mechanisms in increasing invasion is by activating growth factors 
such as EGFR/HER membrane-bound ligands into their active state by shedding their ectodomains. 
The ligands such as epiregulin, TGF-alpha are released and freely associate with EGFR/HER 
receptors. After receptor dimerisation, down-stream signalling pathways such as janus kinase/signal 
transducer and activator of transcription (JAK/STAT) pathway, phosphatidylinositol 3-kinase 
(PI3K) pathway and mitogen-activated protein kinase (MAPK) pathway are then activated. This can 
lead to many hallmarks of cancer such as enhanced cell survival, motility and proliferation (Crown 
et al. 2011). In particularly, ADAM-17 via the PI3K pathway was reported to increase cell 
proliferation (Chopp et al. 2009).  
Another study revealed that ADAM-17 increases migration via the platelet derived growth factor 
receptor beta (PDGFRβ) that stimulates ADAM-17 that in turn releases EGFR ligands and the 
EGFR/ERK signalling pathway (Blobel et al. 2010). This led to ADAM-17 activation, release of 
EGFR ligands and EGFR/ERK signalling.  
Furthermore, stimulating positive growth factors are not the only growth factors that lead to such 
carcinogenic events. Inhibitory growth factors such as TGFβ inhibit cell proliferation in normal and 
benign cells. However, as the cancer progresses, it increases proliferation (Ikushima 2010). 
Thus, findings suggested that PMA stimulates EpCAM release whereas Marimastat has an 
inhibitory effect on EpCAM release. This led to investigations on their effect on cell phenotype 
where Marimastat did not have an inhibitory effect on cell migration but to a limited extent on cell 
viability.  
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5.6 PMA stimulates cell migration and viability.  
PKC is first upregulated but subsequently downregulated which may explain the underlying reasons 
for the results obtained. Charvart et al. states that cell migration is an essential process in 
physiological and pathological conditions such as wound healing and tumour invasion. PKC 
regulates cell migration by stimulating signal transduction that regulate actin cytoskeleton (Parkos 
2013).  
Fagotto et al. revealed that high levels of EpCAM are linked to increased proliferation in normal or 
tumour tissues. EpCAM can act as a cell-cell adhesion molecule and bind to the actin cytoskeleton 
via α-actinin to regulate cell movement. Other possible reasons due to high proliferation rates are 
due to separating α-catenin from E-cadherin (Fagotto et al. 2010). Another reason for the increasing 
effects of EpCAM on proliferation is due to signalling activity of its intracellular domain that can be 
cleaved and can subsequently associate with β-catenin, Lef-1 to stimulate gene transcription of 
oncogenes such as C-myc and cyclins A/E (Fagotto et al. 2010).  
 
5.7 Marimastat has limited effect on cell viability and migration  
Marimastat did not have much inhibitory effect on cell viability and migration. Previous studies 
have shown that Marimastat does inhibit proliferation and migration using human keratinocyte line, 
HaCaT; demonstrating the role of MMPs in cell migration (Auffinger et al. 2013, Charvart et al. 
1999). Gao et al revealed that integrin-linked kinase (ILK) a serine-threonine protein kinase that has 
a major role in many cellular mechanisms increases cell migration via nuclear factor-κB (NF-κB) 
upregulation of MMP-9. Reasons why Marimastat has worked in Charvart et al. study and not this 
present study leads to further investigation where higher concentrations more than 5µM of 
Marimastat will be used.   
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5.8.MMP1 as a prognostic and diagnostic biomarker  
MMP-1 is interstitial collagenases and the structure of its catalytic domain is similar to other MMPs 
(Acharya et al 2006, Chaplain 2013). Urine analysis of UBC patients revealed that it is a poor 
diagnostic and prognostic marker. It was elevated in a proportion of patients. Mellon et al. 
discovered the role of MMP-1 in UBC and revealed similar results to this study where urinary 
MMP-1 was detectable more at higher grade tumours. This opposes Durkan et al. study who 
discovered that MMP1 is a useful prognostic indicator for bladder tumour progression.  
MMP3 may be the recommended urinary metalloproteinases as early diagnostic biomarker in the 
early stages of both types of bladder cancer although both MMP9 and MMP3 can be used in the 
diagnosis of advanced stages. Further studies are required on large number of urine samples to 
confirm these results (El-Sharkawi et al. 2014) 
5.9 Further experiments 
If time was extended, I would like to work on siRNA and get results on how ADAM siRNA effects 
EpCAM release via ELISA and Western blotting. I would also like to measure the following 
potential candidates further: EGFR, PTX3, GSTM1 and CUL-3. I would also like to investigate cell 
surface proteomics where cells are treated with a membrane-impermeant biotinylating reagent to 
label surface-exposed proteins. The cell surface proteome will notify what sheddases are present 
and may identify cancer-specific proteins useful as biomarkers or drug targets.   
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6.0 Conclusion  
Ultimately, many findings can be extracted from this study; firstly, PMA stimulates shedding of 
EpCAM ectodomain whereas Marimastat decreases EpCAM release. In relation to investigations 
conducted on the cell phenotype, Marimastat had minimal inhibitory effect on on cell viability and 
migration. On the other hand, PMA induced cell migration and viability. Many potential biomarkers 
for UBC have been revealed via the two selections: IPA and HPA analysis. From these, potential 
candidates that would be taken further are where EpCAM, EGFR, PTX3, GSTM1 and CUL-3 are 
potential candidates. MMP-1 was detected in urine from UBC patients, with a significant increase in 
concentration with increased stage and grade of tumour. However it is a poor diagnostic and 
prognostic biomarker. We have comprehensively utilized UBC secretomes and further 
bioinformatic analyses e.g. comparison with gene expression data which will facilitate in urinary 
biomarker discovery. 
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8.0 Appendices 
Appendix A 
137 proteins found in all 9 secretomes from the PMA proteomic data. The names of the proteins 
from the accession names were revealed using Panther database (http://www.pantherdb.org/)  
Accession Name of Protein 
K2C1 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 
INHBA Inhibin beta A chain OS=Homo sapiens GN=INHBA PE=1 SV=2 
AGRIN Agrin OS=Homo sapiens GN=AGRN PE=1 SV=4 
A4 Amyloid beta A4 protein OS=Homo sapiens GN=APP PE=1 SV=3 
TENA   
LAMB3   
HS90B Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 
HSP7C Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 
HS90A Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 
JAG1 Protein jagged-1 OS=Homo sapiens GN=JAG1 PE=1 SV=3 
ACTN4 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 
ACTB Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 
APLP2   
K1C10 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 
K22E Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 
K1C9 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 
TIMP1   
K2C6A Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 
ACTN1 Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 
A1AT Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 
GRP78 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 
HSP71 Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 
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K1C16 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 
MMP13   
PTK7   
TPA   
PTX3   
ACLY ATP-citrate synthase OS=Homo sapiens GN=ACLY PE=1 SV=3 
TR11B   
AHNK 
Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 
1433E 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 
HSP13 Heat shock 70 kDa protein 13 OS=Homo sapiens GN=HSPA13 PE=1 SV=1 
IL6 Interleukin-6 OS=Homo sapiens GN=IL6 PE=1 SV=1 
K1H1 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=1 SV=3 
SPIT1   
A2MG Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=2 
IF4A1 Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 
1433Z 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 
ACTC Actin, alpha cardiac muscle 1 OS=Homo sapiens GN=ACTC1 PE=1 SV=1 
CTGF   
ICAM1 Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 
1433T 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 
EPHA2   
IBP7 
Insulin-like growth factor-binding protein 7 OS=Homo sapiens GN=IGFBP7 PE=1 
SV=1 
LSR   
ALDOA Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 
FST   
HSP74 Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 PE=1 SV=4 
K2C6C   
PLOD2   
CO6A2   
GANAB Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 
HSP72 Heat shock-related 70 kDa protein 2 OS=Homo sapiens GN=HSPA2 PE=1 SV=1 
ALBU Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
CO4A2   
CTNA1   
ITB4   
IQGA1 Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 
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SV=1 
ITB1 Integrin beta-1 OS=Homo sapiens GN=ITGB1 PE=1 SV=2 
LIF   
TACD2   
ACTBL Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 
GELS Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 
GBLP 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3 
GSLG1 Golgi apparatus protein 1 OS=Homo sapiens GN=GLG1 PE=1 SV=2 
IDHC 
Isocitrate dehydrogenase [NADP] cytoplasmic OS=Homo sapiens GN=IDH1 PE=1 
SV=2 
PTPRF   
4F2 4F2 cell-surface antigen heavy chain OS=Homo sapiens GN=SLC3A2 PE=1 SV=3 
AMD 
Peptidyl-glycine alpha-amidating monooxygenase OS=Homo sapiens GN=PAM 
PE=1 SV=2 
H4 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 
ITA6 Integrin alpha-6 OS=Homo sapiens GN=ITGA6 PE=1 SV=4 
PAI1   
ECM1   
ITA2 Integrin alpha-2 OS=Homo sapiens GN=ITGA2 PE=1 SV=1 
K2C5 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 
MMP3   
PCDGK   
UPAR   
CATD   
HEXB Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB PE=1 SV=3 
HNRPK 
Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 
SV=1 
IMB1 Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 
1433S 14-3-3 protein sigma OS=Homo sapiens GN=SFN PE=1 SV=1 
CDCP1   
CYR61   
GNAI3 
Guanine nucleotide-binding protein G(k) subunit alpha OS=Homo sapiens 
GN=GNAI3 PE=1 SV=3 
CAB45   
GDIB Rab GDP dissociation inhibitor beta OS=Homo sapiens GN=GDI2 PE=1 SV=2 
GOLM1 Golgi membrane protein 1 OS=Homo sapiens GN=GOLM1 PE=1 SV=1 
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 
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SV=2 
CADH1   
GALT7 N-acetylgalactosaminyltransferase 7 OS=Homo sapiens GN=GALNT7 PE=1 SV=1 
GDF15 Growth/differentiation factor 15 OS=Homo sapiens GN=GDF15 PE=1 SV=2 
ILF2 Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 
PVRL1   
STC1   
TNF6B   
5NTD 5'-nucleotidase OS=Homo sapiens GN=NT5E PE=1 SV=1 
DJB11   
GRP75 Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 
GSTO1 Glutathione S-transferase omega-1 OS=Homo sapiens GN=GSTO1 PE=1 SV=2 
GSTP1 Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 
HS105 Heat shock protein 105 kDa OS=Homo sapiens GN=HSPH1 PE=1 SV=1 
IGSF8 Immunoglobulin superfamily member 8 OS=Homo sapiens GN=IGSF8 PE=1 SV=1 
IPO5 Importin-5 OS=Homo sapiens GN=IPO5 PE=1 SV=4 
IPO7 Importin-7 OS=Homo sapiens GN=IPO7 PE=1 SV=1 
MET   
RHOA   
1A01 
HLA class I histocompatibility antigen, A-1 alpha chain OS=Homo sapiens 
GN=HLA-A PE=1 SV=1 
1C12 
HLA class I histocompatibility antigen, Cw-12 alpha chain OS=Homo sapiens 
GN=HLA-C PE=1 SV=2 
AATC Aspartate aminotransferase, cytoplasmic OS=Homo sapiens GN=GOT1 PE=1 SV=3 
ARPC2 
Actin-related protein 2/3 complex subunit 2 OS=Homo sapiens GN=ARPC2 PE=1 
SV=1 
CATB   
ESM1   
HNRPQ 
Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP 
PE=1 SV=2 
HS74L Heat shock 70 kDa protein 4L OS=Homo sapiens GN=HSPA4L PE=1 SV=2 
N2DL2   
2AAA 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha 
isoform OS=Homo sapiens GN=PPP2R1A PE=1 SV=4 
6PGD 
6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens 
GN=PGD PE=1 SV=3 
AKA12 A-kinase anchor protein 12 OS=Homo sapiens GN=AKAP12 PE=1 SV=3 
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ARP3 Actin-related protein 3 OS=Homo sapiens GN=ACTR3 PE=1 SV=3 
GBB1 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Homo 
sapiens GN=GNB1 PE=1 SV=3 
GDIA Rab GDP dissociation inhibitor alpha OS=Homo sapiens GN=GDI1 PE=1 SV=2 
GDIR1 Rho GDP-dissociation inhibitor 1 OS=Homo sapiens GN=ARHGDIA PE=1 SV=3 
GNAI2 
Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Homo sapiens 
GN=GNAI2 PE=1 SV=3 
GNAS2 
Guanine nucleotide-binding protein G(s) subunit alpha isoforms short OS=Homo 
sapiens GN=GNAS PE=1 SV=1 
H2AY Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=4 
H2B1J Histone H2B type 1-J OS=Homo sapiens GN=HIST1H2BJ PE=1 SV=3 
HEXA Beta-hexosaminidase subunit alpha OS=Homo sapiens GN=HEXA PE=1 SV=1 
K1C13 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 
K1C14 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 
ACTBM Beta-actin-like protein 3 OS=Homo sapiens GN=ACTBL3 PE=1 SV=1 
ADAM9 
Disintegrin and metalloproteinase domain-containing protein 9 OS=Homo 
sapiens GN=ADAM9 PE=1 SV=1 
GGH Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 SV=2 
GLU2B Glucosidase 2 subunit beta OS=Homo sapiens GN=PRKCSH PE=1 SV=2 
HNRPR 
Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens GN=HNRNPR 
PE=1 SV=1 
ITAV Integrin alpha-V OS=Homo sapiens GN=ITGAV PE=1 SV=2 
 
 
 
 
 
 
 
 
 
P a g e  | 113 
 
Appendix B Proteins upregulated by PMA 
The name of the proteins upregulated by PMA with their cellular locations, molecular functions and 
biological functions have been determined using the Panther database (http://www.pantherdb.org/) 
Acces
sion 
Name Name Molecular function Biological function Cellular component 
1433S 
14-3-3 protein 
sigma;SFN;ortholog   cell cycle;cell communication   
2A5G 
Serine/threonine-
protein phosphatase 
2A 56 kDa 
regulatory subunit 
gamma 
isoform;PPP2R5C;or
tholog 
phosphoprotein 
phosphatase 
activity;phosphopr
otein phosphatase 
activity 
protein phosphorylation;cell 
communication   
2AAA 
Serine/threonine-
protein phosphatase 
2A 65 kDa 
regulatory subunit A 
alpha 
isoform;PPP2R1A;or
tholog 
phosphoprotein 
phosphatase 
activity;phosphopr
otein phosphatase 
activity metabolic process   
ABCF
1 
ATP-binding 
cassette sub-family 
F member 
1;ABCF1;ortholog       
ACLY 
ATP-citrate 
synthase;ACLY;ortho
log       
ADA
M9 
Disintegrin and 
metalloproteinase 
domain-containing 
protein 
9;ADAM9;ortholog   
fertilization;apoptotic 
process;neurological system 
process;mesoderm 
development;apoptotic 
process;heart development   
AGRI
N 
Agrin;AGRN;ortholo
g receptor activity 
cell communication;cell-matrix 
adhesion;cell-cell 
adhesion;neurological system 
process;ectoderm 
development 
extracellular 
region;extracellular 
matrix 
AHSA
1 
Activator of 90 kDa 
heat shock protein 
ATPase homolog 
1;AHSA1;ortholog 
catalytic 
activity;protein 
binding;enzyme 
activator activity 
immune system 
process;protein 
folding;response to 
stress;regulation of catalytic 
activity   
AIP 
AH receptor-
interacting   
visual perception;sensory 
perception   
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protein;AIP;ortholog 
ANXA
1 
Annexin 
A1;ANXA1;ortholog   
fatty acid metabolic 
process;cell communication   
ARPC
4 
Actin-related 
protein 2/3 complex 
subunit 
4;ARPC4;ortholog 
structural 
constituent of 
cytoskeleton 
cellular component 
movement;cellular component 
organization 
actin 
cytoskeleton;intracellul
ar 
BLVR
B 
Flavin reductase 
(NADPH);BLVRB;orth
olog 
oxidoreductase 
activity metabolic process   
BROX 
BRO1 domain-
containing protein 
BROX;BROX;ortholo
g       
C1R 
Complement C1r 
subcomponent;C1R;
ortholog 
serine-type 
peptidase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
gamete 
generation;complement 
activation;proteolysis;cellular 
process;blood coagulation   
CADH
2 
Cadherin-
2;CDH2;ortholog binding 
cellular process;visual 
perception;sensory perception 
of sound;mesoderm 
development;nervous system 
development;heart 
development;muscle organ 
development 
plasma membrane;cell 
part 
CADH
3 
Cadherin-
3;CDH3;ortholog binding 
cellular process;visual 
perception;sensory perception 
of sound;mesoderm 
development;nervous system 
development;heart 
development;muscle organ 
development 
plasma membrane;cell 
part 
CALX 
Calnexin;CANX;orth
olog 
calcium ion 
binding 
protein folding;intracellular 
protein transport;exocytosis   
CAPG 
Macrophage-
capping 
protein;CAPG;orthol
og 
structural 
constituent of 
cytoskeleton;calciu
m ion binding;actin 
binding 
cellular process;cellular 
component 
morphogenesis;cellular 
component organization 
actin 
cytoskeleton;intracellul
ar 
CATL
2 
Cathepsin 
L2;CTSL2;ortholog 
cysteine-type 
peptidase activity proteolysis;cell adhesion   
CAYP
1 
Calcyphosin;CAPS;or
tholog 
catalytic 
activity;calcium ion 
binding;receptor 
binding;calmodulin 
metabolic process;cell 
cycle;cell 
communication;cation 
transport;regulation of   
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binding;enzyme 
regulator activity 
catalytic activity 
CEL 
Bile salt-activated 
lipase;CEL;ortholog lipase activity metabolic process 
extracellular 
region;cytoplasm 
CFAB 
Complement factor 
B;CFB;ortholog       
CG05
0 
Uncharacterized 
protein 
C7orf50;C7orf50;ort
holog       
CHST
B 
Carbohydrate 
sulfotransferase 
11;CHST11;ortholog transferase activity 
sulfur compound metabolic 
process   
CLIC1 
Chloride 
intracellular channel 
protein 
1;CLIC1;ortholog       
CLIC1 
Chloride 
intracellular channel 
protein 
1;CLIC1;ortholog       
CN37 
2',3'-cyclic-
nucleotide 3'-
phosphodiesterase;
CNP;ortholog 
phosphoric diester 
hydrolase activity 
cyclic nucleotide metabolic 
process   
CNDP
2 
Cytosolic non-
specific 
dipeptidase;CNDP2;
ortholog 
metallopeptidase 
activity;deacetylas
e activity 
cellular amino acid 
biosynthetic process;protein 
phosphorylation;proteolysis   
CNOT
3 
CCR4-NOT 
transcription 
complex subunit 
3;CNOT3;ortholog       
CO5A
2 
Collagen alpha-2(V) 
chain;COL5A2;orthol
og 
receptor 
activity;extracellul
ar matrix structural 
constituent;transm
embrane 
transporter activity 
macrophage activation;cell 
communication;cell-cell 
adhesion;blood 
circulation;ectoderm 
development;mesoderm 
development;cellular 
component 
morphogenesis;response to 
stimulus;intracellular protein 
transport;receptor-mediated 
endocytosis;regulation of 
liquid surface tension;cellular 
component organization 
extracellular 
region;extracellular 
matrix 
COR1
C 
Coronin-
1C;CORO1C;ortholo
g actin binding 
cellular process;cytoskeleton 
organization 
cytoskeleton;intracellul
ar 
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CPNE
3 
Copine-
3;CPNE3;ortholog   intracellular protein transport   
CTNA
1 
Catenin alpha-
1;CTNNA1;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cell communication;cell 
adhesion;cellular component 
morphogenesis;cellular 
component organization intracellular 
CUL2 
Cullin-
2;CUL2;ortholog 
ubiquitin-protein 
ligase activity proteolysis;cell cycle   
CYTM 
Cystatin-
M;CST6;ortholog 
cysteine-type 
peptidase 
activity;protein 
binding;cysteine-
type 
endopeptidase 
inhibitor activity 
proteolysis;regulation of 
catalytic activity   
DDR1 
Epithelial discoidin 
domain-containing 
receptor 
1;DDR1;ortholog       
DDX5 
Probable ATP-
dependent RNA 
helicase 
DDX5;DDX5;ortholo
g 
RNA helicase 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
nucleobase-containing 
compound metabolic 
process;translation;regulation 
of translation   
DEK 
Protein 
DEK;DEK;ortholog       
DESP 
Desmoplakin;DSP;or
tholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cellular component 
movement;cellular component 
morphogenesis;cellular 
component organization 
actin 
cytoskeleton;intracellul
ar 
DLDH 
Dihydrolipoyl 
dehydrogenase, 
mitochondrial;DLD;o
rtholog 
oxidoreductase 
activity 
respiratory electron transport 
chain;nitrogen compound 
metabolic process;ferredoxin 
metabolic process   
E41L1 
Band 4.1-like 
protein 
1;EPB41L1;ortholog       
EPCR 
Endothelial protein 
C 
receptor;PROCR;ort
holog 
receptor 
activity;protein 
binding 
immune system process;cell 
communication;blood 
coagulation   
ERAP
2 
Endoplasmic 
reticulum 
aminopeptidase 
2;ERAP2;ortholog 
metallopeptidase 
activity proteolysis   
F10A Hsc70-interacting   protein folding;response to   
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1 protein;ST13;orthol
og 
stress 
FHL2 
Four and a half LIM 
domains protein 
2;FHL2;ortholog 
sequence-specific 
DNA binding 
transcription 
factor 
activity;sequence-
specific DNA 
binding 
transcription 
factor activity 
mesoderm 
development;muscle organ 
development   
FRPD
1 
FERM and PDZ 
domain-containing 
protein 
1;FRMPD1;ortholog       
FST 
Follistatin;FST;orthol
og protein binding     
FUBP
1 
Far upstream 
element-binding 
protein 
1;FUBP1;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of apoptosis;RNA 
splicing, via transesterification 
reactions;transcription from 
RNA polymerase II 
promoter;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification 
reactions;protein metabolic 
process;cell 
communication;neurological 
system process;induction of 
apoptosis;intracellular protein 
transport;nuclear transport 
ribonucleoprotein 
complex 
FUBP
2 
Far upstream 
element-binding 
protein 
2;KHSRP;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of apoptosis;RNA 
splicing, via transesterification 
reactions;transcription from 
RNA polymerase II 
promoter;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification 
reactions;protein metabolic 
process;cell 
communication;neurological 
system process;induction of 
apoptosis;intracellular protein 
transport;nuclear transport 
ribonucleoprotein 
complex 
FZD6 
Frizzled-
6;FZD6;ortholog 
guanylate cyclase 
activity;receptor 
activity;protein 
binding 
reproduction;phosphate-
containing compound 
metabolic process;nitrogen 
compound metabolic 
process;biosynthetic 
process;cyclic nucleotide 
plasma 
membrane;intracellular
;neuron projection 
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metabolic process;cell 
communication;cell 
proliferation;single-
multicellular organism 
process;cellular component 
morphogenesis;embryo 
development;cell 
differentiation;nervous system 
development;response to 
stimulus;regulation of 
nucleobase-containing 
compound metabolic 
process;regulation of 
phosphate metabolic 
process;regulation of catalytic 
activity;cellular component 
organization 
G3P 
Glyceraldehyde-3-
phosphate 
dehydrogenase;GAP
DH;ortholog 
oxidoreductase 
activity glycolysis;glycolysis   
GLYG 
Glycogenin-
1;GYG1;ortholog 
transferase 
activity, 
transferring 
glycosyl groups glycogen metabolic process   
GNAI
2 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-
2;GNAI2;ortholog       
GNAI
2 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-
2;GNAI2;ortholog 
pyrophosphatase 
activity;adenylate 
cyclase 
activity;receptor 
binding 
phosphate-containing 
compound metabolic 
process;nitrogen compound 
metabolic process;catabolic 
process;biosynthetic 
process;cyclic nucleotide 
metabolic process;cell 
communication;response to 
stimulus;regulation of 
nucleobase-containing 
compound metabolic 
process;regulation of 
phosphate metabolic 
process;regulation of catalytic 
activity 
plasma 
membrane;protein 
complex;intracellular 
GRN 
Granulins;GRN;orth
olog       
H4 
Histone 
H4;HIST1H4A;orthol
og       
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H4 
Histone 
H4;HIST1H4A;orthol
og       
HCFC
1 
Host cell factor 
1;HCFC1;ortholog 
nucleic acid 
binding;chromatin 
binding spermatogenesis   
HEXB 
Beta-
hexosaminidase 
subunit 
beta;HEXB;ortholog 
hydrolase activity, 
hydrolyzing N-
glycosyl 
compounds 
polysaccharide metabolic 
process;lipid metabolic process   
HSP7
1 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orth
olog       
HSP7
1 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orth
olog       
HSP7
1 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orth
olog       
HSP7
4 
Heat shock 70 kDa 
protein 
4;HSPA4;ortholog   
immune system 
process;protein folding;protein 
complex assembly;response to 
stress;protein complex 
biogenesis   
HSP7
C 
Heat shock cognate 
71 kDa 
protein;HSPA8;ortho
log   
immune system 
process;protein folding;protein 
complex assembly;response to 
stress;protein complex 
biogenesis   
HSPB
1 
Heat shock protein 
beta-
1;HSPB1;ortholog 
structural 
molecule activity 
immune system 
process;protein folding;muscle 
contraction;visual 
perception;sensory 
perception;response to stress   
HTSF
1 
HIV Tat-specific 
factor 
1;HTATSF1;ortholog 
catalytic 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification reactions   
HXK2 
Hexokinase-
2;HK2;ortholog 
carbohydrate 
kinase activity 
generation of precursor 
metabolites and 
energy;phosphate-containing 
compound metabolic 
process;catabolic 
process;monosaccharide 
metabolic process;cellular cytoplasm 
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process;homeostatic process 
HYOU
1 
Hypoxia up-
regulated protein 
1;HYOU1;ortholog       
ICOSL 
ICOS 
ligand;ICOSLG;orthol
og   
system development;cellular 
defense response   
IF2A 
Eukaryotic 
translation initiation 
factor 2 subunit 
1;EIF2S1;ortholog 
translation 
initiation factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
translation;regulation of 
translation   
IF4A2 
Eukaryotic initiation 
factor 4A-
II;EIF4A2;ortholog 
RNA helicase 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
nucleobase-containing 
compound metabolic 
process;translation;regulation 
of translation   
IMPA
1 
Inositol 
monophosphatase 
1;IMPA1;ortholog binding 
sulfur compound metabolic 
process;phospholipid 
metabolic process;nucleobase-
containing compound 
metabolic 
process;phospholipid 
metabolic process;cell 
communication   
INAR
2 
Interferon 
alpha/beta receptor 
2;IFNAR2;ortholog receptor activity 
natural killer cell 
activation;macrophage 
activation;apoptotic 
process;cell 
communication;apoptotic 
process;cellular defense 
response;blood 
coagulation;negative 
regulation of apoptotic process   
INHB
A 
Inhibin beta A 
chain;INHBA;ortholo
g 
growth factor 
activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
IPO7 
Importin-
7;IPO7;ortholog 
GTPase 
activity;transmem
brane transporter 
metabolic process;intracellular 
protein transport;nuclear 
transport   
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activity;protein 
binding 
ITA2 
Integrin alpha-
2;ITGA2;ortholog   cellular process;cell adhesion   
K22E 
Keratin, type II 
cytoskeletal 2 
epidermal;KRT2;orth
olog 
structural 
constituent of 
cytoskeleton 
cellular process;cellular 
component 
morphogenesis;cellular 
component organization 
intermediate filament 
cytoskeleton;intracellul
ar 
KPYM 
Pyruvate kinase 
isozymes 
M1/M2;PKM;orthol
og       
LTBP4 
Latent-transforming 
growth factor beta-
binding protein 
4;LTBP4;ortholog 
extracellular 
matrix structural 
constituent;calciu
m ion 
binding;receptor 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
cell communication;skeletal 
system development 
extracellular 
region;extracellular 
matrix 
LYPA2 
Acyl-protein 
thioesterase 
2;LYPLA2;ortholog 
phospholipase 
activity 
lipid metabolic process;protein 
lipidation;cell communication   
LYPD
3 
Ly6/PLAUR domain-
containing protein 
3;LYPD3;ortholog       
MCM
2 
DNA replication 
licensing factor 
MCM2;MCM2;ortho
log 
DNA helicase 
activity;hydrolase 
activity;nucleic 
acid binding DNA replication;cell cycle   
MCM
4 
DNA replication 
licensing factor 
MCM4;MCM4;ortho
log 
nucleic acid 
binding DNA replication;cell cycle   
MCTS
1 
Malignant T-cell-
amplified sequence 
1;MCTS1;ortholog receptor activity cell cycle   
METK
2 
S-
adenosylmethionine 
synthase isoform 
type-
2;MAT2A;ortholog 
nucleotidyltransfer
ase activity 
cellular amino acid metabolic 
process   
MICB 
MHC class I 
polypeptide-related 
sequence 
B;MICB;ortholog       
MMP Stromelysin- metallopeptidase proteolysis extracellular 
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10 2;MMP10;ortholog activity region;extracellular 
matrix 
MMP
9 
Matrix 
metalloproteinase-
9;MMP9;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracellular 
matrix 
MTN
A 
Methylthioribose-1-
phosphate 
isomerase;MRI1;ort
holog isomerase activity 
sulfur compound metabolic 
process;nitrogen compound 
metabolic process;biosynthetic 
process;cellular amino acid 
biosynthetic process;cellular 
process intracellular 
MVP 
Major vault 
protein;MVP;orthol
og RNA binding   
ribonucleoprotein 
complex 
NEUR
1 
Sialidase-
1;NEU1;ortholog       
NMT1 
Glycylpeptide N-
tetradecanoyltransf
erase 
1;NMT1;ortholog transferase activity protein lipidation   
NP1L
4 
Nucleosome 
assembly protein 1-
like 
4;NAP1L4;ortholog 
phosphatase 
activity;phosphata
se activity;protein 
binding;phosphata
se inhibitor 
activity;phosphata
se regulator 
activity 
apoptotic process;DNA 
replication;cell cycle;apoptotic 
process;regulation of catalytic 
activity;chromatin organization   
NRG1 
Pro-neuregulin-1, 
membrane-bound 
isoform;NRG1;ortho
log 
growth factor 
activity 
cell-cell signaling;ectoderm 
development;nervous system 
development   
OAF 
Out at first protein 
homolog;OAF;orthol
og       
OFUT
1 
GDP-fucose protein 
O-fucosyltransferase 
1;POFUT1;ortholog       
OSTP 
Osteopontin;SPP1;o
rtholog cytokine activity 
immune system 
process;cellular process;cell 
adhesion;cellular component 
morphogenesis;cellular 
component organization 
extracellular 
region;extracellular 
matrix 
OXSR
1 
Serine/threonine-
protein kinase 
OSR1;OXSR1;ortholo
g       
PAI1 
Plasminogen 
activator inhibitor 
serine-type 
peptidase 
proteolysis;regulation of 
biological process;regulation of   
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1;SERPINE1;ortholog activity;peptidase 
inhibitor activity 
catalytic activity 
PARK
7 
Protein DJ-
1;PARK7;ortholog 
sequence-specific 
DNA binding 
transcription 
factor 
activity;cysteine-
type peptidase 
activity;sequence-
specific DNA 
binding 
transcription 
factor activity;RNA 
binding 
transcription from RNA 
polymerase II 
promoter;proteolysis;response 
to stress;regulation of 
transcription from RNA 
polymerase II promoter   
PCBP
3 
Poly(rC)-binding 
protein 
3;PCBP3;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of apoptosis;RNA 
splicing, via transesterification 
reactions;transcription from 
RNA polymerase II 
promoter;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification 
reactions;protein metabolic 
process;cell cycle;cell 
communication;neurological 
system process;induction of 
apoptosis;intracellular protein 
transport;nuclear transport 
ribonucleoprotein 
complex 
PDC6I 
Programmed cell 
death 6-interacting 
protein;PDCD6IP;ort
holog   
induction of 
apoptosis;induction of 
apoptosis   
PDIA3 
Protein disulfide-
isomerase 
A3;PDIA3;ortholog 
protein disulfide 
isomerase activity 
protein folding;cellular protein 
modification process   
PFD4 
Prefoldin subunit 
4;PFDN4;ortholog       
PFD5 
Prefoldin subunit 
5;PFDN5;ortholog       
PKN2 
Serine/threonine-
protein kinase 
N2;PKN2;ortholog 
protein kinase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
protein phosphorylation;cell 
communication   
PLD3 
Phospholipase 
D3;PLD3;ortholog 
phospholipase 
activity lipid metabolic process   
PODX
L 
Podocalyxin;PODXL;
ortholog       
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PRIO 
Major prion 
protein;PRNP;orthol
og       
PRS4 
26S protease 
regulatory subunit 
4;PSMC1;ortholog hydrolase activity proteolysis   
PSA1 
Proteasome subunit 
alpha type-
1;PSMA1;ortholog peptidase activity proteolysis   
PSA4 
Proteasome subunit 
alpha type-
4;PSMA4;ortholog peptidase activity proteolysis   
PSB1 
Proteasome subunit 
beta type-
1;PSMB1;ortholog peptidase activity proteolysis   
PTN1
1 
Tyrosine-protein 
phosphatase non-
receptor type 
11;PTPN11;ortholog 
phosphoprotein 
phosphatase 
activity;phosphopr
otein phosphatase 
activity 
cellular protein modification 
process cytoplasm 
PUR8 
Adenylosuccinate 
lyase;ADSL;ortholog lyase activity 
purine nucleobase metabolic 
process;cellular amino acid 
metabolic process   
PVRL
1 
Poliovirus receptor-
related protein 
1;PVRL1;ortholog receptor activity 
cell communication;cell-cell 
adhesion   
PVRL
2 
Poliovirus receptor-
related protein 
2;PVRL2;ortholog receptor activity 
cell communication;cell-cell 
adhesion   
PVRL
4 
Poliovirus receptor-
related protein 
4;PVRL4;ortholog receptor activity 
cell communication;cell-cell 
adhesion   
PYR1 
CAD 
protein;CAD;ortholo
g 
transferase 
activity;ligase 
activity 
nitrogen compound metabolic 
process;pyrimidine nucleobase 
metabolic process;cellular 
amino acid biosynthetic 
process   
PZP 
Pregnancy zone 
protein;PZP;ortholo
g 
peptidase 
activity;cytokine 
activity;serine-type 
endopeptidase 
inhibitor activity 
complement 
activation;proteolysis;cellular 
process;response to 
stimulus;regulation of catalytic 
activity   
RAB1
3 
Ras-related protein 
Rab-
13;RAB13;ortholog       
RHOA 
Transforming 
protein 
RhoA;RHOA;ortholo
g 
GTPase 
activity;protein 
binding 
metabolic process;cell 
communication;intracellular 
protein transport;receptor-
mediated endocytosis   
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RIC8A 
Synembryn-
A;RIC8A;ortholog       
RL19 
60S ribosomal 
protein 
L19;RPL19;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RL23
A 
60S ribosomal 
protein 
L23a;RPL23A;orthol
og 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RLA2 
60S acidic ribosomal 
protein 
P2;RPLP2;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RNT2 
Ribonuclease 
T2;RNASET2;ortholo
g 
endoribonuclease 
activity;nucleic 
acid binding RNA catabolic process   
ROAA 
Heterogeneous 
nuclear 
ribonucleoprotein 
A/B;HNRNPAB;ortho
log 
catalytic 
activity;structural 
constituent of 
ribosome;poly(A) 
RNA binding 
DNA replication;RNA splicing, 
via transesterification 
reactions;mRNA splicing, via 
spliceosome;mRNA 
polyadenylation;RNA splicing, 
via transesterification 
reactions;rRNA metabolic 
process;protein metabolic 
process;cell cycle;neurological 
system process;ectoderm 
development;nervous system 
development 
ribonucleoprotein 
complex 
RPN1 
Dolichyl-
diphosphooligosacc
haride--protein 
glycosyltransferase 
subunit 
1;RPN1;ortholog 
transferase 
activity, 
transferring 
glycosyl groups 
translation;protein 
glycosylation   
RS27
A 
Ubiquitin-40S 
ribosomal protein 
S27a;RPS27A;orthol
og 
structural 
constituent of 
ribosome;nucleic 
acid binding proteolysis   
RS9 
40S ribosomal 
protein 
S9;RPS9;ortholog       
RSMB 
Small nuclear 
ribonucleoprotein-
associated proteins 
B and 
B';SNRPB;ortholog 
catalytic 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification reactions   
S10A
6 
Protein S100-
A6;S100A6;ortholog 
calcium ion 
binding;growth 
macrophage activation;DNA 
replication;cell cycle;cell   
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factor 
activity;calmodulin 
binding 
communication 
S30B
P 
SAP30-binding 
protein;SAP30BP;ort
holog 
sequence-specific 
DNA binding 
transcription 
factor 
activity;sequence-
specific DNA 
binding 
transcription 
factor activity 
transcription from RNA 
polymerase II promoter   
SAFB
1 
Scaffold attachment 
factor 
B1;SAFB;ortholog       
SC23
A 
Protein transport 
protein 
Sec23A;SEC23A;orth
olog 
catalytic 
activity;protein 
binding;small 
GTPase regulator 
activity 
metabolic process;cell 
communication;intracellular 
protein 
transport;exocytosis;regulation 
of catalytic activity   
SDC1 
Syndecan-
1;SDC1;ortholog 
structural 
constituent of 
cytoskeleton;recep
tor binding 
macrophage activation;cell 
communication;cell 
adhesion;skeletal system 
development 
extracellular 
region;cytoskeleton;intr
acellular 
SEM4
C 
Semaphorin-
4C;SEMA4C;ortholo
g receptor binding 
immune system process;cell 
communication;neurological 
system process;ectoderm 
development;mesoderm 
development;angiogenesis;ner
vous system 
development;heart 
development   
SEM5
A 
Semaphorin-
5A;SEMA5A;ortholo
g receptor binding 
immune system process;cell 
communication;neurological 
system process;ectoderm 
development;mesoderm 
development;angiogenesis;ner
vous system 
development;heart 
development   
SK2L2 
Superkiller viralicidic 
activity 2-like 
2;SKIV2L2;ortholog 
DNA helicase 
activity;RNA 
helicase 
activity;hydrolase 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification 
reactions;cell cycle   
SLIT1 
Slit homolog 1 
protein;SLIT1;orthol
og receptor activity 
immune system 
process;transcription from 
RNA polymerase II 
extracellular 
region;extracellular 
matrix 
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promoter;protein 
phosphorylation;cellular 
component movement;cell-cell 
signaling;cell-cell 
adhesion;sensory 
perception;ectoderm 
development;nervous system 
development;regulation of 
transcription from RNA 
polymerase II promoter 
SMD2 
Small nuclear 
ribonucleoprotein 
Sm 
D2;SNRPD2;ortholog mRNA binding mRNA processing   
SMRC
2 
SWI/SNF complex 
subunit 
SMARCC2;SMARCC2
;ortholog 
transcription 
cofactor 
activity;sequence-
specific DNA 
binding 
transcription 
factor 
activity;sequence-
specific DNA 
binding 
transcription 
factor 
activity;chromatin 
binding;protein 
binding 
transcription from RNA 
polymerase II 
promoter;regulation of 
transcription from RNA 
polymerase II promoter   
SNAA 
Alpha-soluble NSF 
attachment 
protein;NAPA;orthol
og   intracellular protein transport   
SPIT1 
Kunitz-type protease 
inhibitor 
1;SPINT1;ortholog 
peptidase 
activity;protein 
binding;serine-
type 
endopeptidase 
inhibitor activity 
immune system 
process;proteolysis;blood 
coagulation;regulation of 
catalytic activity   
SPSY 
Spermine 
synthase;SMS;orthol
og transferase activity metabolic process   
SRRM
2 
Serine/arginine 
repetitive matrix 
protein 
2;SRRM2;ortholog       
STK24 
Serine/threonine-
protein kinase 
24;STK24;ortholog       
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SYK 
Lysine--tRNA 
ligase;KARS;ortholog 
aminoacyl-tRNA 
ligase activity;RNA 
binding translation   
TB18
2 
182 kDa tankyrase-
1-binding 
protein;TNKS1BP1;o
rtholog   
mitosis;chromosome 
segregation   
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBL1R 
F-box-like/WD 
repeat-containing 
protein 
TBL1XR1;TBL1XR1;or
tholog       
TCP4 
Activated RNA 
polymerase II 
transcriptional 
coactivator 
p15;SUB1;ortholog       
TCPE 
T-complex protein 1 
subunit 
epsilon;CCT5;orthol
og   protein folding   
TGFB
1 
Transforming 
growth factor beta-
1;TGFB1;ortholog 
growth factor 
activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
TIMP
1 
Metalloproteinase 
inhibitor 
1;TIMP1;ortholog 
peptidase 
activity;protein 
binding;metalloen
dopeptidase 
inhibitor activity 
proteolysis;regulation of 
catalytic activity   
TPA 
Tissue-type 
plasminogen 
activator;PLAT;ortho
log 
serine-type 
peptidase activity proteolysis;blood coagulation extracellular region 
TPD5
2 
Tumor protein 
D52;TPD52;ortholog       
TSN1 
Tetraspanin-
1;TSPAN1;ortholog 
receptor 
activity;receptor 
binding 
gamete generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological system   
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process;blood coagulation 
TTL12 
Tubulin--tyrosine 
ligase-like protein 
12;TTLL12;ortholog 
ligase 
activity;structural 
constituent of 
cytoskeleton protein metabolic process 
microtubule;cytoskelet
on;intracellular 
TXD1
7 
Thioredoxin domain-
containing protein 
17;TXNDC17;ortholo
g 
transmembrane 
transporter activity 
respiratory electron transport 
chain;transport   
U520 
U5 small nuclear 
ribonucleoprotein 
200 kDa 
helicase;SNRNP200;
ortholog 
DNA helicase 
activity;RNA 
helicase 
activity;hydrolase 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA splicing, via 
spliceosome;RNA splicing, via 
transesterification 
reactions;meiosis   
UBQL
1 
Ubiquilin-
1;UBQLN1;ortholog   proteolysis   
 
UN45
A 
 
Protein unc-45 
homolog 
A;UNC45A;ortholog   
 
immune system 
process;protein 
folding;response to stress   
VAS1 
V-type proton 
ATPase subunit 
S1;ATP6AP1;ortholo
g 
hydrolase 
activity;cation 
transmembrane 
transporter 
activity;proton-
transporting ATP 
synthase activity, 
rotational 
mechanism 
nucleobase-containing 
compound metabolic 
process;cation transport 
proton-transporting 
ATP synthase 
complex;intracellular 
XPO1 
Exportin-
1;XPO1;ortholog receptor activity 
transcription from RNA 
polymerase II promoter;mRNA 
transcription;mRNA 
transcription;protein 
metabolic process;intracellular 
protein transport;nucleobase-
containing compound 
transport   
XPOT 
Exportin-
T;XPOT;ortholog RNA binding tRNA metabolic process   
ZN20
7 
Zinc finger protein 
207;ZNF207;ortholo
g DNA binding 
nucleobase-containing 
compound metabolic process   
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Appendix C 
Proteins down-regulated by Marimastat half-fold. Their cellular location, biological function and 
molecular function have been determined using Panther database (http://www.pantherdb.org/)  
Accessi
on 
Name Name Molecular function Biological function Cellular component 
1433S 
14-3-3 protein 
sigma;SFN;ortholog   
cell cycle;cell 
communication   
2A5G 
Serine/threonine-
protein phosphatase 
2A 56 kDa regulatory 
subunit gamma 
isoform;PPP2R5C;orth
olog 
phosphoprotein 
phosphatase 
activity;phosphoprot
ein phosphatase 
activity 
protein 
phosphorylation;cell 
communication   
2AAA 
Serine/threonine-
protein phosphatase 
2A 65 kDa regulatory 
subunit A alpha 
isoform;PPP2R1A;orth
olog 
phosphoprotein 
phosphatase 
activity;phosphoprot
ein phosphatase 
activity metabolic process   
ABCF1 
ATP-binding cassette 
sub-family F member 
1;ABCF1;ortholog       
ACLY 
ATP-citrate 
synthase;ACLY;orthol
og       
ADAM9 
Disintegrin and 
metalloproteinase 
domain-containing 
protein 
9;ADAM9;ortholog   
fertilization;apoptotic 
process;neurological 
system 
process;mesoderm 
development;apoptotic 
process;heart 
development   
AGRIN Agrin;AGRN;ortholog receptor activity 
cell 
communication;cell-
matrix adhesion;cell-
cell 
adhesion;neurological 
system 
process;ectoderm 
development 
extracellular 
region;extracellular 
matrix 
AHSA1 
Activator of 90 kDa 
heat shock protein 
ATPase homolog 
catalytic 
activity;protein 
binding;enzyme 
immune system 
process;protein 
folding;response to   
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1;AHSA1;ortholog activator activity stress;regulation of 
catalytic activity 
AIP 
AH receptor-
interacting 
protein;AIP;ortholog   
visual 
perception;sensory 
perception   
ANXA1 
Annexin 
A1;ANXA1;ortholog   
fatty acid metabolic 
process;cell 
communication   
ARPC4 
Actin-related protein 
2/3 complex subunit 
4;ARPC4;ortholog 
structural 
constituent of 
cytoskeleton 
cellular component 
movement;cellular 
component 
organization 
actin 
cytoskeleton;intracellular 
BLVRB 
Flavin reductase 
(NADPH);BLVRB;ortho
log 
oxidoreductase 
activity metabolic process   
BROX 
BRO1 domain-
containing protein 
BROX;BROX;ortholog       
C1R 
Complement C1r 
subcomponent;C1R;or
tholog 
serine-type 
peptidase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
gamete 
generation;complemen
t 
activation;proteolysis;c
ellular process;blood 
coagulation   
CADH2 
Cadherin-
2;CDH2;ortholog binding 
cellular process;visual 
perception;sensory 
perception of 
sound;mesoderm 
development;nervous 
system 
development;heart 
development;muscle 
organ development 
plasma membrane;cell 
part 
CADH3 
Cadherin-
3;CDH3;ortholog binding 
cellular process;visual 
perception;sensory 
perception of 
sound;mesoderm 
development;nervous 
system 
development;heart 
development;muscle 
organ development 
plasma membrane;cell 
part 
CALX 
Calnexin;CANX;orthol
og calcium ion binding 
protein 
folding;intracellular 
protein 
transport;exocytosis   
CAPG Macrophage-capping structural cellular process;cellular actin 
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protein;CAPG;ortholo
g 
constituent of 
cytoskeleton;calciu
m ion binding;actin 
binding 
component 
morphogenesis;cellular 
component 
organization 
cytoskeleton;intracellular 
CATL2 
Cathepsin 
L2;CTSL2;ortholog 
cysteine-type 
peptidase activity 
proteolysis;cell 
adhesion   
CAYP1 
Calcyphosin;CAPS;ort
holog 
catalytic 
activity;calcium ion 
binding;receptor 
binding;calmodulin 
binding;enzyme 
regulator activity 
metabolic process;cell 
cycle;cell 
communication;cation 
transport;regulation of 
catalytic activity   
CEL 
Bile salt-activated 
lipase;CEL;ortholog lipase activity metabolic process 
extracellular 
region;cytoplasm 
CFAB 
Complement factor 
B;CFB;ortholog       
CG050 
Uncharacterized 
protein 
C7orf50;C7orf50;orth
olog       
CHSTB 
Carbohydrate 
sulfotransferase 
11;CHST11;ortholog transferase activity 
sulfur compound 
metabolic process   
CLIC1 
Chloride intracellular 
channel protein 
1;CLIC1;ortholog       
CLIC1 
Chloride intracellular 
channel protein 
1;CLIC1;ortholog       
CN37 
2',3'-cyclic-nucleotide 
3'-
phosphodiesterase;C
NP;ortholog 
phosphoric diester 
hydrolase activity 
cyclic nucleotide 
metabolic process   
CNDP2 
Cytosolic non-specific 
dipeptidase;CNDP2;or
tholog 
metallopeptidase 
activity;deacetylase 
activity 
cellular amino acid 
biosynthetic 
process;protein 
phosphorylation;proteo
lysis   
CNOT3 
CCR4-NOT 
transcription complex 
subunit 
3;CNOT3;ortholog       
CO5A2 
Collagen alpha-2(V) 
chain;COL5A2;ortholo
g 
receptor 
activity;extracellular 
matrix structural 
constituent;transme
mbrane transporter 
activity 
macrophage 
activation;cell 
communication;cell-cell 
adhesion;blood 
circulation;ectoderm 
development;mesoder
m development;cellular 
extracellular 
region;extracellular 
matrix 
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component 
morphogenesis;respons
e to 
stimulus;intracellular 
protein 
transport;receptor-
mediated 
endocytosis;regulation 
of liquid surface 
tension;cellular 
component 
organization 
COR1C 
Coronin-
1C;CORO1C;ortholog actin binding 
cellular 
process;cytoskeleton 
organization cytoskeleton;intracellular 
CPNE3 
Copine-
3;CPNE3;ortholog   
intracellular protein 
transport   
CTNA1 
Catenin alpha-
1;CTNNA1;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cell communication;cell 
adhesion;cellular 
component 
morphogenesis;cellular 
component 
organization intracellular 
CUL2 
Cullin-
2;CUL2;ortholog 
ubiquitin-protein 
ligase activity proteolysis;cell cycle   
CYTM 
Cystatin-
M;CST6;ortholog 
cysteine-type 
peptidase 
activity;protein 
binding;cysteine-
type endopeptidase 
inhibitor activity 
proteolysis;regulation 
of catalytic activity   
DDR1 
Epithelial discoidin 
domain-containing 
receptor 
1;DDR1;ortholog       
DDX5 
Probable ATP-
dependent RNA 
helicase 
DDX5;DDX5;ortholog 
RNA helicase 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
nucleobase-containing 
compound metabolic 
process;translation;reg
ulation of translation   
DEK 
Protein 
DEK;DEK;ortholog       
DESP 
Desmoplakin;DSP;orth
olog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cellular component 
movement;cellular 
component 
morphogenesis;cellular 
actin 
cytoskeleton;intracellular 
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component 
organization 
DLDH 
Dihydrolipoyl 
dehydrogenase, 
mitochondrial;DLD;ort
holog 
oxidoreductase 
activity 
respiratory electron 
transport 
chain;nitrogen 
compound metabolic 
process;ferredoxin 
metabolic process   
E41L1 
Band 4.1-like protein 
1;EPB41L1;ortholog       
EPCR 
Endothelial protein C 
receptor;PROCR;ortho
log 
receptor 
activity;protein 
binding 
immune system 
process;cell 
communication;blood 
coagulation   
ERAP2 
Endoplasmic 
reticulum 
aminopeptidase 
2;ERAP2;ortholog 
metallopeptidase 
activity proteolysis   
F10A1 
Hsc70-interacting 
protein;ST13;ortholog   
protein 
folding;response to 
stress   
FHL2 
Four and a half LIM 
domains protein 
2;FHL2;ortholog 
sequence-specific 
DNA binding 
transcription factor 
activity;sequence-
specific DNA binding 
transcription factor 
activity 
mesoderm 
development;muscle 
organ development   
FRPD1 
FERM and PDZ 
domain-containing 
protein 
1;FRMPD1;ortholog       
FST 
Follistatin;FST;ortholo
g protein binding     
FUBP1 
Far upstream 
element-binding 
protein 
1;FUBP1;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of 
apoptosis;RNA splicing, 
via transesterification 
reactions;transcription 
from RNA polymerase II 
promoter;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions;protein 
metabolic process;cell 
communication;neurolo
gical system 
process;induction of 
ribonucleoprotein 
complex 
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apoptosis;intracellular 
protein 
transport;nuclear 
transport 
FUBP2 
Far upstream 
element-binding 
protein 
2;KHSRP;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of 
apoptosis;RNA splicing, 
via transesterification 
reactions;transcription 
from RNA polymerase II 
promoter;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions;protein 
metabolic process;cell 
communication;neurolo
gical system 
process;induction of 
apoptosis;intracellular 
protein 
transport;nuclear 
transport 
ribonucleoprotein 
complex 
FZD6 
Frizzled-
6;FZD6;ortholog 
guanylate cyclase 
activity;receptor 
activity;protein 
binding 
reproduction;phosphat
e-containing compound 
metabolic 
process;nitrogen 
compound metabolic 
process;biosynthetic 
process;cyclic 
nucleotide metabolic 
process;cell 
communication;cell 
proliferation;single-
multicellular organism 
process;cellular 
component 
morphogenesis;embryo 
development;cell 
differentiation;nervous 
system 
development;response 
to stimulus;regulation 
of nucleobase-
containing compound 
metabolic 
process;regulation of 
phosphate metabolic 
process;regulation of 
plasma 
membrane;intracellular;n
euron projection 
P a g e  | 136 
 
catalytic activity;cellular 
component 
organization 
G3P 
Glyceraldehyde-3-
phosphate 
dehydrogenase;GAPD
H;ortholog 
oxidoreductase 
activity glycolysis;glycolysis   
GLYG 
Glycogenin-
1;GYG1;ortholog 
transferase activity, 
transferring glycosyl 
groups 
glycogen metabolic 
process   
GNAI2 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-
2;GNAI2;ortholog       
GNAI2 
Guanine nucleotide-
binding protein G(i) 
subunit alpha-
2;GNAI2;ortholog 
pyrophosphatase 
activity;adenylate 
cyclase 
activity;receptor 
binding 
phosphate-containing 
compound metabolic 
process;nitrogen 
compound metabolic 
process;catabolic 
process;biosynthetic 
process;cyclic 
nucleotide metabolic 
process;cell 
communication;respons
e to stimulus;regulation 
of nucleobase-
containing compound 
metabolic 
process;regulation of 
phosphate metabolic 
process;regulation of 
catalytic activity 
plasma 
membrane;protein 
complex;intracellular 
GRN 
Granulins;GRN;orthol
og       
H4 
Histone 
H4;HIST1H4A;ortholo
g       
H4 
Histone 
H4;HIST1H4A;ortholo
g       
HCFC1 
Host cell factor 
1;HCFC1;ortholog 
nucleic acid 
binding;chromatin 
binding spermatogenesis   
HEXB 
Beta-hexosaminidase 
subunit 
beta;HEXB;ortholog 
hydrolase activity, 
hydrolyzing N-
glycosyl compounds 
polysaccharide 
metabolic process;lipid 
metabolic process   
HSP71 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orthol       
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og 
HSP71 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orthol
og       
HSP71 
Heat shock 70 kDa 
protein 
1A/1B;HSPA1A;orthol
og       
HSP74 
Heat shock 70 kDa 
protein 
4;HSPA4;ortholog   
immune system 
process;protein 
folding;protein complex 
assembly;response to 
stress;protein complex 
biogenesis   
HSP7C 
Heat shock cognate 
71 kDa 
protein;HSPA8;orthol
og   
immune system 
process;protein 
folding;protein complex 
assembly;response to 
stress;protein complex 
biogenesis   
HSPB1 
Heat shock protein 
beta-
1;HSPB1;ortholog 
structural molecule 
activity 
immune system 
process;protein 
folding;muscle 
contraction;visual 
perception;sensory 
perception;response to 
stress   
HTSF1 
HIV Tat-specific factor 
1;HTATSF1;ortholog 
catalytic 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions   
HXK2 
Hexokinase-
2;HK2;ortholog 
carbohydrate kinase 
activity 
generation of precursor 
metabolites and 
energy;phosphate-
containing compound 
metabolic 
process;catabolic 
process;monosaccharid
e metabolic 
process;cellular 
process;homeostatic 
process cytoplasm 
HYOU1 
Hypoxia up-regulated 
protein       
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1;HYOU1;ortholog 
ICOSL 
ICOS 
ligand;ICOSLG;ortholo
g   
system 
development;cellular 
defense response   
IF2A 
Eukaryotic translation 
initiation factor 2 
subunit 
1;EIF2S1;ortholog 
translation initiation 
factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
translation;regulation 
of translation   
IF4A2 
Eukaryotic initiation 
factor 4A-
II;EIF4A2;ortholog 
RNA helicase 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity;translation 
initiation factor 
activity 
nucleobase-containing 
compound metabolic 
process;translation;reg
ulation of translation   
IMPA1 
Inositol 
monophosphatase 
1;IMPA1;ortholog binding 
sulfur compound 
metabolic 
process;phospholipid 
metabolic 
process;nucleobase-
containing compound 
metabolic 
process;phospholipid 
metabolic process;cell 
communication   
INAR2 
Interferon alpha/beta 
receptor 
2;IFNAR2;ortholog receptor activity 
natural killer cell 
activation;macrophage 
activation;apoptotic 
process;cell 
communication;apopto
tic process;cellular 
defense response;blood 
coagulation;negative 
regulation of apoptotic 
process   
INHBA 
Inhibin beta A 
chain;INHBA;ortholog 
growth factor 
activity 
female gamete 
generation;cell 
communication;ectoder
m 
development;mesoder
m development;skeletal 
system 
development;heart 
development;muscle 
organ development   
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IPO7 
Importin-
7;IPO7;ortholog 
GTPase 
activity;transmembr
ane transporter 
activity;protein 
binding 
metabolic 
process;intracellular 
protein 
transport;nuclear 
transport   
ITA2 
Integrin alpha-
2;ITGA2;ortholog   
cellular process;cell 
adhesion   
K22E 
Keratin, type II 
cytoskeletal 2 
epidermal;KRT2;ortho
log 
structural 
constituent of 
cytoskeleton 
cellular process;cellular 
component 
morphogenesis;cellular 
component 
organization 
intermediate filament 
cytoskeleton;intracellular 
KPYM 
Pyruvate kinase 
isozymes 
M1/M2;PKM;ortholog       
LTBP4 
Latent-transforming 
growth factor beta-
binding protein 
4;LTBP4;ortholog 
extracellular matrix 
structural 
constituent;calcium 
ion binding;receptor 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
cell 
communication;skeletal 
system development 
extracellular 
region;extracellular 
matrix 
LYPA2 
Acyl-protein 
thioesterase 
2;LYPLA2;ortholog 
phospholipase 
activity 
lipid metabolic 
process;protein 
lipidation;cell 
communication   
LYPD3 
Ly6/PLAUR domain-
containing protein 
3;LYPD3;ortholog       
MCM2 
DNA replication 
licensing factor 
MCM2;MCM2;ortholo
g 
DNA helicase 
activity;hydrolase 
activity;nucleic acid 
binding 
DNA replication;cell 
cycle   
MCM4 
DNA replication 
licensing factor 
MCM4;MCM4;ortholo
g nucleic acid binding 
DNA replication;cell 
cycle   
MCTS1 
Malignant T-cell-
amplified sequence 
1;MCTS1;ortholog receptor activity cell cycle   
METK2 
S-adenosylmethionine 
synthase isoform 
type-
2;MAT2A;ortholog 
nucleotidyltransfera
se activity 
cellular amino acid 
metabolic process   
MICB 
MHC class I 
polypeptide-related 
sequence       
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B;MICB;ortholog 
MMP10 
Stromelysin-
2;MMP10;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracellular 
matrix 
MMP9 
Matrix 
metalloproteinase-
9;MMP9;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracellular 
matrix 
MTNA 
Methylthioribose-1-
phosphate 
isomerase;MRI1;ortho
log isomerase activity 
sulfur compound 
metabolic 
process;nitrogen 
compound metabolic 
process;biosynthetic 
process;cellular amino 
acid biosynthetic 
process;cellular process intracellular 
MVP 
Major vault 
protein;MVP;ortholog RNA binding   
ribonucleoprotein 
complex 
NEUR1 
Sialidase-
1;NEU1;ortholog       
NMT1 
Glycylpeptide N-
tetradecanoyltransfer
ase 1;NMT1;ortholog transferase activity protein lipidation   
NP1L4 
Nucleosome assembly 
protein 1-like 
4;NAP1L4;ortholog 
phosphatase 
activity;phosphatase 
activity;protein 
binding;phosphatas
e inhibitor 
activity;phosphatase 
regulator activity 
apoptotic process;DNA 
replication;cell 
cycle;apoptotic 
process;regulation of 
catalytic 
activity;chromatin 
organization   
NRG1 
Pro-neuregulin-1, 
membrane-bound 
isoform;NRG1;ortholo
g 
growth factor 
activity 
cell-cell 
signaling;ectoderm 
development;nervous 
system development   
OAF 
Out at first protein 
homolog;OAF;ortholo
g       
OFUT1 
GDP-fucose protein O-
fucosyltransferase 
1;POFUT1;ortholog       
OSTP 
Osteopontin;SPP1;ort
holog cytokine activity 
immune system 
process;cellular 
process;cell 
adhesion;cellular 
component 
morphogenesis;cellular 
component 
organization 
extracellular 
region;extracellular 
matrix 
OXSR1 
Serine/threonine-
protein kinase       
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OSR1;OXSR1;ortholog 
PAI1 
Plasminogen activator 
inhibitor 
1;SERPINE1;ortholog 
serine-type 
peptidase 
activity;peptidase 
inhibitor activity 
proteolysis;regulation 
of biological 
process;regulation of 
catalytic activity   
PARK7 
Protein DJ-
1;PARK7;ortholog 
sequence-specific 
DNA binding 
transcription factor 
activity;cysteine-
type peptidase 
activity;sequence-
specific DNA binding 
transcription factor 
activity;RNA binding 
transcription from RNA 
polymerase II 
promoter;proteolysis;re
sponse to 
stress;regulation of 
transcription from RNA 
polymerase II promoter   
PCBP3 
Poly(rC)-binding 
protein 
3;PCBP3;ortholog 
catalytic 
activity;mRNA 
binding;protein 
binding 
induction of 
apoptosis;RNA splicing, 
via transesterification 
reactions;transcription 
from RNA polymerase II 
promoter;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions;protein 
metabolic process;cell 
cycle;cell 
communication;neurolo
gical system 
process;induction of 
apoptosis;intracellular 
protein 
transport;nuclear 
transport 
ribonucleoprotein 
complex 
PDC6I 
Programmed cell 
death 6-interacting 
protein;PDCD6IP;orth
olog   
induction of 
apoptosis;induction of 
apoptosis   
PDIA3 
Protein disulfide-
isomerase 
A3;PDIA3;ortholog 
protein disulfide 
isomerase activity 
protein folding;cellular 
protein modification 
process   
PFD4 
Prefoldin subunit 
4;PFDN4;ortholog       
PFD5 
Prefoldin subunit 
5;PFDN5;ortholog       
PKN2 
Serine/threonine-
protein kinase 
N2;PKN2;ortholog 
protein kinase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
protein 
phosphorylation;cell 
communication   
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dependent 
phospholipid 
binding 
PLD3 
Phospholipase 
D3;PLD3;ortholog 
phospholipase 
activity lipid metabolic process   
PODXL 
Podocalyxin;PODXL;or
tholog       
PRIO 
Major prion 
protein;PRNP;ortholo
g       
PRS4 
26S protease 
regulatory subunit 
4;PSMC1;ortholog hydrolase activity proteolysis   
PSA1 
Proteasome subunit 
alpha type-
1;PSMA1;ortholog peptidase activity proteolysis   
PSA4 
Proteasome subunit 
alpha type-
4;PSMA4;ortholog peptidase activity proteolysis   
PSB1 
Proteasome subunit 
beta type-
1;PSMB1;ortholog peptidase activity proteolysis   
PTN11 
Tyrosine-protein 
phosphatase non-
receptor type 
11;PTPN11;ortholog 
phosphoprotein 
phosphatase 
activity;phosphoprot
ein phosphatase 
activity 
cellular protein 
modification process cytoplasm 
PUR8 
Adenylosuccinate 
lyase;ADSL;ortholog lyase activity 
purine nucleobase 
metabolic 
process;cellular amino 
acid metabolic process   
PVRL1 
Poliovirus receptor-
related protein 
1;PVRL1;ortholog receptor activity 
cell 
communication;cell-cell 
adhesion   
PVRL2 
Poliovirus receptor-
related protein 
2;PVRL2;ortholog receptor activity 
cell 
communication;cell-cell 
adhesion   
PVRL4 
Poliovirus receptor-
related protein 
4;PVRL4;ortholog receptor activity 
cell 
communication;cell-cell 
adhesion   
PYR1 
CAD 
protein;CAD;ortholog 
transferase 
activity;ligase 
activity 
nitrogen compound 
metabolic 
process;pyrimidine 
nucleobase metabolic 
process;cellular amino 
acid biosynthetic 
process   
PZP 
Pregnancy zone 
protein;PZP;ortholog 
peptidase 
activity;cytokine 
complement 
activation;proteolysis;c   
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activity;serine-type 
endopeptidase 
inhibitor activity 
ellular 
process;response to 
stimulus;regulation of 
catalytic activity 
RAB13 
Ras-related protein 
Rab-
13;RAB13;ortholog       
RHOA 
Transforming protein 
RhoA;RHOA;ortholog 
GTPase 
activity;protein 
binding 
metabolic process;cell 
communication;intracel
lular protein 
transport;receptor-
mediated endocytosis   
RIC8A 
Synembryn-
A;RIC8A;ortholog       
RL19 
60S ribosomal protein 
L19;RPL19;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RL23A 
60S ribosomal protein 
L23a;RPL23A;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RLA2 
60S acidic ribosomal 
protein 
P2;RPLP2;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding translation   
RNT2 
Ribonuclease 
T2;RNASET2;ortholog 
endoribonuclease 
activity;nucleic acid 
binding RNA catabolic process   
ROAA 
Heterogeneous 
nuclear 
ribonucleoprotein 
A/B;HNRNPAB;orthol
og 
catalytic 
activity;structural 
constituent of 
ribosome;poly(A) 
RNA binding 
DNA replication;RNA 
splicing, via 
transesterification 
reactions;mRNA 
splicing, via 
spliceosome;mRNA 
polyadenylation;RNA 
splicing, via 
transesterification 
reactions;rRNA 
metabolic 
process;protein 
metabolic process;cell 
cycle;neurological 
system 
process;ectoderm 
development;nervous 
system development 
ribonucleoprotein 
complex 
RPN1 
Dolichyl-
diphosphooligosaccha
transferase activity, 
transferring glycosyl 
translation;protein 
glycosylation   
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ride--protein 
glycosyltransferase 
subunit 
1;RPN1;ortholog 
groups 
RS27A 
Ubiquitin-40S 
ribosomal protein 
S27a;RPS27A;ortholog 
structural 
constituent of 
ribosome;nucleic 
acid binding proteolysis   
RS9 
40S ribosomal protein 
S9;RPS9;ortholog       
RSMB 
Small nuclear 
ribonucleoprotein-
associated proteins B 
and 
B';SNRPB;ortholog 
catalytic 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions   
S10A6 
Protein S100-
A6;S100A6;ortholog 
calcium ion 
binding;growth 
factor 
activity;calmodulin 
binding 
macrophage 
activation;DNA 
replication;cell 
cycle;cell 
communication   
S30BP 
SAP30-binding 
protein;SAP30BP;orth
olog 
sequence-specific 
DNA binding 
transcription factor 
activity;sequence-
specific DNA binding 
transcription factor 
activity 
transcription from RNA 
polymerase II promoter   
SAFB1 
Scaffold attachment 
factor 
B1;SAFB;ortholog       
SC23A 
Protein transport 
protein 
Sec23A;SEC23A;orthol
og 
catalytic 
activity;protein 
binding;small 
GTPase regulator 
activity 
metabolic process;cell 
communication;intracel
lular protein 
transport;exocytosis;re
gulation of catalytic 
activity   
SDC1 
Syndecan-
1;SDC1;ortholog 
structural 
constituent of 
cytoskeleton;recept
or binding 
macrophage 
activation;cell 
communication;cell 
adhesion;skeletal 
system development 
extracellular 
region;cytoskeleton;intra
cellular 
SEM4C 
Semaphorin-
4C;SEMA4C;ortholog receptor binding 
immune system 
process;cell 
communication;neurolo
gical system 
process;ectoderm   
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development;mesoder
m 
development;angiogen
esis;nervous system 
development;heart 
development 
SEM5A 
Semaphorin-
5A;SEMA5A;ortholog receptor binding 
immune system 
process;cell 
communication;neurolo
gical system 
process;ectoderm 
development;mesoder
m 
development;angiogen
esis;nervous system 
development;heart 
development   
SK2L2 
Superkiller viralicidic 
activity 2-like 
2;SKIV2L2;ortholog 
DNA helicase 
activity;RNA helicase 
activity;hydrolase 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions;cell cycle   
SLIT1 
Slit homolog 1 
protein;SLIT1;ortholog receptor activity 
immune system 
process;transcription 
from RNA polymerase II 
promoter;protein 
phosphorylation;cellula
r component 
movement;cell-cell 
signaling;cell-cell 
adhesion;sensory 
perception;ectoderm 
development;nervous 
system 
development;regulatio
n of transcription from 
RNA polymerase II 
promoter 
extracellular 
region;extracellular 
matrix 
SMD2 
Small nuclear 
ribonucleoprotein Sm 
D2;SNRPD2;ortholog mRNA binding mRNA processing   
SMRC2 
SWI/SNF complex 
subunit 
SMARCC2;SMARCC2;o
rtholog 
transcription 
cofactor 
activity;sequence-
specific DNA binding 
transcription factor 
transcription from RNA 
polymerase II 
promoter;regulation of 
transcription from RNA 
polymerase II promoter   
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activity;sequence-
specific DNA binding 
transcription factor 
activity;chromatin 
binding;protein 
binding 
SNAA 
Alpha-soluble NSF 
attachment 
protein;NAPA;ortholo
g   
intracellular protein 
transport   
SPIT1 
Kunitz-type protease 
inhibitor 
1;SPINT1;ortholog 
peptidase 
activity;protein 
binding;serine-type 
endopeptidase 
inhibitor activity 
immune system 
process;proteolysis;blo
od 
coagulation;regulation 
of catalytic activity   
SPSY 
Spermine 
synthase;SMS;ortholo
g transferase activity metabolic process   
SRRM2 
Serine/arginine 
repetitive matrix 
protein 
2;SRRM2;ortholog       
STK24 
Serine/threonine-
protein kinase 
24;STK24;ortholog       
SYK 
Lysine--tRNA 
ligase;KARS;ortholog 
aminoacyl-tRNA 
ligase activity;RNA 
binding translation   
TB182 
182 kDa tankyrase-1-
binding 
protein;TNKS1BP1;ort
holog   
mitosis;chromosome 
segregation   
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBB5 
Tubulin beta 
chain;TUBB;ortholog       
TBL1R 
F-box-like/WD repeat-
containing protein 
TBL1XR1;TBL1XR1;ort
holog       
TCP4 
Activated RNA 
polymerase II 
transcriptional 
coactivator 
p15;SUB1;ortholog       
TCPE 
T-complex protein 1 
subunit   protein folding   
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epsilon;CCT5;ortholog 
TGFB1 
Transforming growth 
factor beta-
1;TGFB1;ortholog 
growth factor 
activity 
female gamete 
generation;cell 
communication;ectoder
m 
development;mesoder
m development;skeletal 
system 
development;heart 
development;muscle 
organ development   
TIMP1 
Metalloproteinase 
inhibitor 
1;TIMP1;ortholog 
peptidase 
activity;protein 
binding;metalloendo
peptidase inhibitor 
activity 
proteolysis;regulation 
of catalytic activity   
TPA 
Tissue-type 
plasminogen 
activator;PLAT;orthol
og 
serine-type 
peptidase activity 
proteolysis;blood 
coagulation extracellular region 
TPD52 
Tumor protein 
D52;TPD52;ortholog       
TSN1 
Tetraspanin-
1;TSPAN1;ortholog 
receptor 
activity;receptor 
binding 
gamete 
generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological 
system process;blood 
coagulation   
TTL12 
Tubulin--tyrosine 
ligase-like protein 
12;TTLL12;ortholog 
ligase 
activity;structural 
constituent of 
cytoskeleton 
protein metabolic 
process 
microtubule;cytoskeleton
;intracellular 
TXD17 
Thioredoxin domain-
containing protein 
17;TXNDC17;ortholog 
transmembrane 
transporter activity 
respiratory electron 
transport 
chain;transport   
U520 
U5 small nuclear 
ribonucleoprotein 200 
kDa 
helicase;SNRNP200;or
tholog 
DNA helicase 
activity;RNA helicase 
activity;hydrolase 
activity;mRNA 
binding 
RNA splicing, via 
transesterification 
reactions;mRNA 
splicing, via 
spliceosome;RNA 
splicing, via 
transesterification 
reactions;meiosis   
UBQL1 
Ubiquilin-
1;UBQLN1;ortholog   proteolysis   
UN45A 
Protein unc-45 
homolog 
A;UNC45A;ortholog   
immune system 
process;protein 
folding;response to   
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stress 
VAS1 
V-type proton ATPase 
subunit 
S1;ATP6AP1;ortholog 
hydrolase 
activity;cation 
transmembrane 
transporter 
activity;proton-
transporting ATP 
synthase activity, 
rotational 
mechanism 
nucleobase-containing 
compound metabolic 
process;cation 
transport 
proton-transporting ATP 
synthase 
complex;intracellular 
XPO1 
Exportin-
1;XPO1;ortholog receptor activity 
transcription from RNA 
polymerase II 
promoter;mRNA 
transcription;mRNA 
transcription;protein 
metabolic 
process;intracellular 
protein 
transport;nucleobase-
containing compound 
transport   
XPOT 
Exportin-
T;XPOT;ortholog RNA binding tRNA metabolic process   
ZN207 
Zinc finger protein 
207;ZNF207;ortholog DNA binding 
nucleobase-containing 
compound metabolic 
process   
1433F 
14-3-3 protein 
eta;YWHAH;ortholog   
cell cycle;cell 
communication   
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Appendix D 
The mean, standard deviation and T-test value of the Marimastat MTT data. 
 Conditions 
Name of 
Cell Mean SD t test 
Serum-Free (Control) SW780 0.1535 0.193   
Serum-Free (5µM M)   0.1548 0.1216 0.991 
Fetal Calf Serum (control)   0.1493 0.0858   
Fetal Calf Serum (5µM M)   0.1553 0.0377 0.9193 
Serum-Free (Control) VMCUB 0.501 0.2499   
Serum-Free (5µM M)   1.4876 0.1484 0.0215 
Fetal Calf Serum (control)   1.0644 0.2031   
Fetal Calf Serum (5µM M)   1.0243 0.1679 0.8616 
Serum-Free (Control) UROTsa 0.314 0.0628   
Serum-Free (5µM M)   0.302 0.012 0.8282 
Fetal Calf Serum (control)   0.334 0.0913   
Fetal Calf Serum (5µM M)   0.228 0.3202 0.7221 
Serum-Free (Control) T 24 0.2333 0.2203   
Serum-Free (5µM M)   0.1338 0.0797 0.6664 
Fetal Calf Serum (control)   0.2282 0.2414   
Fetal Calf Serum (5µM M)   0.1142 0.0777 0.5058 
Serum-Free (Control) 5637 0.606 0.0326   
Serum-Free (5µM M)   0.545 0.0242 0.0009 
Fetal Calf Serum (control)   0.883 0.0496   
Fetal Calf Serum (5µM M)   0.771 0.0726 0.0033 
Serum-Free (Control) rt112m 0.331 0.0401   
Serum-Free (5µM M)   0.291 0.0305 0.0417 
Fetal Calf Serum (control)   0.662 0.0273   
Fetal Calf Serum (5µM M)   0.404 0.0234 ###### 
Serum-Free (Control) HBCLS2 0.126 0.0167 0.3442 
Serum-Free (5µM M)   0.1148 0.022   
Fetal Calf Serum (control)   0.1275 0.0181 0.8861 
Fetal Calf Serum (5µM M)   0.1145 0.0275   
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Appendix E 
The mean, standard deviation and T-test value of the PMA-MTT data. 
Name of cell line Condition Mean SD t test 
MGUH Serum free 0.1105 0.01587 0.00531 
  Serum free and PMA 0.15359 0.02755   
  Fetal calf serum 0.12549 0.03105 0.05452 
  
Fetal calf serum and 
PMA 0.18542 0.06425   
RT4 Serum free 0.3482 0.05571 0.06568 
  Serum free and PMA 0.48316 0.15617   
  Fetal calf serum 0.4343 0.06697 0.00352 
  
Fetal calf serum and 
PMA 0.66687 0.13959   
SW780 Serum free 0.4893 0.05043 2.39E-06 
  Serum free and PMA 0.85758 0.09996   
  Fetal calf serum 0.48466 0.01284 3.33E-08 
  
Fetal calf serum and 
PMA 0.86443 0.04992   
RT112M Serum free 0.46599 0.14541 0.00089 
  Serum free and PMA 0.78975 0.12919   
  Fetal calf serum 0.71077 0.1012 0.45959 
  
Fetal calf serum and 
PMA 0.74518 0.06129   
VMCUB Serum free 0.01625 0.00279 1.45E-08 
  Serum free and PMA 0.07446 0.00784   
  Fetal calf serum 0.15141 0.05432 0.6627 
  
Fetal calf serum and 
PMA 0.16341 0.05339   
T24 Serum free 0.19921 0.19921 2.39E-06 
  Serum free and PMA 0.34308 0.34308   
  Fetal calf serum 0.51463 0.06394 0.74488 
  
Fetal calf serum and 
PMA 0.55825 0.08953   
HB-CLS-2 Serum free 0.126 0.01669 0.39734 
HB-CLS-2 Serum free and PMA 0.133 0.00772   
  Fetal calf serum 0.127 0.01814 0.09751 
  
Fetal calf serum and 
PMA 0.20753 0.096121754    
 
P a g e  | 151 
 
Appendix F 
The 83 proteins that were present in both HPA and PMA proteomic data. The Panther database 
(http://www.pantherdb.org/) was used to determine their molecular function, biological function and 
cellular component.  
Name of protein Molecular function Biological function Cellular component 
ATP-citrate 
synthase;ACLY;ortholog       
Disintegrin and 
metalloproteinase 
domain-containing 
protein 
9;ADAM9;ortholog   
fertilization;apoptotic 
process;neurological system 
process;mesoderm 
development;apoptotic 
process;heart development   
Annexin 
A1;ANXA1;ortholog   
fatty acid metabolic 
process;cell communication   
Caveolin-
1;CAV1;ortholog 
catalytic 
activity;structural 
molecule 
activity;protein 
binding;small 
GTPase regulator 
activity 
lipid metabolic 
process;cellular 
process;extracellular 
transport;lipid 
transport;intracellular 
protein 
transport;endocytosis;regula
tion of catalytic activity   
Cullin-2;CUL2;ortholog 
ubiquitin-protein 
ligase activity proteolysis;cell cycle   
Protein 
DEK;DEK;ortholog       
Fibroblast growth factor 
19;FGF19;ortholog 
growth factor 
activity 
cell cycle;cell-cell 
signaling;mesoderm 
development;angiogenesis;n
ervous system development   
Follistatin;FST;ortholog protein binding     
Growth factor receptor-
bound protein 
2;GRB2;ortholog receptor binding 
immune system 
process;cellular component 
movement;cell 
communication;ectoderm 
development;mesoderm 
development;nervous 
system development;cellular 
defense response   
Heme oxygenase 
1;HMOX1;ortholog 
oxidoreductase 
activity 
porphyrin-containing 
compound metabolic 
process   
Heat shock protein 
beta-1;HSPB1;ortholog 
structural molecule 
activity 
immune system 
process;protein 
folding;muscle 
contraction;visual   
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perception;sensory 
perception;response to 
stress 
Inhibin beta A 
chain;INHBA;ortholog 
growth factor 
activity 
female gamete 
generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
Fructose-bisphosphate 
aldolase 
A;ALDOA;ortholog       
Apolipoprotein 
E;APOE;ortholog       
Calreticulin;CALR;orthol
og calcium ion binding protein folding   
Macrophage colony-
stimulating factor 
1;CSF1;ortholog cytokine activity 
immune 
response;macrophage 
activation;cell 
communication;mesoderm 
development;hemopoiesis;re
sponse to stimulus   
Ephrin type-A receptor 
2;EPHA2;ortholog   
nervous system 
development   
Fascin;FSCN1;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cellular component 
movement 
actin 
cytoskeleton;intracellular 
Glucose-6-phosphate 1-
dehydrogenase;G6PD;o
rtholog 
oxidoreductase 
activity 
monosaccharide metabolic 
process   
Interleukin-
11;IL11;ortholog       
Interleukin enhancer-
binding factor 
3;ILF3;ortholog 
kinase 
activity;hydrolase 
activity;deaminase 
activity;DNA 
binding;RNA 
binding;protein 
binding;kinase 
activator 
activity;kinase 
regulator activity 
spermatogenesis;response to 
interferon-gamma;apoptotic 
process;purine nucleobase 
metabolic process;protein 
metabolic process;cell 
cycle;neurological system 
process;anterior/posterior 
axis 
specification;anterior/posteri
or axis 
specification;apoptotic 
process;response to 
stimulus;RNA 
localization;regulation of   
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catalytic activity 
L-lactate 
dehydrogenase A 
chain;LDHA;ortholog 
oxidoreductase 
activity 
glycolysis;glycolysis;tricarbox
ylic acid cycle   
CD9 
antigen;CD9;ortholog 
receptor 
activity;receptor 
binding 
gamete generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological 
system process;blood 
coagulation   
Ephrin-
A5;EFNA5;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous 
system development   
Receptor tyrosine-
protein kinase erbB-
2;ERBB2;ortholog   
apoptotic process;cell 
proliferation;cell-cell 
adhesion;apoptotic 
process;nervous system 
development   
Laminin subunit beta-
1;LAMB1;ortholog receptor activity 
cell communication;cell-
matrix adhesion;cell-cell 
adhesion;neurological 
system process;ectoderm 
development;nervous 
system development 
extracellular 
region;extracellular matrix 
Leukemia inhibitory 
factor;LIF;ortholog cytokine activity 
immune system 
process;induction of 
apoptosis;cell-cell 
signaling;neurological system 
process;induction of 
apoptosis;response to 
stress;negative regulation of 
apoptotic process   
Bleomycin 
hydrolase;BLMH;orthol
og       
Eukaryotic translation 
initiation factor 3 
subunit 
H;EIF3H;ortholog 
sequence-specific 
DNA binding 
transcription factor 
activity;sequence-
specific DNA 
binding 
transcription factor 
activity primary metabolic process   
Ephrin type-A receptor 
7;EPHA7;ortholog   
nervous system 
development   
Protein ETHE1, 
mitochondrial;ETHE1;or
tholog hydrolase activity 
metabolic process;response 
to toxic substance   
Fatty acid-binding lipid binding lipid metabolic process;cell   
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protein, 
adipocyte;FABP4;orthol
og 
communication;ectoderm 
development;lipid 
transport;vitamin transport 
Growth/differentiation 
factor 
15;GDF15;ortholog 
growth factor 
activity 
female gamete 
generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
Glutathione S-
transferase Mu 
3;GSTM3;ortholog       
Kallikrein-
6;KLK6;ortholog 
serine-type 
peptidase activity 
proteolysis;response to 
stimulus   
ATP-citrate 
synthase;ACLY;ortholog 
transferase 
activity;lyase 
activity;ligase 
activity 
generation of precursor 
metabolites and 
energy;coenzyme metabolic 
process;carbohydrate 
metabolic 
process;tricarboxylic acid 
cycle;lipid metabolic process   
Annexin 
A4;ANXA4;ortholog   fatty acid metabolic process   
Apolipoprotein 
D;APOD;ortholog       
Breast cancer type 2 
susceptibility 
protein;BRCA2;ortholog DNA binding     
Monocyte 
differentiation antigen 
CD14;CD14;ortholog       
Epidermal growth 
factor 
receptor;EGFR;ortholog   
apoptotic process;cell 
proliferation;cell-cell 
adhesion;apoptotic 
process;nervous system 
development   
Ephrin type-A receptor 
4;EPHA4;ortholog   
nervous system 
development   
Ephrin type-B receptor 
2;EPHB2;ortholog   
nervous system 
development   
Ephrin type-B receptor 
6;EPHB6;ortholog   
nervous system 
development   
Fatty acid 
synthase;FASN;ortholog 
oxidoreductase 
activity;methyltrans
ferase 
activity;transferase 
activity, transferring 
cellular amino acid metabolic 
process;fatty acid 
biosynthetic process   
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acyl 
groups;hydrolase 
activity, acting on 
ester bonds;ligase 
activity 
Fructose-bisphosphate 
aldolase 
C;ALDOC;ortholog       
Annexin 
A2;ANXA2;ortholog   
fatty acid metabolic 
process;mesoderm 
development   
AP-2 complex subunit 
beta;AP2B1;ortholog   
intracellular protein 
transport;vesicle-mediated 
transport   
DNA-(apurinic or 
apyrimidinic site) 
lyase;APEX1;ortholog       
Brain-specific 
angiogenesis inhibitor 
1;BAI1;ortholog 
G-protein coupled 
receptor activity 
spermatogenesis;immune 
response;synaptic 
transmission;neurotransmitt
er secretion;mesoderm 
development;heart 
development;response to 
stress;intracellular protein 
transport;synaptic vesicle 
exocytosis   
Caspase-
3;CASP3;ortholog 
cysteine-type 
peptidase 
activity;protein 
binding;peptidase 
inhibitor activity 
apoptotic 
process;proteolysis;apoptoti
c process;regulation of 
catalytic activity   
CD44 
antigen;CD44;ortholog       
CD59 
glycoprotein;CD59;orth
olog receptor binding immune system process   
CD70 
antigen;CD70;ortholog       
CD82 
antigen;CD82;ortholog 
receptor 
activity;receptor 
binding 
gamete generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological 
system process;blood 
coagulation   
CAP-Gly domain-
containing linker 
protein 
1;CLIP1;ortholog 
structural 
constituent of 
cytoskeleton;microt
ubule binding 
protein folding;cellular 
process;cellular component 
morphogenesis;intracellular 
protein transport;vesicle-
mediated transport;cellular 
microtubule;cytoskeleton;intr
acellular 
P a g e  | 156 
 
component organization 
Connective tissue 
growth 
factor;CTGF;ortholog 
growth factor 
activity 
cellular component 
movement;cell cycle;cell-cell 
signaling;cell-matrix 
adhesion;mesoderm 
development;angiogenesis   
C-X-C motif chemokine 
5;CXCL5;ortholog chemokine activity 
immune 
response;macrophage 
activation;cell 
communication;angiogenesis
;cellular defense 
response;response to 
external stimulus   
DNA damage-binding 
protein 
2;DDB2;ortholog 
damaged DNA 
binding DNA repair   
Ephrin type-B receptor 
4;EPHB4;ortholog   
nervous system 
development   
Flap endonuclease 
1;FEN1;ortholog       
Insulin-like growth 
factor II;IGF2;ortholog 
hormone 
activity;growth 
factor activity 
carbohydrate metabolic 
process;cell 
cycle;carbohydrate transport   
Annexin 
A7;ANXA7;ortholog   fatty acid metabolic process   
Ephrin-
A1;EFNA1;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous 
system development   
Ephrin-
B1;EFNB1;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous 
system development   
Exostosin-
1;EXT1;ortholog 
transferase activity, 
transferring glycosyl 
groups 
polysaccharide metabolic 
process;protein glycosylation   
Glutathione S-
transferase 
P;GSTP1;ortholog       
Interleukin-1 receptor 
type 2;IL1R2;ortholog receptor activity cellular process   
Laminin subunit 
gamma-
1;LAMC1;ortholog receptor activity 
cell communication;cell-
matrix adhesion;cell-cell 
adhesion;neurological 
system process;ectoderm 
development;nervous 
system development 
extracellular 
region;extracellular matrix 
Legumain;LGMN;orthol
og 
cysteine-type 
peptidase activity proteolysis   
Apolipoprotein A-
I;APOA1;ortholog   blood circulation   
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Aspartyl/asparaginyl 
beta-
hydroxylase;ASPH;ortho
log 
oxidoreductase 
activity 
cellular protein modification 
process;cell communication   
Complement 
component 1 Q 
subcomponent-binding 
protein, 
mitochondrial;C1QBP;o
rtholog       
Hsp90 co-chaperone 
Cdc37;CDC37;ortholog 
kinase 
activity;protein 
binding;kinase 
activator 
activity;kinase 
regulator activity 
protein 
folding;cytokinesis;mitosis;ce
ll communication;cellular 
component 
morphogenesis;regulation of 
catalytic activity;cellular 
component organization   
Granulocyte colony-
stimulating 
factor;CSF3;ortholog cytokine activity 
immune response;cell-cell 
signaling;response to 
stimulus   
Epithelial cell adhesion 
molecule;EPCAM;orthol
og receptor activity cell communication   
Ephrin type-A receptor 
1;EPHA1;ortholog   
nervous system 
development   
Fatty acid-binding 
protein, 
epidermal;FABP5;orthol
og lipid binding 
lipid metabolic process;cell 
communication;ectoderm 
development;lipid 
transport;vitamin transport   
Tumor necrosis factor 
receptor superfamily 
member 6;FAS;ortholog 
cytokine receptor 
activity;tumor 
necrosis factor-
activated receptor 
activity 
B cell mediated 
immunity;macrophage 
activation;induction of 
apoptosis;cell-cell 
signaling;ectoderm 
development;induction of 
apoptosis;nervous system 
development;cellular 
defense response;negative 
regulation of apoptotic 
process   
Filamin-
B;FLNB;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cellular component 
movement;cellular 
component 
morphogenesis;cellular 
component organization 
actin 
cytoskeleton;intracellular 
Glutathione S-
transferase Mu 
1;GSTM1;ortholog       
Intercellular adhesion receptor binding immune system   
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molecule 
1;ICAM1;ortholog 
process;cellular process;cell 
adhesion 
Interleukin-
6;IL6;ortholog 
cytokine receptor 
binding;cytokine 
receptor binding 
immune system 
process;apoptotic 
process;cell-cell 
signaling;apoptotic 
process;negative regulation 
of apoptotic process   
Kallikrein-
10;KLK10;ortholog 
serine-type 
peptidase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
gamete generation;immune 
system 
process;proteolysis;cellular 
process;blood coagulation   
Lipocalin-
1;LCN1;ortholog 
isomerase 
activity;binding 
fatty acid biosynthetic 
process;cell 
communication;response to 
pheromone;transport   
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Appendix H 
The 83 proteins that were present in both HPA and PMA proteomic data underwent further 
investigation. Here,the Panther database (http://www.pantherdb.org/) was used to determine their 
molecular function, biological function and cellular component and whether they were present in 
higher grade but not lower grade or both. In addition, whether they have been down-regulated by 
Marimastat is also included. EFNB1 and FGF19 were the only two proteins down-regulated by 
Marimastat 
Accessi
on 
name Name Molecular function Biological function 
HIGH grade 
but not low 
grade 
ACLY 
ATP-citrate 
synthase;ACLY;ortholog 
transferase 
activity;lyase 
activity;ligase activity 
generation of precursor 
metabolites and 
energy;coenzyme metabolic 
process;carbohydrate 
metabolic process;tricarboxylic 
acid cycle;lipid metabolic 
process HIGH 
ANXA1 
Annexin 
A1;ANXA1;ortholog   
fatty acid metabolic 
process;cell communication HIGH 
ANXA2 
Annexin 
A2;ANXA2;ortholog   
fatty acid metabolic 
process;mesoderm 
development HIGH 
AP2B1 
AP-2 complex subunit 
beta;AP2B1;ortholog   
intracellular protein 
transport;vesicle-mediated 
transport HIGH 
APEX1 
DNA-(apurinic or 
apyrimidinic site) 
lyase;APEX1;ortholog     HIGH 
APOA1 
Apolipoprotein A-
I;APOA1;ortholog   blood circulation HIGH 
APOE 
Apolipoprotein 
E;APOE;ortholog     HIGH 
ASPH 
Aspartyl/asparaginyl beta-
hydroxylase;ASPH;ortholo
g 
oxidoreductase 
activity 
cellular protein modification 
process;cell communication HIGH 
BAI1 
Brain-specific 
angiogenesis inhibitor 
1;BAI1;ortholog 
G-protein coupled 
receptor activity 
spermatogenesis;immune 
response;synaptic 
transmission;neurotransmitter 
secretion;mesoderm 
development;heart 
development;response to 
stress;intracellular protein 
transport;synaptic vesicle 
exocytosis HIGH 
BRCA2 Breast cancer type 2 DNA binding   HIGH 
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susceptibility 
protein;BRCA2;ortholog 
C1QBP 
Complement component 
1 Q subcomponent-
binding protein, 
mitochondrial;C1QBP;orth
olog     HIGH 
CALR Calreticulin;CALR;ortholog calcium ion binding protein folding HIGH 
CASP3 Caspase-3;CASP3;ortholog 
cysteine-type 
peptidase 
activity;protein 
binding;peptidase 
inhibitor activity 
apoptotic 
process;proteolysis;apoptotic 
process;regulation of catalytic 
activity HIGH 
CAV1 Caveolin-1;CAV1;ortholog 
catalytic 
activity;structural 
molecule 
activity;protein 
binding;small GTPase 
regulator activity 
lipid metabolic process;cellular 
process;extracellular 
transport;lipid 
transport;intracellular protein 
transport;endocytosis;regulatio
n of catalytic activity HIGH 
CD14 
Monocyte differentiation 
antigen 
CD14;CD14;ortholog     HIGH 
CD44 
CD44 
antigen;CD44;ortholog     HIGH 
CD59 
CD59 
glycoprotein;CD59;orthol
og receptor binding immune system process HIGH 
CD70 
CD70 
antigen;CD70;ortholog     HIGH 
CD82 
CD82 
antigen;CD82;ortholog 
receptor 
activity;receptor 
binding 
gamete generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological system 
process;blood coagulation HIGH 
CD9 CD9 antigen;CD9;ortholog 
receptor 
activity;receptor 
binding 
gamete generation;immune 
system process;cell 
communication;cell-cell 
adhesion;neurological system 
process;blood coagulation 
LOW GRADE 
THAN HIGH 
GRADE 
CDC37 
Hsp90 co-chaperone 
Cdc37;CDC37;ortholog 
kinase activity;protein 
binding;kinase 
activator 
activity;kinase 
regulator activity 
protein 
folding;cytokinesis;mitosis;cell 
communication;cellular 
component 
morphogenesis;regulation of 
catalytic activity;cellular 
component organization HIGH 
CLIP1 
CAP-Gly domain-
containing linker protein 
structural constituent 
of 
protein folding;cellular 
process;cellular component slight high 
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1;CLIP1;ortholog cytoskeleton;microtu
bule binding 
morphogenesis;intracellular 
protein transport;vesicle-
mediated transport;cellular 
component organization 
CSF1 
Macrophage colony-
stimulating factor 
1;CSF1;ortholog cytokine activity 
immune response;macrophage 
activation;cell 
communication;mesoderm 
development;hemopoiesis;resp
onse to stimulus HIGH 
CSF3 
Granulocyte colony-
stimulating 
factor;CSF3;ortholog cytokine activity 
immune response;cell-cell 
signaling;response to stimulus HIGH 
CTGF 
Connective tissue growth 
factor;CTGF;ortholog growth factor activity 
cellular component 
movement;cell cycle;cell-cell 
signaling;cell-matrix 
adhesion;mesoderm 
development;angiogenesis HIGH 
CUL2 Cullin-2;CUL2;ortholog 
ubiquitin-protein 
ligase activity proteolysis;cell cycle HIGH 
CUL4A Cullin-4A;CUL4A;ortholog 
ubiquitin-protein 
ligase activity 
induction of 
apoptosis;proteolysis;cell 
cycle;induction of apoptosis HIGH 
CXCL5 
C-X-C motif chemokine 
5;CXCL5;ortholog chemokine activity 
immune response;macrophage 
activation;cell 
communication;angiogenesis;c
ellular defense 
response;response to external 
stimulus HIGH 
DDB2 
DNA damage-binding 
protein 2;DDB2;ortholog damaged DNA binding DNA repair 
Low grade 
than high 
grade 
DEK Protein DEK;DEK;ortholog     high 
EFNA1 Ephrin-A1;EFNA1;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous system 
development high 
EFNA5 Ephrin-A5;EFNA5;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous system 
development high 
EFNB1 Ephrin-B1;EFNB1;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous system 
development high 
EGFR 
Epidermal growth factor 
receptor;EGFR;ortholog   
apoptotic process;cell 
proliferation;cell-cell 
adhesion;apoptotic 
process;nervous system 
development high 
EIF3H 
Eukaryotic translation 
initiation factor 3 subunit 
sequence-specific 
DNA binding primary metabolic process 
Low grade 
than high 
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H;EIF3H;ortholog transcription factor 
activity;sequence-
specific DNA binding 
transcription factor 
activity 
grade 
EPCAM 
Epithelial cell adhesion 
molecule;EPCAM;ortholog receptor activity cell communication high 
EPHA1 
Ephrin type-A receptor 
1;EPHA1;ortholog   nervous system development high 
EPHA2 
Ephrin type-A receptor 
2;EPHA2;ortholog   nervous system development high 
EPHA4 
Ephrin type-A receptor 
4;EPHA4;ortholog   nervous system development high 
EPHA7 
Ephrin type-A receptor 
7;EPHA7;ortholog   nervous system development high 
EPHB2 
Ephrin type-B receptor 
2;EPHB2;ortholog   nervous system development high 
EPHB4 
Ephrin type-B receptor 
4;EPHB4;ortholog   nervous system development high 
ERBB2 
Receptor tyrosine-protein 
kinase erbB-
2;ERBB2;ortholog   
apoptotic process;cell 
proliferation;cell-cell 
adhesion;apoptotic 
process;nervous system 
development high 
ETHE1 
Protein ETHE1, 
mitochondrial;ETHE1;orth
olog hydrolase activity 
metabolic process;response to 
toxic substance high 
EXT1 Exostosin-1;EXT1;ortholog 
transferase activity, 
transferring glycosyl 
groups 
polysaccharide metabolic 
process;protein glycosylation 
Low grade 
than high 
grade 
FABP4 
Fatty acid-binding protein, 
adipocyte;FABP4;ortholog lipid binding 
lipid metabolic process;cell 
communication;ectoderm 
development;lipid 
transport;vitamin transport high 
FAS 
Fatty acid 
synthase;FASN;ortholog 
oxidoreductase 
activity;methyltransfe
rase 
activity;transferase 
activity, transferring 
acyl groups;hydrolase 
activity, acting on 
ester bonds;ligase 
activity 
cellular amino acid metabolic 
process;fatty acid biosynthetic 
process high 
FAS 
Tumor necrosis factor 
receptor superfamily 
member 6;FAS;ortholog 
cytokine receptor 
activity;tumor 
necrosis factor-
activated receptor 
activity 
B cell mediated 
immunity;macrophage 
activation;induction of 
apoptosis;cell-cell 
signaling;ectoderm high 
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development;induction of 
apoptosis;nervous system 
development;cellular defense 
response;negative regulation of 
apoptotic process 
FEN1 
Flap endonuclease 
1;FEN1;ortholog     high 
FGF19 
Fibroblast growth factor 
19;FGF19;ortholog growth factor activity 
cell cycle;cell-cell 
signaling;mesoderm 
development;angiogenesis;ner
vous system development high 
FSCN1 Fascin;FSCN1;ortholog 
structural constituent 
of cytoskeleton;actin 
binding cellular component movement high 
FST Follistatin;FST;ortholog protein binding   high 
G6PD 
Glucose-6-phosphate 1-
dehydrogenase;G6PD;ort
holog 
oxidoreductase 
activity 
monosaccharide metabolic 
process equal 
GDF15 
Growth/differentiation 
factor 15;GDF15;ortholog growth factor activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development high 
GRB2 
Growth factor receptor-
bound protein 
2;GRB2;ortholog receptor binding 
immune system 
process;cellular component 
movement;cell 
communication;ectoderm 
development;mesoderm 
development;nervous system 
development;cellular defense 
response high 
GSTM1 
Glutathione S-transferase 
Mu 1;GSTM1;ortholog     equal 
GSTM3 
Glutathione S-transferase 
Mu 3;GSTM3;ortholog     high 
GSTP1 
Glutathione S-transferase 
P;GSTP1;ortholog     equal 
HSPB1 
Heat shock protein beta-
1;HSPB1;ortholog 
structural molecule 
activity 
immune system 
process;protein folding;muscle 
contraction;visual 
perception;sensory 
perception;response to stress high 
IGF2 
Insulin-like growth factor 
II;IGF2;ortholog 
hormone 
activity;growth factor 
activity 
carbohydrate metabolic 
process;cell cycle;carbohydrate 
transport high 
IL11 Interleukin-     high 
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11;IL11;ortholog 
IL1R2 
Interleukin-1 receptor 
type 2;IL1R2;ortholog receptor activity cellular process high 
IL6 Interleukin-6;IL6;ortholog 
cytokine receptor 
binding;cytokine 
receptor binding 
immune system 
process;apoptotic process;cell-
cell signaling;apoptotic 
process;negative regulation of 
apoptotic process equal 
ILF3 
Interleukin enhancer-
binding factor 
3;ILF3;ortholog 
kinase 
activity;hydrolase 
activity;deaminase 
activity;DNA 
binding;RNA 
binding;protein 
binding;kinase 
activator 
activity;kinase 
regulator activity 
spermatogenesis;response to 
interferon-gamma;apoptotic 
process;purine nucleobase 
metabolic process;protein 
metabolic process;cell 
cycle;neurological system 
process;anterior/posterior axis 
specification;anterior/posterior 
axis specification;apoptotic 
process;response to 
stimulus;RNA 
localization;regulation of 
catalytic activity equal 
INHBA 
Inhibin beta A 
chain;INHBA;ortholog growth factor activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development high 
KLK10 
Kallikrein-
10;KLK10;ortholog 
serine-type peptidase 
activity;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid binding 
gamete generation;immune 
system 
process;proteolysis;cellular 
process;blood coagulation slight high 
KLK6 Kallikrein-6;KLK6;ortholog 
serine-type peptidase 
activity 
proteolysis;response to 
stimulus high 
LAMB1 
Laminin subunit beta-
1;LAMB1;ortholog receptor activity 
cell communication;cell-matrix 
adhesion;cell-cell 
adhesion;neurological system 
process;ectoderm 
development;nervous system 
development high 
LCN1 Lipocalin-1;LCN1;ortholog 
isomerase 
activity;binding 
fatty acid biosynthetic 
process;cell 
communication;response to 
pheromone;transport high 
LDHA 
L-lactate dehydrogenase 
A chain;LDHA;ortholog 
oxidoreductase 
activity 
glycolysis;glycolysis;tricarboxyli
c acid cycle low 
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LGMN Legumain;LGMN;ortholog 
cysteine-type 
peptidase activity proteolysis HIGH 
LIF 
Leukemia inhibitory 
factor;LIF;ortholog cytokine activity 
immune system 
process;induction of 
apoptosis;cell-cell 
signaling;neurological system 
process;induction of 
apoptosis;response to 
stress;negative regulation of 
apoptotic process HIGH 
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Appendix H 
The 60 proteins that were present in both HPA and Marimastat proteomic data underwent further 
investigation. Here,the Panther database (http://www.pantherdb.org/) was used to determine their 
molecular function, biological function and cellular component.  
Nam
e of 
prot
ein Molecular function Biological function Cellular component   
TIM
P1 
Metalloproteinase inhibitor 
1;TIMP1;ortholog 
peptidase 
activity;protein 
binding;metalloend
opeptidase 
inhibitor activity 
proteolysis;regulation of 
catalytic activity   
ANX
A1 Annexin A1;ANXA1;ortholog   
fatty acid metabolic 
process;cell communication   
ADA
M9 
Disintegrin and 
metalloproteinase domain-
containing protein 
9;ADAM9;ortholog   
fertilization;apoptotic 
process;neurological system 
process;mesoderm 
development;apoptotic 
process;heart development   
INHB
A 
Inhibin beta A 
chain;INHBA;ortholog 
growth factor 
activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
ACLY 
ATP-citrate 
synthase;ACLY;ortholog       
MC
M2 
DNA replication licensing 
factor 
MCM2;MCM2;ortholog 
DNA helicase 
activity;hydrolase 
activity;nucleic acid 
binding DNA replication;cell cycle   
TGF
B1 
Transforming growth factor 
beta-1;TGFB1;ortholog 
growth factor 
activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
FST Follistatin;FST;ortholog protein binding     
HSP
B1 
Heat shock protein beta-
1;HSPB1;ortholog 
structural molecule 
activity 
immune system 
process;protein folding;muscle 
contraction;visual 
perception;sensory 
perception;response to stress   
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ALD
OA 
Fructose-bisphosphate 
aldolase A;ALDOA;ortholog       
LDH
A 
L-lactate dehydrogenase A 
chain;LDHA;ortholog 
oxidoreductase 
activity 
glycolysis;glycolysis;tricarboxyli
c acid cycle   
FSCN
1 Fascin;FSCN1;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding cellular component movement 
actin 
cytoskeleton;int
racellular 
G6P
D 
Glucose-6-phosphate 1-
dehydrogenase;G6PD;orthol
og 
oxidoreductase 
activity 
monosaccharide metabolic 
process   
UBA
1 
Ubiquitin-like modifier-
activating enzyme 
1;UBA1;ortholog ligase activity 
coenzyme metabolic 
process;cellular protein 
modification 
process;proteolysis;cell 
communication;intracellular 
protein transport;nuclear 
transport   
CALR Calreticulin;CALR;ortholog calcium ion binding protein folding   
ILF3 
Interleukin enhancer-
binding factor 
3;ILF3;ortholog 
kinase 
activity;hydrolase 
activity;deaminase 
activity;DNA 
binding;RNA 
binding;protein 
binding;kinase 
activator 
activity;kinase 
regulator activity 
spermatogenesis;response to 
interferon-gamma;apoptotic 
process;purine nucleobase 
metabolic process;protein 
metabolic process;cell 
cycle;neurological system 
process;anterior/posterior axis 
specification;anterior/posterior 
axis specification;apoptotic 
process;response to 
stimulus;RNA 
localization;regulation of 
catalytic activity   
NUC
B2 
Nucleobindin-
2;NUCB2;ortholog 
nucleic acid 
binding;calcium ion 
binding;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding 
cellular calcium ion 
homeostasis   
LAM
B1 
Laminin subunit beta-
1;LAMB1;ortholog receptor activity 
cell communication;cell-matrix 
adhesion;cell-cell 
adhesion;neurological system 
process;ectoderm 
development;nervous system 
development 
extracellular 
region;extracell
ular matrix 
NRP
1 Neuropilin-1;NRP1;ortholog 
oxidoreductase 
activity;serine-type 
peptidase 
activity;metallopep
immune system 
process;proteolysis;synaptic 
transmission;cell-cell 
adhesion;visual 
extracellular 
region;extracell
ular matrix 
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tidase 
activity;receptor 
activity;lipid 
transporter 
activity;transmemb
rane transporter 
activity;receptor 
binding;enzyme 
regulator activity 
perception;sensory 
perception;ectoderm 
development;mesoderm 
development;response to 
external stimulus;lipid 
transport;intracellular protein 
transport;endocytosis;vitamin 
transport;regulation of 
catalytic activity 
TIM
P2 
Metalloproteinase inhibitor 
2;TIMP2;ortholog 
peptidase 
activity;protein 
binding;metalloend
opeptidase 
inhibitor activity 
proteolysis;regulation of 
catalytic activity   
LIF 
Leukemia inhibitory 
factor;LIF;ortholog cytokine activity 
immune system 
process;induction of 
apoptosis;cell-cell 
signaling;neurological system 
process;induction of 
apoptosis;response to 
stress;negative regulation of 
apoptotic process   
MM
P1 
Interstitial 
collagenase;MMP1;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracell
ular matrix 
MM
P13 
Collagenase 
3;MMP13;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracell
ular matrix 
GDF
15 
Growth/differentiation 
factor 15;GDF15;ortholog 
growth factor 
activity 
female gamete generation;cell 
communication;ectoderm 
development;mesoderm 
development;skeletal system 
development;heart 
development;muscle organ 
development   
NEO
1 Neogenin;NEO1;ortholog 
phosphoprotein 
phosphatase 
activity;phosphopr
otein phosphatase 
activity;receptor 
activity 
immune system 
process;induction of 
apoptosis;cellular protein 
modification process;cell 
cycle;cell-cell signaling;cell-cell 
adhesion;muscle 
contraction;neurological 
system process;ectoderm 
development;mesoderm 
development;induction of 
apoptosis;angiogenesis;nervou
s system development;muscle 
organ development   
GST Glutathione S-transferase       
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M3 Mu 3;GSTM3;ortholog 
KLK6 Kallikrein-6;KLK6;ortholog 
serine-type 
peptidase activity 
proteolysis;response to 
stimulus   
LMN
A 
Prelamin-
A/C;LMNA;ortholog 
structural 
constituent of 
cytoskeleton 
cellular process;cellular 
component 
morphogenesis;cellular 
component organization 
intermediate 
filament 
cytoskeleton;int
racellular 
FAS 
Fatty acid 
synthase;FASN;ortholog 
oxidoreductase 
activity;methyltran
sferase 
activity;transferase 
activity, 
transferring acyl 
groups;hydrolase 
activity, acting on 
ester bonds;ligase 
activity 
cellular amino acid metabolic 
process;fatty acid biosynthetic 
process   
NAM
PT 
Nicotinamide 
phosphoribosyltransferase;
NAMPT;ortholog cytokine activity cellular process   
RBB
P4 
Histone-binding protein 
RBBP4;RBBP4;ortholog receptor activity 
DNA repair;mRNA splicing, via 
spliceosome;cell 
communication;intracellular 
protein transport;peroxisomal 
transport;chromatin 
organization   
EGF
R 
Epidermal growth factor 
receptor;EGFR;ortholog   
apoptotic process;cell 
proliferation;cell-cell 
adhesion;apoptotic 
process;nervous system 
development   
MM
P13 
Collagenase 
3;MMP13;ortholog       
ACLY 
ATP-citrate 
synthase;ACLY;ortholog 
transferase 
activity;lyase 
activity;ligase 
activity 
generation of precursor 
metabolites and 
energy;coenzyme metabolic 
process;carbohydrate 
metabolic process;tricarboxylic 
acid cycle;lipid metabolic 
process   
APO
D 
Apolipoprotein 
D;APOD;ortholog       
SLPI 
Antileukoproteinase;SLPI;or
tholog 
peptidase 
activity;protein 
binding;serine-type 
endopeptidase 
inhibitor activity 
proteolysis;regulation of 
catalytic activity   
ST14 
Suppressor of 
tumorigenicity 14 
peptidase 
activity;receptor 
fertilization;immune system 
process;apoptotic process;lipid   
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protein;ST14;ortholog activity;calcium ion 
binding;hormone 
activity;calmodulin 
binding;calcium-
dependent 
phospholipid 
binding;peptidase 
inhibitor activity 
metabolic process;blood 
circulation;mesoderm 
development;apoptotic 
process;angiogenesis;blood 
coagulation;lipid 
transport;regulation of 
catalytic activity 
APEX
1 
DNA-(apurinic or 
apyrimidinic site) 
lyase;APEX1;ortholog       
CD4
4 CD44 antigen;CD44;ortholog       
ANX
A2 Annexin A2;ANXA2;ortholog   
fatty acid metabolic 
process;mesoderm 
development   
ALD
OC 
Fructose-bisphosphate 
aldolase C;ALDOC;ortholog       
NQO
1 
NAD(P)H dehydrogenase 
[quinone] 1;NQO1;ortholog       
STRA
P 
Serine-threonine kinase 
receptor-associated 
protein;STRAP;ortholog   cellular process   
FEN1 
Flap endonuclease 
1;FEN1;ortholog       
PRD
X2 
Peroxiredoxin-
2;PRDX2;ortholog 
oxidoreductase 
activity;peroxidase 
activity 
immune system 
process;metabolic process   
GSTP
1 
Glutathione S-transferase 
P;GSTP1;ortholog       
LAM
C1 
Laminin subunit gamma-
1;LAMC1;ortholog receptor activity 
cell communication;cell-matrix 
adhesion;cell-cell 
adhesion;neurological system 
process;ectoderm 
development;nervous system 
development 
extracellular 
region;extracell
ular matrix 
LGM
N Legumain;LGMN;ortholog 
cysteine-type 
peptidase activity proteolysis   
MET 
Hepatocyte growth factor 
receptor;MET;ortholog       
EFN
A1 Ephrin-A1;EFNA1;ortholog receptor binding 
cell-cell signaling;ectoderm 
development;nervous system 
development   
EXT1 Exostosin-1;EXT1;ortholog 
transferase activity, 
transferring 
glycosyl groups 
polysaccharide metabolic 
process;protein glycosylation   
PIGR 
Polymeric immunoglobulin 
receptor;PIGR;ortholog receptor activity 
immune system 
process;response to 
stimulus;intracellular protein   
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transport;receptor-mediated 
endocytosis 
RAC
1 
Ras-related C3 botulinum 
toxin substrate 
1;RAC1;ortholog 
GTPase 
activity;protein 
binding 
metabolic process;cell 
communication;intracellular 
protein transport;receptor-
mediated endocytosis   
FLNB Filamin-B;FLNB;ortholog 
structural 
constituent of 
cytoskeleton;actin 
binding 
cellular component 
movement;cellular component 
morphogenesis;cellular 
component organization 
actin 
cytoskeleton;int
racellular 
FAS 
Tumor necrosis factor 
receptor superfamily 
member 6;FAS;ortholog 
cytokine receptor 
activity;tumor 
necrosis factor-
activated receptor 
activity 
B cell mediated 
immunity;macrophage 
activation;induction of 
apoptosis;cell-cell 
signaling;ectoderm 
development;induction of 
apoptosis;nervous system 
development;cellular defense 
response;negative regulation 
of apoptotic process   
MM
P2 
72 kDa type IV 
collagenase;MMP2;ortholog 
metallopeptidase 
activity proteolysis 
extracellular 
region;extracell
ular matrix 
SRC 
Proto-oncogene tyrosine-
protein kinase 
Src;SRC;ortholog 
non-membrane 
spanning protein 
tyrosine kinase 
activity 
apoptotic process;protein 
phosphorylation;cell-cell 
signaling;cell proliferation;cell 
adhesion;apoptotic 
process;cell differentiation cytoplasm 
FABP
5 
Fatty acid-binding protein, 
epidermal;FABP5;ortholog lipid binding 
lipid metabolic process;cell 
communication;ectoderm 
development;lipid 
transport;vitamin transport   
IL6 Interleukin-6;IL6;ortholog 
cytokine receptor 
binding;cytokine 
receptor binding 
immune system 
process;apoptotic process;cell-
cell signaling;apoptotic 
process;negative regulation of 
apoptotic process   
PAR
P1 
Poly [ADP-ribose] 
polymerase 
1;PARP1;ortholog 
transferase activity, 
transferring 
glycosyl groups 
DNA repair;protein ADP-
ribosylation;protein ADP-
ribosylation;response to stress   
CSF3 
Granulocyte colony-
stimulating 
factor;CSF3;ortholog cytokine activity 
immune response;cell-cell 
signaling;response to stimulus   
GST
M1 
Glutathione S-transferase 
Mu 1;GSTM1;ortholog       
LCN
1 Lipocalin-1;LCN1;ortholog 
isomerase 
activity;binding 
fatty acid biosynthetic 
process;cell 
communication;response to 
pheromone;transport   
P a g e  | 172 
 
 
